Determinants of the absorption of the dietary flavonoid quercetin in man by Hollman, P.C.H.
DETERMINANTS OF THE 
ABSORPTION OF THE DIETARY 
FLAVONOID QUERCETIN IN MAN 
Peter C.H. Hollman 
Promotoren: Dr. J.C.A.J. Hautvast 
Hoogleraar in de leer van de voeding van de mens 
Dr. M.B. Katan 
Universitair hoofddocent aan de Vakgroep Humane Voeding 
Bijzonder hoogleraar in de voedingsleer van de mens aan de 
Katholieke Universiteit Nijmegen 
Co-promotor: Dr. O. Korver 
Hoofd Unilever Nutrition Centre 
Unilever Research Laboratorium Vlaardingen 
^MoB2oi, £ 2 8 3 
DETERMINANTS OF THE ABSORPTION 
OF THE DIETARY FLAVONOID 
QUERCETIN IN MAN 
Peter C.H. Hollman 
Proefschrift 
ter verkrijging van de graad van doctor 
op gezag van de rector magnificus 
van de Landbouwuniversiteit Wageningen 
dr.C.M. Karssen, 
in het openbaar te verdedigen 
op woensdag 18 juni 1997 
des namiddags om half twee in de Aula 
l o n 3 M i 4 1 
The research described in this thesis was carried out at the State Institute for Quality 
Control of Agricultural Products (RIKILT-DLO) and the Department of Human 
Nutrition, Wageningen Agricultural University. 
The research was financially supported by the Netherlands Heart Foundation 
(94.128), the Foundation for Nutrition and Health Research, and the Agricultural 
Research Department (DLO). 
Determinants of the absorption of the dietary flavonoid quercetin in man 
Peter C.H. Hollman 
ISBN 90-5485-691-2 
Cover: Frans Hollman 
"Still life with onions" (fragment) 
Maastricht 1994 
Pastel on paper 40 cm x 23 cm 
Printing: Grafisch Bedrijf Ponsen & Looijen BV, Wageningen, The Netherlands 
© 1997 P.C.H. Hollman 
BIBLIOTHEEK 
LANDBOUWUNIVERSITEIT 
WAGENINGEN 
Stellingen 
1. Chromosomen hebben met betrekking tot hun synaptisch gedrag een geheugen. 
Dit proefschrift 
2. Homo- of heterozygotie voor de Robertsonische translocatie Rb(11.13)4Bnr (Rb4) heeft 
niet altijd een reducerend effect op de mannelijke vruchtbaarheid. Afhankelijk van de overige 
in het karyotype aanwezige chromosoomafwijkingen kan Rb4 ook stimulerend werken. 
Dit proefschrift 
3. Niet-homologe chromosoom synapsis in afwezigheid van meiotische recombinatie leidt 
niet tot dominante of recessieve vormen van chromosoom instabiliteit. In aanwezigheid van 
recombinatie mogelijk wel. 
Dit proefschrift 
4. Klassieke chromosoom mutanten kunnen een vergrootglas funktie vervullen bij meiotisch 
cytologisch onderzoek. 
Plug et al., Nature Genetics, in press 
5. - Publiceerbaarheid van gegevens bepaalt niet alleen het plezier in wetenschappelijk 
onderzoek. Het kan dit wel versterken. 
6. Moleculair biologen leven in zwart/wit, cytologen in kleur. 
7. Sonore koorzang is het zoeken naar harmonie tussen het individu en het collectief. 
8. Helaas zijn veel (vooraanstaande) wetenschappers geen goede koorzangers. 
9. Nalatige hooggeplaatsten zijn ware alchemisten: het lukt hen vaak het vuil aan hun handen 
om te zetten in goud. 
10. Email maakt onmogelijke relaties mogelijk. 
11. Het betere is de vijand van het goede. 
Stellingen behorende bij het proefschrift 
"Non-homologous chromosome synapsis during mouse meiosis: 
consequences for male fertility and survival of progeny" 
Wageningen, 21 november 1997 Antoine H.F.M. Peters 
Stellingen 
10. De overhead van een onderzoeksorganisatie gedraagt zich als overgewicht. 
Voorkomen ervan vereist een streng dieet, maar dat blijkt moeilijk vol te 
houden. 
11. De wachtgeldfobie van de overheid wordt duur betaald. 
12. Het Kenniscentrum Wageningen werkt. 
Dit proefschrift. 
13. Ofschoon niet ontworpen voor gebruik op de elektronische snelweg, is de 
fiets een onmisbaar hulpmiddel in het Wageningse netwerk. 
14. Voor het milieu is nalaten beter dan doen. 
Lyklema H. Chemisch Weekblad 1996;92(48):2. 
15. 'Natuurlijk' is niet per definitie gezonder. 
Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad 
Sei USA 1995;92:5258-5265. 
16. Gelukkig zijn er wetenschappers die 'nutteloos' onderzoek verrichten. 
Chemisch Weekblad 1997;93(11):2 
17. Als Eva dit proefschrift had kunnen lezen, dan zou zij de verleiding van de 
appel wellicht hebben weerstaan, maar in plaats daarvan bezweken zijn voor 
een gefruit uitje. 
Little pieces in a giant jigsaw 
Voor Paula, Pascal en Danielle 
Abstract 
Determinants of the absorption of the dietary flavonoid quercetin in man 
PhD thesis by Peter C.H. Hollman, State Institute for Quality Control of Agricultural 
Products (RIKILT-DLO), Wageningen, the Netherlands, lune 18, 1997 
Oxidation of low density lipoprotein is hypothesised to play an important role in the 
development of cardiovascular disease. It might be prevented by dietary antioxi-
dants. Quercetin is a dietary flavonoid antioxidant and its intake was inversely 
associated with cardiovascular disease in some studies. Absorption from the diet is 
a prerequisite for its potentially beneficial role. This thesis describes studies on the 
absorption and elimination kinetics of dietary quercetin in humans. 
To perform these absorption studies, we developed a postcolumn chelation 
technique for quercetin in HPLC with fluorescence detection using aluminum. Only 
flavonols that contain a free 3-hydroxyl and 4-keto oxygen binding site formed 
fluorescent complexes with Al3+ . This method improved detectability of quercetin 
300 fold as compared to conventional UV detection. 
We studied the absorption of quercetin in healthy ileostomy subjects so as 
to avoid losses caused by colonic bacteria. Absorption of quercetin was 52 ± 15% 
for quercetin glucosides found in onions, 17 ± 15% for quercetin rutinoside a 
major quercetin glycoside of tea, and 24 + 9% for free quercetin aglycone. 
The time course of the plasma quercetin concentration was studied in normal 
subjects with an intact colon who ingested major dietary sources of quercetin, viz. 
fried onions containing glucose conjugates of quercetin, apples containing both 
glucose- and non-glucose quercetin glycosides, and of quercetin-3-rutinoside. Peak 
plasma levels of quercetin were reached <0.7 h after ingestion of the onions, 2.5 
h after the apples, and 9 h after the rutinoside. Bioavailability of both quercetin from 
apples and of pure quercetin rutinoside was 30% relative to onions. Half-lives of 
elimination were independent of the quercetin source and were about 24 h. 
We confirmed that the sugar moiety of the glycoside is an important 
determinant of absorption in a study with volunteers who ingested solutions of pure 
quercetin-4'-glucoside and of pure quercetin-3-rutinoside. 
In conclusion, absorption of dietary quercetin glycosides can be appreciable 
and depends on the type of sugar moiety of the glycoside. We propose that the 
sodium-glucose cotransporter is involved in the absorption of quercetin-4'-
glucoside. Elimination of quercetin from the blood is slow. Repeated consumption 
of quercetin-containing foods therefore will lead to accumulation of quercetin in 
plasma. 
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Background 
Flavonoids comprise a large class of polyphenols components and are common 
ingredients in foods of plant origin. The basic structure of flavonoids (Figure 7) 
allows a multitude of substitution patterns in the benzene rings A and B, and 
variations also can occur in the heterocyclic ring C, giving rise to flavonols, 
flavones, catechins, flavanones, anthocyanidins, and isoflavonoids. Over 4000 
different naturally occurring flavonoids have been described1 and this list is still 
growing. Recently, much attention has been paid to their antioxidant properties2 
which may protect tissues against oxygen free radicals and lipid peroxidation. 
Oxygen free radicals and lipid peroxidation are thought to play a role in several 
pathological conditions such as atherosclerosis, cancer, and chronic inflammation.3 
Cardiovascular disease is the major cause of death in Western societies. In 
1994, 20 700 people died from coronary heart disease and 12 600 people from 
stroke in the Dutch population which comprises more than 15 million people.4 
Coronary heart disease and stroke were placed number one and two in the top ten 
of causes of death in the Netherlands. The impact of cardiovascular disease on the 
nations health is even more pronounced when one considers that the number of 
people suffering from this disease is 10-fold higher than the number of mortalities. 
The quality of life of this group of people is reduced and involves reliance on 
medical care and hospitalization, sick leave, disablement, health impairment and 
handicaps.5 
A number of risk factors for coronary heart disease have been described.5 
These risk factors include high blood pressure, high total cholesterol, low 
cholesterol in high density lipoprotein particles, obesity and diabetes. Lifestyle 
factors, such as smoking and physical inactivity, also play an important role.5 
Atherosclerosis is the prime cause of coronary heart disease and is also 
important in thrombotic stroke. It is characterized by thickening and narrowing of 
arteries because of the formation of fibrofatty and fibrous lesions which obstruct the 
blood flow. A major hypothesis proposes that oxidised low density lipoprotein 
(LDL) particles, which constitute one of the carriers of cholesterol, play a key role 
in the development of atherosclerosis.6"10 Consequently, the avoidance or delay of 
LDL oxidation by dietary antioxidants might provide a promising strategy for preven-
ting atherosclerosis and consequently coronary heart disease. However, the ability 
of dietary antioxidants to inhibit LDL in vivo still has to be established. Flavonoids 
are such dietary antioxidants and epidemiological data support a potential role for 
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the subclass of flavonols, with quercetin as the major representative, in the preventi-
on of cardiovascular disease.'1 However, the role of flavonoids in human 
physiology is largely unknown and hampers an evaluation of their potential health 
effects. Animal studies suggested that gastro-intestinal absorption from foods of most 
flavonoids will be marginal, because they are linked to sugars.12 These so-called 
glycosides are reported to be non-absorbable and require hydrolysis by bacteria in 
the colon, where absorption is inefficient and degradation immanent.13 
This thesis describes studies on the absorption and elimination kinetics of the 
major dietary flavonol quercetin in healthy humans. Epidemiological studies on the 
relation between dietary flavonol intake and the risk of cardiovascular disease are 
summarised in this introduction, and the usefullness of kinetic studies is briefly 
discussed. Finally, the purpose of the research of this thesis and an overall outline 
of the thesis are given. 
Figure 1. General structure of flavonoids. Classification into flavones, flavonols, 
flavanones, catechins, anthocyanidins, isoflavones is based on variations in the 
heterocyclic C-ring. A multitude of substitutions in the ring systems occur: 
R, R,. = H, OH, O-sugar (glycosides), 0-CH3, sulfate, O-glucuronic acid, or 
O (only RJ 
Quercetin: R3 Rs R7 R3. R4, = OH; R4 = O ; R2. Rs. = H; double 
bond between C2 and C3 
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Flavonoids and cardiovascular disease risk 
The only studies relating the intake of dietary flavonoids to risk of disease have been 
observational in nature. These studies were only possible after development of 
quantitative methods of analysis and their application to the quantification of flavo-
noids in foods. Until the end of the 1980s, the methods of flavonoid analysis were 
qualitative since they had been primarily developed for taxonomie studies. The aim 
of the taxonomie studies was to unequivocally characterise the flavonoids present 
in individual plant species. To date, quantitative data for only two subclasses of 
flavonoids, the flavonols and flavones, have been published.14"16 These compounds 
are present in plants bound to sugars, the so-called glycosides (Figure 7). Flavonols 
are by far the most important of these two classes of flavonoids since flavones were 
only found in a few foods. Quercetin is the most important flavonol found in plant 
foods. 
We determined the average dietary flavonol and flavone intake as it was 
around 1960 in 16 cohorts participating in the Seven Countries Study. The average 
flavonol and flavone intake was inversely correlated to mortality rates of coronary 
heart disease after 25 years of follow-up (Table 7).17 The intake of flavonols and 
flavones, together with smoking and the intake of saturated fat, explained about 
90% of the variance in coronary heart disease mortality rates across the 16 cohorts. 
Five prospective within-population cohort studies have been carried out 
(Table 1). Coronary heart disease mortality was strongly inversely associated with 
flavonol and flavone intake in the Zutphen Elderly Study18 with a reduction in 
mortality risk of more than 50% being recorded (Table 7) in the highest tertile of 
flavonol intake. Average flavonol intake in the highest tertile was 42 mg/day, and 
in the lowest 12 mg/day. Recently, the ten year follow-up of the Zutphen Elderly 
Study was completed with results strengthening the findings of the five year follow-
up (M.G.L. Hertog, personal communication). Unlike the findings of the five year 
follow-up, a clear dose-response relationship between flavonol intake and coronary 
heart disease mortality was now recorded. 
The association between flavonol and flavone intake and risk of stroke was 
studied in a cohort of 550 middle-aged men19 (Table 7). These men were followed 
for 15 years, and the men in the highest quartile of flavonol and flavone intake 
(> 30 mg/ day) showed a considerably reduced risk of the disease of about 60%. 
Mortality from coronary heart disease was weakly inversely associated with 
flavonol and flavone intake in a cohort of 5130 Finnish men and women aged 30 -
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69 years followed over a 20 years period20 (Table 7). The relative risks of mortality 
from coronary heart disease between the highest (>5 mg/day) and lowest quartiles 
(<2.5 mg/day) of flavonol and flavone intake were 0.73 for women and 0.67 for 
men. 
Table 1. Summary of epidemiological prospective studies on flavonol and flavone 
intake and coronary heart disease (CHD) and stroke risk 
Population 
Cohort studies 
CHD, 805 men; 
Zutphen (The Netherlands)'8 
CHD, 5133 men + women; 
Finland20 
CHD, 34 789 men 
Health Professionals (U.S.A.)21 
CHD, 1900 men 
Caerphilly (U.K.)22 
Stroke, 552.men; 
Zutphen (The Netherlands)19 
Cross-cultural study 
CHD, 12 763 men 
Seven Countries Study17 
Age 
(y) 
65 -84 
30-69 
40 -75 
49 -59 
50-69 
40 -59 
Follow-up 
(y) 
5 
20 
6 
14 
15 
25 
Relative Risk1 
(95% Confidence 
Interval) 
0.32 
(0.15-0.71) 
¥:0.73 
(0.41 - 1.32) 
c?: 0.67 
(0.44 - 1.00) 
1.08 
(0.81 - 1.43) 
1.6 
(0.9-2.9) 
0.27 
(0.11 -0.70) 
r = -0.50 
(P = 0.01) 
1
 Relative risk of highest versus lowest flavonol intake group, adjusted for age, diet and other risk 
factors for coronary heart disease 
Recently, in male US health professionals a modest, but non-significant, 
inverse association between flavonol and flavone intake and coronary mortality was 
found only in men with previous history of coronary heart disease21 (Table 1). 
Median flavonol intake in the highest quintile was 40 mg/day and 7 mg/day in the 
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lowest. 
In contrast to the above studies, increased mortality of ischaemic heart 
disease was found in Welsh men22 in all quartiles of high flavonol intake compared 
to the lowest quartile (Table 7). Mean flavonol intake in the highest quartile was 43 
mg/day, and 14 mg/day in the lowest quartile. 
To summarise, a protective role for flavonols-in cardiovascular disease was 
found in 3 out of 5 prospective cohort studies, in addition to one cross-cultural 
study. One prospective cohort study showed no association, and one a weakly 
positive association between flavonol intake and coronary heart disease. So far, the 
epidemiological evidence points to a protective effect of antioxidant flavonols in 
cardiovascular disease but it is not conclusive. 
Kinetic studies on absorption and elimination 
For quercetin to act as a potential antioxidant in humans it is required to enter the 
blood circulation. Thus, after consumption, quercetin has to pass across the 
intestinal wall and resist metabolism in the liver. The bioavailability of quercetin in 
various foods, i.e. the fraction of quercetin molecules that successfully survives 
these barriers,23 will be an important determinant of exposure. This fraction, called 
'absolute bioavailability', is determined experimentally by administrating quercetin 
either orally or intravenously and then comparing the ratio of the areas under the 
plasma quercetin versus time curve. The studies in this thesis did not include 
intravenous administration of quercetin glycosides. The approach used in this thesis 
only gave data on the relative bioavailability of quercetin present in quercetin-rich 
foods and of selected pure quercetin glycosides. Thus, a comparison of the potential 
of various foods to increase plasma levels of quercetin could be made. 
As all tissues are supplied with plasma, there will be a relationship between 
the concentration of quercetin in the plasma and that at its site of action. The plasma 
concentration of quercetin will change with time, and as a consequence also its 
effect in the body. The time course of the quercetin concentration in plasma after 
oral ingestion of a known amount of quercetin present in foods or in some 
glycosidic form, is used to calculate kinetic parameters of absorption and 
elimination, such as half-lives. Absorption kinetics may give information on the 
mechanisms of absorption involved and consequently on determinants which affect 
absorption. 
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Oxidants, such as free radicals, are continuously generated by cells and can 
potentially cause damage to these cells. A steady-state antioxidant concentration 
which is sufficiently high to prevent this deleterious oxidation, would probably be 
beneficial. Because food is not consumed continuously over 24 hours, the input of 
dietary antioxidants such as quercetin to the body may occur as a series of pulses 
separated by many hours. Rapid elimination of these antioxidants from the body 
after a meal would be undesirable. Accumulation of dietary antioxidants in the body 
may occur, but that depends on their elimination half-lives and consumption 
intervals. The average steady-state level of a dietary antioxidant achieved will 
additionally depend both on the amount ingested and its bioavailability.23 It is 
feasible that kinetic parameters vary between foods. Thus, kinetic studies on 
absorption and elimination will enable us to compare the supply of quercetin to the 
body from the habitual consumption of various foods and to predict plasma steady-
state levels of these potentially beneficial antioxidants in the diet. As a second step, 
the efficacy of these quercetin concentrations in vivo has to be determined. 
Purpose of the studies and outline of this thesis 
The aim of this thesis was to determine whether the proposed role of flavonols in 
the protection against cardiovascular disease, is supported by their physiological 
behaviour. To this purpose, the rate and extent of absorption and elimination of 
dietary quercetin and of quercetin glycosides were studied in human volunteers. 
Chapter 2 reviews studies on the absorption, metabolism and bioavailability 
of flavonoids reported in the literature. This review is updated with the main results 
of our research presented in the subsequent chapters. Chapter 3 describes the 
development of a postcolumn derivatization method for the analysis of flavonols by 
HPLC using fluorescence detection. This technique was essential since the methods 
available lacked sufficient sensitivity to allow the determination of quercetin in 
blood plasma of subjects after consumption of flavonoid-rich supplements. We 
performed a mass balance study with ileostomy volunteers, reported in Chapter 4, 
to quantify the absorption of quercetin from fried onions (rich in quercetin 
glucosides), pure quercetin rutinoside (a major quercetin glycoside of tea), and pure 
quercetin aglycone. In Chapter 5, we present a pilot study on the plasma kinetics 
of quercetin after consumption of a single dose of fried onions by two normal 
healthy human subjects. The bioavailability of quercetin glycosides from onions and 
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apples, and of the pure quercetin rutinoside in nine healthy subjects is compared 
in Chapter 6. The role of the sugar moiety of quercetin glycosides as a potential 
determinant of absorption is studied in Chapter 7. Finally, Chapter 8 discusses the 
main results. 
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Abstract 
Flavonoids are dietary polyphenols with potential health benefits. This review 
discusses results of studies on the absorption, metabolism and pharmacokinetics of 
flavonoids. Most studies have been carried out with aglycones in rodents using 
unphysiologically high doses. Absorption depended on the type of flavonoid and 
was between 4 and 58%. The absorption from dietary sources is largely unknown. 
In the metabolism of flavonoids the liver and the colon are important. Evidence for 
phase II biotransformation reactions in the liver is abundant. Colonic bacteria are 
involved in hydrolysis of glycosides and conjugates and in ring fission producing 
phenolic acids which are absorbed. Three types of ring fission depending on the 
structure of the flavonoid C-ring have been described. The susceptibility to ring 
cleavage is determined by the pattern of free hydroxyl groups in the flavonoid 
molecule. Very few quantitative data on metabolism are available. Pharmacokinetic 
data on flavonoids are scarce and absolute bioavailability of dietary flavonoids has 
not been determined. 
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INTRODUCTION 
Flavonoids are polyphenolic compounds that occur ubiquitously in foods of plant 
origin. They comprise 2-phenylbenzo-y-pyrones, -dihydropyrones, -dihydropyrans, 
and -pyryliums. Variations in the oxygen-containing heterocyclic ring give rise to 
catechins (dihydropyrans), flavonols and flavones (y-pyrones), flavanones (dihydro-
pyrones), and anthocyanidins (pyryliums) (Figure 1). Attachment of the second 
benzene ring to the 3 instead of the 2 position creates isoflavonoids (Figure J). In 
addition, the basic structure of flavonoids allows a multitude of substitution patterns 
in the two benzene rings within each class of flavonoids. Over 4000 different 
naturally occurring flavonoids have been described1 and this list is still growing. 
OH O 
Flavones 
OH O 
Flavanones 
OH O 
Flavonols 
Catechins 
OH 
Anthocyanidins 
Figure 1. Subclasses of flavonoids. Classification is based on variations in the 
heterocyclic C-ring. 
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Major dietary sources of flavonoids are vegetables, fruits, and beverages such 
as tea and red wine.27 Kühnau 4 estimated that the total flavonoid intake in the 
U.S.A. was 1 g/day expressed as glycosides or 650 mg/day expressed as aglycones, 
but most likely this estimate is too high. New, more specific food analyses2,3 
suggested that the Dutch intake of flavonols and flavones was 23 mg/day (expressed 
as aglycones),8 as opposed to Kühnau's estimate of 115 mg/day (expressed as 
aglycones) in the U.S.A.4 
History 
In 1936 it was observed that a mixture of two flavanones decreased capillary 
permeability and fragility in humans. This gave rise to a claim for vitamin action of 
flavonoids (Vitamin P). Doubts about the evidence for these claims prompted the 
US Council on Foods and Nutrition to issue a report on the absorption and 
excretion of flavonoids.9 It was concluded that flavonoids are probably largely 
destroyed in the mammalian gastro-intestinal tract, thus strengthening the scepticism 
about "Vitamin P". The possibility was suggested that one or more metabolites were 
responsible for the potential therapeutic effects. 
In the 1950s and 1960s research on absorption and metabolism of flavonoids 
was advanced by Booth, Das, and Griffiths who published many articles exploring 
the metabolic routes of various flavonoids in animals. Several review articles 
describe these achievements.4,10,11 However, most of these studies used high doses, 
mainly because the analytical techniques used for identification of metabolites 
lacked sensitivity. Details of the metabolic pathway still had to be unravelled. 
Recent developments 
A multitude of in vitro studies suggested that flavonoids inhibited, and sometimes 
induced, a large variety of mammalian enzyme systems.1 Some of these enzymes 
are involved in cell division and proliferation, platelet aggregation, detoxification, 
and inflammatory and immune responses. Thus, it is not surprising that effects of 
flavonoids on different stages in the cancer process, on the immune system, and on 
haemostasis were reported in cell systems and animals.1,12 Recently, much attention 
has been paid to the antioxidant properties of flavonoids, caused by their ability to 
scavenge oxygen free radicals.13"15 Oxygen free radicals and lipid peroxidation might 
be involved in atherosclerosis, and a role has also been suggested in cancer and 
chronic inflammation.16 There is indeed some epidemiological evidence for an 
inverse association of the intake of flavonols and flavones with subsequent coronary 
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heart disease,17 although the association is still controversial]8 No association of 
flavonoid intake and cancer risk in man has been established.17 
Scope of this review 
The increasing awareness of a potential beneficial role of flavonoids in human 
health provided new perspectives for flavonoid research. Knowledge of the 
pharmacokinetics and bioavailability of flavonoids in man is indispensable to fully 
evaluate this role. Metabolic transformations of flavonoids in the human system may 
be crucial for their biological effect. This chapter focuses on the fate of dietary flavo-
noids, except isoflavonoids, in mammals, and thus updates the reviews publish-
ed.4,1011 Pharmaceutical preparations are dealt with only where that helps to 
understand general principles of bioavailability. 
ABSORPTION 
The major questions here are to what extent flavonoids are absorbed from the 
gastro-intestinal tract, and which factors affect absorption. Absorption of flavonoids 
from the diet was long considered to be negligible, as most of the flavonoids, except 
catechins, are present in plants bound to sugars as glycosides, and these were 
considered non-absorbable. Studies with germ-free rats indeed showed that large 
amounts of unchanged glycosides were excreted with faeces, whereas only small 
amounts of glycosides were found in faeces of rats with a normal microflora.19 
Evidently, enzymes that can split these predominantly ß-glycosidic bonds were not 
secreted into the gut or present in the intestinal wall. Bacteria in the colon were able 
to hydrolyse flavonoid glycosides20'22 but at the same time degraded the liberated 
flavonoid aglycones (see page 30). In addition, the absorption capacity of the colon 
is far less than that of the small intestine. The assumption that only free flavonoids 
(aglycones) are absorbed by the gut and that glycosides are not is a classic example 
of "conventional wisdom". It was never seriously questioned even though there was 
little evidence to support it. 
Absorption of pure compounds 
Balance studies with radioactively labelled flavonoid aglycones were used in the 
1970s and 1980s to quantify the absorption of ( + )-catechin, quercetin, and flavan-
ones in rodents, monkeys and man (Table 7), always without their attached sugars. 
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In these studies total radioactivity was measured in urine, faeces, expired air, and 
sometimes also in tissues.28,31 As a consequence, the excreted radioactivity included 
the intact administered compound, if any, and metabolites that contained radio-
active atoms. Catechins and their microbial degradation products were well absor-
bed as judged by excretion of 47% to 58% of the total administered radioactivity 
into urine. The administered dose did not seem to be an important variable, and 
absorption in rodents, monkeys and man was similar. It was suggested23 that the 
radioactivity not accounted for, some 20%, had possibly been incorporated into 
tissues. Excretion of unchanged catechin aglycones in urine was only 0.1 - 2% of 
the dose. 
Radioactive quercetin aglycone was less well absorbed than catechins, with 
only 4 - 13% recovered in urine (Table ?). About 40% was excreted with faeces. 
The high excretion of radioactivity associated with C02 could originate to some 
extent from absorbed quercetin metabolites through ß-oxidation of phenylpropionic 
acids (see page 49). In rats, 1 % of the administered dose of quercetin was excreted 
as quercetin (conjugates).28 However, after oral administration of quercetin aglycone 
to humans the aglycone or its conjugates could not be detected in urine.29 These 
investigators concluded that less than 1 % of the administered quercetin could have 
been absorbed.29 This conclusion was based on the limit of detection of their 
analytical method. Absorption of the flavanone aglycones and their metabolites was 
somewhat higher than that of quercetin aglycone: about 30% was excreted with 
urine (Table 1). 
Absorption of flavonoids from foods 
Previous studies did not address the absorption from foods, but only of pure 
aglycones. We ourselves were interested in the absorption of flavonoids from 
regular foods, and in man rather than in animals. To circumvent the problem of 
microbial degradation we employed ileostomy subjects.30 To our surprise, the 
quercetin glycosides from onions were absorbed far better than the pure aglycone 
(Table 1). Absorption from onions was 52% of the ingested amount, while only 
24 % of the aglycone, and 17% of rutin (quercetin-3-O-rutinoside) were absorbed. 
A small percentage (< 0.5%) of the absorbed quercetin was excreted into urine as 
the intact quercetin molecule, conjugated or otherwise. Thus, glycosides can be 
absorbed in man as such without prior hydrolysis by microorganisms. Evidence for 
direct absorption of glycosides was also found in rats; oral administration of naringin 
(5,7,4'-trihydroxyflavanone-7-neohesperidoside) and hesperidin (5,7,3'-trihydroxy-
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4'-methoxyflavanone-7-rutinoside) showed that the parent glycosides were secreted 
with bile,33 which implied that glycosides were transported across intestinal 
membranes. 
As far as the catechins are concerned, epigallocatechins present in green tea 
were shown to be absorbed in rats. The following compounds were identified in the 
portal vein after their oral administration: (-)-epigallocatechin-3-gallate (ECCg), 
(-)-epigallocatechin (ECC), (-)-epicatechin-3-gallate (ECg) and (-)-epicatechin (EC).34,35 
It was reported that 2% of ingested green tea catechins were excreted into urine in 
humans.36 
Data on mechanisms of flavonoid absorption across the intestinal membrane 
itself are scarce. The absorption of ( + )-catechin, epicatechin-2-sulfonate, and 
7,3',4'-tri-0-(ß-hydroxy-ethyl)quercetin-3-rutinoside was studied in the rat everted 
sac model, and the rate of passive transport was in the order epicatechin-2-sulfonate 
> ( + )-catechin > trihydroxyrutinoside.37 However, of these three flavonoids only 
( + )-catechin was absorbed in an in situ perfused small intestine segment of the rat.38 
This demonstrated the limitations of the everted sac model. 
In conclusion, the absorption of flavonoid aglycones in rats was estimated at 
4 - 58% of ingested radioactive aglycones as judged by the amount of radioactivity 
excreted into urine. Contrary to the common belief that only aglycones can be 
absorbed, flavonol glycosides were well absorbed in man without prior hydrolysis 
by microorganisms, and similar observations have been made in rats. Only a small 
fraction of the flavonols subsequently excreted with urine had an intact flavonoid 
structure. 
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METABOLISM 
Introduction 
Metabolism of flavonoids is relevant because a major part of administered 
flavonoids is excreted in urine only after more or less extensive modification in the 
body. Thus, a potential biological effect predicted from in vitro studies may be 
modulated in vivo due to metabolism after ingestion of the parent compounds. The 
major questions are which products are formed and to what extent, and what is their 
potential biological effect. 
In the metabolism of flavonoids, two compartments are important. The first 
consists of tissues in the body, such as the liver where biotransformation enzymes 
act upon absorbed flavonoids and their absorbed colonic metabolites. The second 
metabolically active compartment is the colon where microorganisms degrade 
unabsorbed flavonoids and flavonoids absorbed and then secreted with bile. 
Metabolism by the liver. 
Flavonoids absorbed as such as well as their degradation products absorbed from 
the colon after bacterial action are subsequently metabolised by enzymes located 
mainly in the liver. The kidney and the small intestine might also contain enzymes 
capable of biotransformation of flavonoids.39 The general phase I biotransformation 
reactions introduce or expose polar groups.39 These may be less relevant to naturally 
occurring flavonoids and their colonic degradation products because these already 
contain several polar hydroxyl groups. Indeed, phase I transformations have been 
reported almost exclusively for synthetic flavonoids lacking hydroxyl groups.11 
Conjugation of these polar hydroxyl groups with glucuronic acid, sulfate, or glycine 
constitutes phase II biotransformation reactions,39 and these have been reported 
both for flavonoids and for their colonic metabolites. The water-soluble conjugates 
thus formed can be excreted into urine. In addition, the molecular weight increases 
which promotes secretion into bile.40 Finally, O-methylation by the enzyme 
catechol-O-methyltransferase plays an important role in the inactivation of the 
catechol moiety,41 i.e. the two adjacent (ortho) aromatic hydroxyl groups, of 
flavonoids and their colonic metabolites. 
Metabolism by the colonic flora. 
Flavonoids can reach the colon by two different ways; unabsorbed flavonoids 
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passing through the small intestine, and absorbed flavonoids secreted as conjugates 
into the duodenum via the gal I bladder. In the colon both are stripped of their sugar 
moieties, glucuronic acids and sulfates by glycosidases, glucuronidases and 
sulfatases of colonic bacteria.42 Hydrolysis by bacterial enzymes enables absorption 
in the colon because the aglycones formed are less polar.3943 As a result, secreted 
glucuronides and sulfates can be reabsorbed thus entering an enterohepatic cycle. 
Another possibility exists in that the heterocyclic oxygen-containing ring is 
split. The subsequent degradation products can evidently be absorbed because they 
are found in urine. These include a variety of phenolic acids which, depending on 
the hydroxylation pattern, are antioxidants themselves44 and may thus contribute to 
the biological effects of dietary flavonoids. The type of ring fission depends on the 
type of flavonoids; as a result, primary ring fission products of catechins, flavonols, 
and flavones and flavanones are all different. Hydroxyl groups are necessary for ring 
cleavage, and the hydroxylation pattern of the flavonoids determines their 
susceptibility to microbial degradation in the colon.21 Free hydroxyl groups at 
positions 5 and 7 together with a free hydroxyl group at the 4' position are 
necessary for ring fission of the heterocyclic C-ring.21 Whether or not the position 
of the free hydroxyl group in ring B is essential is not known. A flavonoid that has 
only one free hydroxyl group in ring A at position 7, e.g. 7,4'-dihydroxyflavone, 
withstands ring fission. Whether two hydroxyls in ring A, or a single hydroxyl group 
at position 5 are sufficient for ring fission is not known. The presence of O-methyl 
substitution in these essential positions reduces susceptibility to cleavage. 
Methylation of the 3-hydroxyl group in the C-ring of ( + )-catechin also increases 
resistance to ring scission. The most widespread dietary flavonoids have a 5,7,3',4'-
hydroxylation pattern which will enhance ring cleavage by bacteria after hydrolysis 
of the glycosides in the colon. 
Thus, the formation of potentially active metabolites through bacterial 
degradation in the colon is highly dependent on structural details of the dietary 
flavonoids involved. 
Catechins 
After oral administration of labelled catechins to humans some 50% of the 
radioactivity was recovered in urine, and only 0.5 - 3% of this was in the form of 
catechin aglycone. Thus, catechins are extensively metabolized.25,26 
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Enzymatic transformations of catechins in body tissues 
Unfortunately phase I transformation reactions for catechins have not been 
described; information on metabolism in liver and other organs is limited to the 
attachment of various substituents to existing hydroxyl groups, and most of this 
information is qualitative only. This subject evidently needs closer study. 
Sulfates and glucuronides of ( + )-catechin were identified after oral 
administration of ( + )-catechin to rodents, monkeys and man (Table 2). Intravenous 
and intraperitoneal administration of this flavonoid to rodents and monkeys also 
produced these conjugates. Thus, glucuronidation and sulfation in body tissues was 
demonstrated. Rats and humans excreted sulfates and glucuronides of 3-methoxy-
( + )-catechin into urine, plasma and bile after intravenous injection of this 
compound.26,51 Because catechins are polyhydroxylated compounds, several sites 
offer themselves for binding of glucuronic acid or sulfate. In human urine, two 
glucuronides of 3,3'-dimethoxy-( + )-catechin and of 3-methoxy-( + )-catechin, and 
a sulfate conjugate of 3-methoxy-( + )-catechin were found.26 The position of these 
groups could not be determined. Two different sulfates and a mixed sulfate/glu-
curonide of ( + )-catechin were detected in perfusate and bile of a perfused isolated 
rat liver.52 After oral administration of (-)-epigallocatechin-3-gallate and (-)-epicate-
chin of green tea to human volunteers the major conjugates found in plasma were 
sulfates, whereas the (-)-epigallocatechin circulated as the glucuronide.36 Some 20% 
of the (-)-epigallocatechin-3-gallate was also present as unconjugated compound. 
In addition to conjugates of ( + )-catechin, glucuronides of the main colonic 
metabolites, the three valerolactones and 3-hydroxyphenylpropionic acid (Figure 
2), were identified in urine of humans.47 Sulfates of ö-(3-hydroxyphenyl)-y-
valerolactone and 3-hydroxyphenylpropionic acid were also present. 
In vitro incubation of ( + )-catechin in liver homogenates produced 3'-
methoxy-( + )-catechin, thus showing that O-methylation had occurred.49 Purified 
catechol-O-methyl transferase (E.C.2.1.1.3) was also able to form the 3'-methoxy 
compound.49 Only the 3'-hydroxyl group of ( + )-catechin or 3-methoxy-( + )-catechin 
was methylated, thus suggesting that catechol-O-methyl transferase was also 
involved in vivo. Additional evidence for the role of catechol-O-methyl transferase 
in O-methylation came from experiments with oral administration of valerolactones, 
the primary bacterial ring fission products of ( + )-catechin, to guinea pigs.46 Only 5-
(3-4-dihydroxyphenyl)-Y-valerolactone was O-methylated, whereas 5-(3-hydroxy-
phenyl)-Y-valerolactone that lacks a catechol group was not O-methylated. 
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In conclusion, catechins were metabolised by liver enzymes to give sulfates, 
glucuronides, and mixed sulfates/glucuronides which were excreted into bile, urine 
and plasma. In addition, O-methylated catechin conjugates were produced by 
catechol-O-methyl transferase in the liver. Because of the specificity of this enzyme 
only ortho-hydroxy-methoxy metabolites were formed. These phase II reactions 
occurred in rodents as well in humans. Types of glucuronides depended on species, 
and preference for sulfation was found in humans.26 
Bacterial ring cleavage of catechins in the colon 
According to Das et al.,23 the catechin ring is cleaved by microorganisms at the 
positions indicated by arrows in Figure 2. This type of fission is decisive for the 
basic structures of the successive metabolites: valerolactones (phenyl-C5: a benzene 
ring with a side chain of 5 C-atoms), phenylpropionic acids (phenyl-C3) and benzoic 
acids (phenyl-C,). Variations in substituent patterns of these basic structures occur-
red and were to some extent species dependent {Table 2). Identification of the vale-
rolactones was pioneered by Watanabe53"56 and was the first step in the elucidation 
of the bacterial metabolism of ( + )-catechin in the colon. Catechin labelled with 14C 
in the A-ring only ([ring A-14C]catechin) and uniformly 14C-labelled catechin ([U-
14C]-catechin) were used to further substantiate this general scheme.23 Oral 
administration of valerolactones to rats and guinea pigs23,46 gave rise to the propio-
nic and benzoic acids depicted in Figure 2. The free hydroxyl group at the 3 posi-
tion of catechin was essential for ring fission in the colon by bacteria, as 3-methoxy-
( + )-catechin was resistant to ring fission in rat, mouse, marmoset57 and man.26 
Animal experiments showed that heterocyclic ring fission of ( + )-catechin was 
wholly mediated by microorganisms in the colon. In the presence of antibiotics 
which kill the microorganisms, the ring fission products were not produced.46,50 
These metabolites also were formed upon in vitro incubation of catechin with 
intestinal contents and again their formation could be suppressed by addition of 
antibiotics. Ligation of the bile duct prevents bile that contains conjugated ( + )-
catechin after intravenous injection to flow into the small intestine. After 
intravenous injection of ( + )-catechin to bile-duct ligated rats no ring fission products 
were detectable in urine,45 again showing the crucial role of the gut. 
In rats, biliary circulation was an important phenomenon in catechin metabo-
lism. Studies with bile-duct cannulated rats, showed that about 40% of orally 
administered absorbed ( + )-catechin was secreted with bile into the small 
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OH 
(+)-catechin 
Tissues 
'OH 
OH 
3'-methoxy-(+)-catechin 
- (4-hydroxy-3-methoxyphenyl) - y - valerolactone 
Tissues 
6 - (3,4-dihydroxyphenyl) - y - valerolactone 
ô - (3-hydroxyphenyl) - y - valerolactone 
3-hydroxyphenylpropionic acid 
Tissues 
3-hydroxybenzoic acid 
Figure 2. Metabolic reactions ofcatechins in body tissues and colon. (+)-Catechin 
is shown as an example. Conjugation reactions are not shown. 
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intestine.11 Only glucuronide or sulfate conjugates of catechins and 3'-methoxy-( + )-
catechin (Figure 2), the major hepatic metabolite,49 were secreted with bile. 
Catechins secreted with bile were prone to microbial degradation. Subsequently, 
after hydrolysis of the conjugates, catechin and its phenolic acid and lactone 
metabolites were reabsorbed.45,49 About 60% of the metabolites of 3-methoxy-( + )-
catechin that were secreted with bile were reabsorbed in the first enterohepatic 
circulation.57 
In conclusion, bacteria of the colon cleaved the heterocyclic ring of ( + )-
catechin to form phenyl-C5 and phenyl-C3 metabolites, which were absorbed and 
excreted into urine both in rodents and in man. In rats secretion of catechin 
conjugates into bile exposed them anew to bacterial degradation. Presence of a 
methoxy group at position 3 in ( + )-catechin made the molecule resisitant to ring 
fission in rodents as well in man. Ring fission of other types of catechins was not 
studied. 
Extent of catechin metabolism and species differences 
Unconjugated ( + )-catechin, valerolactones and phenolic acids excreted into urine 
represented only 3% of the orally administered [U-14C]-( + )-catechin in rats.23 As 
58% of the dose was excreted in urine (Table I), only 5% of this radioactivity was 
identified. On oral administration of [U-14C]-( + )-catechin to monkeys a considerably 
higher percentage, 20% of the dose, was excreted in urine as unconjugated catechin 
and its phenyl-C5, phenyl-C3, and phenyl-C, metabolites.24 Catechin accounted for 
3%, and the main metabolite 5-(3-hydroxyphenyl)-Y-valerolactone for 8% of the 
dose; conjugates of some of these metabolites and of catechin were present, but 
were not quantified. Ingestion of [U-14C]-( + )-catechin by human volunteers showed 
that ring fission was only a minor metabolic route;25 90% of the urinary radioactivity 
(50% of the dose) was composed of conjugates of ( + )-catechin and 3'-
methoxycatecbin, and their aglycones accounted for 3% of the dose. Oral 
administration of 3-[14C]-methoxy-( + )-catechin to humans showed that less than 
0.5% of the dose was excreted unchanged in urine; major metabolites were 
conjugates of the parent compound and of 3,3'-dimethoxycatechin.26 O-methylation 
of 3-methoxy-( + )-catechin was less important in man than in rodents where O-
methylation was almost 100%.26 Thus in man a major part of ( + )-catechin is 
absorbed and subsequently excreted with urine as conjugates. 
Only monkeys and humans excreted 3-hydroxyphenylhydracrylic acid in 
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urine after an oral ( + )-catechin dose (Table 2).24,47 The traces of 4-hydroxyphenolic 
acids in urine reported in one study with rats45 are puzzling, because only 3-hydro-
xyphenolic acids are expected based on the scheme depicted in Figure 2. Possibly 
some of these metabolites originate from dietary tyrosine.50 
Thus, only a few percent of orally administered ( + )-catechin and 3-methoxy-
( + )-catechin escaped metabolism. The major metabolic reactions were conjugation 
and O-methylation performed by liver cells. In man, ring fission by bacteria in the 
colon was only of minor importance for these two catechins. Only very limited data 
were found on the metabolism of an important group of dietary catechins, the 
epicatechins of tea. 
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Flavonols 
Enzymatic transformations of flavonols in body tissues 
As for catechins phase I transformation reactions for flavonols have not been 
described, and this part of their metabolism awaits study. The role of the liver in rats 
in glucuronidation and O-methylation was demonstrated by intraperitoneal injection 
of rutin (quercetin-3-rutinoside) and quercetin.58 3'-Methoxyquercetin-3-rutinoside 
and its glucuronide, and conjugates of quercetin, isorhamnetin (3'-methoxy-
quercetin) and rutin were found in bile. Both 3'-methoxyquercetin and 4'-methox-
yquercetin were reported in urine and bile of rats.28 The presence of the 4'-methoxy 
isomer was confirmed by NMR and a specific chemical reaction. Again, only o-
hydroxy-methoxy metabolites were found (Table 3), suggesting that catechol-O-
methyl transferase was involved.41 Sulfation of quercetin was studied by using 
perfusion of isolated rat liver.52 Two double sulfate/glucuronide conjugates 
constituted 85% of the biliary secreted sulfate-containing conjugates. Sulfation in 
male rats was twice that in female rats. In vitro incubations with unfractionated 
sulfotransferases of rat liver confirmed these results. 
Human data are limited. We found circumstantial evidence for the presence 
of quercetin conjugates in urine and plasma after oral administration of dietary 
quercetin to human subjects;30,62,63 acid hydrolysis of urine and plasma increased the 
concentration measured. We also found 3'-methoxyquercetin in plasma and urine 
of these subjects (Hollman et al., unpublished). 
Thus, in rats major enzymatic metabolic reactions of flavonols were located 
in the liver, and they were similar to those of catechins: glucuronidation and 
sulfation of hydroxyl groups, and O-methylation of catechol groups. Conjugation 
and O-methylation of quercetin also occurred in humans. 
Bacterial ring cleavage of flavonols in the colon 
The proposed flavonol-specific sites of ring fission are depicted by arrows in Figure 
3. The proposed scheme accounts for the phenylacetic acids (phenyl-C2) and the 
phenylpropionic acids (phenyl-C3) found in various species (Table 3). However, 
direct experimental proof for these types of ring fission in flavonols is not available. 
The phloroglucinol (1,3,5-trihydroxybenzene) and phloroglucinolcarboxylic acid 
(2,4,6,-trihydroxybenzoic acid) found in urine of rats after oral administration of 
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o C H 3 
OH 
ÓH 6 
3'-methoxyquercetin 
OH O 
quercetin 
Colon 
Colon 
OH 
H 0 Y ^ 
OH 
3,4-dihydroxycinnamic acid 
Colon 
3,4-dihydroxyphenylpropionic acid 
Tissues Colon 
OCH3 
3,4-dihydroxyphenylacetic acid 4-hydroxy-3-methoxyphenylpropionic acid 3-hydroxyphenylpropionic acid 
Colon Tissues 
OH OCH3 
OH 
HO HO 
3-hydroxyphenylacetic acid 4-hydroxy-3-methoxyphenylacetic acid 
Tissues 
OH 
HO 
3-hydroxybenzoic acid 
Figure 3. Metabolic reactions of flavonols in body tissues and colon. Quercetin is 
shown as an example. Conjugation reactions are not shown. 
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quercetin pointed to metabolites with an intact A-ring of quercetin,64 but they turned 
out to be analytical artefacts.27,61 Oral administration of 3,4,5-trihydroxyphenylacetic 
acid to rats produced 3,4- dihydroxy- and 3-hydroxyphenylacetic acid, which are 
metabolites of myricetin (3,5,7,3',4',5'-hexahydroxyflavone).22 Similar to ( + )-
catechin, these results indicated that the phenolic acids formed only had an intact 
B-ring {Figure 3). Microorganisms mediated these dehydroxylation reactions. 
The phenylacetic acids, typical for the proposed ring fission of quercetin, 
rutin (quercetin-3-O-rutinoside) and myricetin were not found in rats treated with 
an antibiotic to suppress microorganisms.22,59,65 In vitro anaerobic incubation of 
myricetin, myricitrin (myricetin-3-0-rhamnoside)22and rutin65 with rat caecal micro-
organisms also produced the metabolites observed in urine after oral administration. 
Mucosal membranes of the small intestine as well as contents of duodenum, 
jejunum and ileum were unable to metabolise quercetin in rats,28 as opposed to the 
contents of caecum and colon. Thus, microorganisms in the colon cause ring fission 
of flavonols. The absence of these ring fission products after intraperitoneal injection 
of rutin in bile duct cannulated rats is an additional indication for the exclusive role 
of microorganisms in ring fission of flavonols.65 Biliary circulation of quercetin was 
indicated by the occurrence of glucuronides and sulfates of quercetin in bile.28,58 
However, no data are available about the extent of biliary secretion and 
reabsorption. 
In plant foods flavonols mainly occur as glycosides. As expected, the 
metabolites of quercetin and of rutin, the 3-rutinoside of quercetin, were similar 
(Table 3 and 4); microorganisms of the colon probably first hydrolysed rutin to 
produce quercetin. The rutinose moiety was also removed from quercetin-7-0-(ß-
hydroxyethyl)rutinoside by microorganisms in the colon of dogs,67 but, this 
aglycone was stable against ring fission. The explanation is probably that the ß-
hydroxyethyl group is resistant to microbial hydrolysis. This showed that substitu-
ents bound to hydroxyls that are resistant to hydrolysis by the gut microorganisms, 
can have a profound effect on the stability of the ring system. However, the 
microflora of rats was capable of ring fission of quercetin-7-0-(ß-hydroxyethyl)-
rutinoside,68 but failed in the case of quercetin-7,3',4'-tri-0- and quercetin-5,7,3',4'-
tetra-0-(ß-hydroxyethyl)rutinoside. Another interesting observation was made by 
Griffiths22 who found that robinetin (3,7,3',4',5'-pentahydroxyflavone) was not 
degraded to phenolic acids in rats, and also was stable upon incubation with 
microorganisms. Robinetin lacks the hydroxyl group at position 5 as compared to 
myricetin which is degraded as expected (Table 4). 
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In summary, bacteria of the colon cleaved the heterocyclic ring of flavonols 
to form phenyl-C3 and phenyl-C2 metabolites, which were absorbed and excreted 
into urine. These metabolites were found in rodents as well in humans, although 
most of these studies were performed with rodents. Glycosylation could not 
stabilize the ring structure as opposed to substituents that formed non-hydrolysabie 
bonds with hydroxy I groups. Secretion into bile of flavonol conjugates may 
contribute to additional bacterial degradation. 
Extent of flavonol metabolism 
Quantitave studies are limited, and available only for quercetin. Rats did not excrete 
the aglycone in urine after oral administration of quercetin aglycone;28 1.7% of the 
dose was excreted as glucuronide and sulfate conjugates of quercetin, while 
monomethoxylated quercetin conjugates accounted for 3.6%. This accounts for 
about half of the urinary metabolites in these rats, as 13% of the administered 
radioactivity was excreted in urine (Table 1). 
In humans, less than 1 % of the orally administered aglycone was estimated 
to reach the circulation unchanged.29 We found that humans who were fed 
quercetin or quercetin glycosides excreted only 0.1% to 0.3% of the dose as 
unchanged quercetin or its conjugates in urine (Table 7), whereas absorption 
amounted to 20 - 50%.30 In these human subjects less than 0.5% of the dose was 
excreted as 3'-methoxyquercetin (Hollman et al., unpublished). 
These data indicate that quercetin is extensively metabolised in rats and 
humans. Only a small part of these metabolites has been quantified. In contrast with 
( + )-catechin in humans, quercetin is metabolised only to a limited extent via 
conjugation with sulfate, glucuronic acid or O-methylation. 
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Flavones and flavanones 
Enzymatic transformations of flavones and flavanones in body tissues 
Evidence for oxidative phase I reactions of flavones was found in guinea pigs. After 
intraperitoneal and oral administration of a synthetic flavone lacking hydroxyl 
groups both 4'-hydroxy-and 3',4'-dihydroxyflavone were excreted in urine.69 Oral 
administration of a flavanone lacking hydroxyl groups to rats introduced hydroxyl 
groups at the 3 or 6 position,32,70 and these metabolites were excreted in urine. 
However, proof for the involvement of the liver was not given. Several metabolites 
formed by reduction of the carbonyl group, for instance flavan-4-a-ol, were 
identified. However, the corresponding reduction of flavone was never found.69 
Phase II reactions were demonstrated by many workers. Conjugation of baicalein 
(5,6,7-trihydroxyflavone) and baicalein-6-glucuronide was shown in rats: five con-
jugates were identified in bile.71 Baicalein conjugated with two glucuronic acid 
molecules and the mixed conjugate containing one glucuronic acid and one sulfate 
predominated.71 This is in accordance with observations that high molecular weight 
and high polarity of compounds facilitates their secretion with bile.40 A study with 
isolated perfused rat liver72 showed that diosmin (5,7,3'-trihydroxy-4'-methoxy-
flavone-7-rutinoside) was secreted with bile as such and as its glucuronide 
conjugate; diosmetin (5,7,3'-trihydroxy-4'-methoxyflavone) was only secreted as 
sulfate and glucuronide conjugates. Oral administration of naringin (5,7,4'-
trihydroxyflavanone-7-rhamnoglucoside) and hesperidin (5,7,3'-trihydroxy-4'-
methoxyflavanone-7-rutinoside) to rats showed that, besides the glucuronides, also 
the parent glycosides were secreted into bile.33 On oral administration of diosmetin 
to rats its glucuronide appeared within minutes in portal venous blood, and no 
aglycone could be detected.73 This suggests that the glucuronide was produced on 
absorption at the level of the intestinal mucosa. It is documented74 that intestinal 
mucosa were important for extrahepatic glucuronidation. In vivo as well in vitro (rat 
liver microsomes), 5-hydroxyflavone was glucuronidated.73 This is remarkable, 
because the 5-hydroxyl group is strongly stabilized by the 4-keto group, or is 
involved in chelation. Glucuronidation in rats of 7,5-dihydroxyflavone occurred 
mainly at the 7-position, and of 5,7,3'-trihydroxyflavone at the 7- and 3'-position.73 
Tangeretin (5,6,7,8,4'-pentamethoxyflavone) was O-demethylated by rat and 
human liver microsomes;75 the metabolites formed were not identified separately. 
Anaerobic incubation of [3-,4C]hesperetin with rat caecal microorganisms 
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only produced phenylpropionic acids and no 14C02 nor phenylbenzoic acids 
{Figure 4).TW\s suggested that ß-oxidation of the propyl chain of the phenylpropionic 
acids was not mediated by bacterial enzymes, but by mammalian enzymes.31 
In conclusion, flavones and flavanones were metabolised by liver enzymes 
to give sulfates, glucuronides, and mixed sulfates/glucuronides which were excreted 
into bile, urine and plasma. Only glucuronides or sulfates were secreted with bile, 
except for rhamnoglucosides which were secreted as such. Glucuronidation in the 
intestinal mucosa was observed. These studies were only performed with rats. In 
addition, O-methylation of catechol groups and O-demethylation occurred in 
humans and rats. ß-Oxidation of phenylpropionic acids was found in rats. 
Bacterial ring cleavage of flavanones and flavones in the colon 
The specific sites of ring fission for flavones and flavanones are shown by arrows in 
Figure 4. The proposed scheme accounts for the phenylpropionic acids (phenyl-C3) 
reported in body fluids of various species after various flavones and flavanones 
(Table 5,6). A study with 14C-labelled hesperetin ([3- 14 C]5,7,3'-trihydroxy-4'-
methoxyflavanone) in rats identified the predicted 14C-labelled phenylpropionic 
acids.31 Anaerobic incubation of [3-14C]hesperetin with caecal microorganisms did 
not produce 14C02, which indicated that ß-oxidation of the propyl chain of the 
phenylpropionic acid was not caused by bacterial enzymes but by mammalian 
enzymes. 
The dose clearly affected the metabolites formed. After a very low oral dose, 
only ring cleavage products were found in urine,31 whereas a more than 100 fold 
increase of the oral dose, the common dose in these experiments, also produced 
metabolites with an intact ring structure.33,77 
The synthetic flavone69 and flavanone76 both lacking hydroxyl groups were 
not cleaved by microorganisms, as no phenolic acids were excreted, and metabo-
lites did not change after administration of antibiotics.69 Experiments with various 
flavones with 5,7-hydroxylation showed that at least one free hydroxyl group in ring 
B was required for ring fission.22 
To summarise, microorganisms in the colon of rats cleaved the heterocyclic 
ring only of hydroxylated flavones and flavanones to form phenyl-C3 metabolites, 
which were absorbed and excreted into urine. Metabolism of flavanones by bacteria 
in rodents and humans lead to similar metabolites. Human data on metabolism of 
flavones are not available. 
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OCH3 
HO. 
3-hydroxybenzoic acid 
Colon 
Tissues 
HO. 
OH 
3-hydroxy-4-methoxycinnamic acid 
OCH3 
3-hydroxy-4-methoxyphenylpropionicacid 
OH 
3,4-dihydroxyphenylpropionic acid 
3-hydroxyphenylpropionic acid 
Figure 4. Metabolic reactions of flavanones in body tissues and colon. Hesperetin 
is shown as an example. Flavones show similar reactions. Conjugation reactions are 
not shown. 
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58 CHAPTER 2 
Anthocyanidins 
The limited data available on the metabolism of anthocyanidins indicate that these 
flavylium flavonoids are metabolised to a much more limited extent than other 
flavonoids. Cyanidin (3,5,7,3',4'-pentahydroxyflavylium) was not converted to 
phenolic metabolites when incubated with rat caecal bacteria.20 Delphinidin (3,5,7,-
3',4',5'-hexahydroxyflavilium) and malvin (3,5,7,4'-tetrahydroxy-3',5'-dimethoxy 
flavylium-3,5-diglucoside) fed to rats or incubated with microorganisms were not 
metabolized to identifiable compounds, but phenolic compounds could be 
excluded.22 After intravenous administration of an extract of Vaccinium myrtillus to 
rats, 20% of the administered dose (based on direct colorimetric measurement) was 
excreted as such into urine.81 
Phenolic acids 
Ring fission of flavonoids generates phenolic acids that are absorbed and excreted 
into urine (Tables 1 - 6). The primary ring fission products (Figure 2-4) are suscep-
tible to supplemental metabolism by bacteria in the colon and, after absorption, also 
by enzymes in body tissues. The major questions are: what are the metabolic reac-
tions acting upon these primary phenolic acids, and what affects these reactions? 
Degradation of primary ring fission products of flavonoids by bacteria in the colon 
In vitro incubations of cinnamic (phenyl-C3), phenylpropionic (phenyl-C3), and phe-
nylacetic (phenyl-C2) acids with rat caecal bacteria82 demonstrated that these 
microorganisms performed the following metabolic reactions. Dehydroxylation of 
3,4-dihydroxyphenylpropionic and 3,4-dihydroxyphenylacetic acids to produce 3-
hydroxyphenolic acids.22 Demethylation of o-hydroxymethoxyphenolic acids. 
Reduction of the double bond of cinnamic acids to produce phenylpropionic acids. 
Decarboxylation of cinnamic and phenylacetic acids, but only when a hydroxyl 
group at position 4 was present. Decarboxylation of the phenylpropionic acids did 
not occur. Also after oral administration of 3,4,5-trihydroxyphenylacetic acid, a pro-
posed primary fission product of myricetin, to rats, dehydroxylation was confirmed 
and produced 3,4-dihydroxyphenylacetic and 3-hydroxyphenylacetic acid which 
were excreted in urine.22 Dehydroxylation of 5-(3,4-dihydroxyphenyl)-Y-valero-
ABSORPTION AND DISPOSITION OF FLAVONOIDS 59 
lactone, the primary ring fission product of ( + )-catechin, was demonstrated in 
guinea pigs.46 
Species differences in these metabolic reactions of bacteria were observed. 
In rabbits no decarboxylation of 3,4-dihydroxyphenylacetic acid occurred.83 ß; 
Hydroxylation of phenylpropionic acids which produced phenylhydracrylic acids 
was only observed in man and monkeys24'65,66,77 and it was demonstrated that 
bacteria in the colon carried out this reaction. 
Enzymatic transformations of phenolic acids in body tissues 
Conjugation of 3-hydroxybenzoic acid with glycine to form 3-hydroxyhippuric acid 
occurred in rodents and man (Table 2), probably in the renal tissues.84 Conjugation 
with glucuronic acid or sulfate of valerolactones,47 of phenylpropionic acids24,31,46,47 
and phenylacetic acids61 was generally found. o-Hydroxymethoxy phenolic acids 
excreted in urine (Table 2 - 6 ) could have originated from ring fission of O-
methylated flavonoids secreted with bile. However absorbed ring fission products 
were also O-methylated in guinea pigs,46 rats,85"87 and man.87 
Phenylpropionic acids were converted to benzoic acids by ß-oxidation of the propyl 
chain in all species.2325,3'46,59,77 It was shown that only tissue enzymes could have 
been involved. 
In conclusion, administration of flavonoids in vivo yielded a range of 
substituted phenolic acids in urine (Table 2 -6). The presence of these compounds 
could be explained by the bacterial and tissue enzymatic reactions that act upon 
phenolic acids. Species differences in these metabolic reactions occurred to some 
extent. 
PHARMACOKINETICS 
A quantity of major interest in assessing the biological effects of flavonoids, or 
indeed of any food component or drug, is the bioavailability. Bioavailability 
quantitates the exposure of the body (excluding gut and liver) to the substance in 
question. Bioavailability is often mistakenly equated with absorption. However, 
bioavailability also includes first-pass metabolism. Bioavailability is defined as the 
percentage of the ingested flavonoid amount that enters the blood circulation intact 
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after passage through the liver.40 It is determined experimentally by giving a 
flavonoid orally and intravenously and then measuring the ratio of the areas under 
the plasma flavonoid concentration versus time curves (AUCs). The fate of flavo-
noids in the body after ingestion is determined by their absorption, distribution and 
elimination, which each have their own rates and extents. Pharmacokinetic para-
meters are needed to describe and to predict these processes. Subsequently, 
predictions of dosage-dependency of plasma levels, achievable plasma levels, and 
accumulation can be made. 
Catechins 
The maximum plasma concentration of ( + )-catechin and its metabolites was reach-
ed after 1 - 3 h, and elimination half-life of the aglycone was about 1 h (Table 7). By 
the time that the maximum concentration in plasma was reached, only about 10% 
of the catechin was present unchanged.25 Differences between Cmaxs found by 48 
and88 are probably explained by the inclusion of conjugates in the data of48 but not 
of.88 In plasma, 14C activity was present up to 120 hours, indicating a long persis-
tence of metabolites.25 A linear relation between the administered dose and the area 
under the plasma concentration versus time curve (AUC) was found in humans.88 
This indicates that there was no saturable gastro-intestinal absorption and/or no dose 
dependent first-pass effect of the liver up to an oral dose of 30 mg/kg. The rate of ab-
sorption of 3-methoxy-( + )-catechin26 was similar to that of ( + )-catechin {Table 7). 
However, the elimination half-life of total 14C activity after 3-methoxy-( + )-catechin 
was considerably higher, whereas the elimination of the parent 3-methoxy-( + )-
catechin appeared to be very rapid. This could point to storage of 3-methoxy-( + )-
catechin or a metabolite in tissues, and subsequent slow release of metabolites. The 
rate of absorption of various epicatechins of green tea seemed to be dependent on 
the type of catechin.36 
Thus, pharmacokinetic data of catechins are scarce, and bioavailability has 
not been determined. Absorption was moderately rapid, and elimination of the ( + )-
catechin aglycone was rapid. 
Flavonols 
After a high oral dose of quercetin aglycone no quercetin aglycone was detected in 
plasma in man29 (Table 7). Possibly the major fraction of plasma quercetin is conju-
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gated to g lucuronic acid or sulfate. This cou ld explain w h y Gugler et a l . 2 9 detected 
no quercet in in plasma: these authors determined on l y the aglycone, using a 
me thod w i t h a high l imi t of detect ion (100 ng/ml). Flavonol glycosides showed 
moderate to rapid absorpt ion in man.62 ,63 ,90 We62,63 compared the absorpt ion of 
quercet in f rom on ions, apples and rut in , and found dist inct differences in rates of 
absorpt ion. On ions contain main ly quercetin-ß-glucosides, whereas apples conta in 
a m ix tu re of quercetin-ß-D-galactosides, and ß-D-xylosides, whereas quercet in is 
bound to a disaccharide in rut in. W e hypothesized that the rapid and better absorp-
t ion of the quercet in g lucoside in onions was caused by the glucose transporter in 
the small intestine.30 '62 '63 Indeed model studies95 showed that naphthol glucosides 
were transported by the active NaVglucose transporter across the intestinal wa l l of 
rats. The e l im ina t ion of quercet in f rom plasma was s low in our studies, w h i c h im -
p l ied that quercet in may accumulate in plasma throughout the day w i t h repeated 
dietary intake. The bioavai labi l i ty of quercetin in apples and of rutin were both 3 0 % 
of that in on ions. The important role of the sugar moie ty in the absorpt ion of 
-cetin was also found in a study w i th i leostomy subjects w h o lack a co lon w i t h 
' ia l f lora.3 0 The quercet in glucoside in onions was very we l l absorbed, 
^ i o n of the pure quercet in aglycone and quercet in rut inoside was 
'r inary excretion of total quercetin in these subjects was highest 
~osides. Thus, the dif ferent types of glycosides in these 
~>nd metabol ism. 
'ai labi l i ty of f lavonols has not been determined, 
bsorption of quercet in varied between food 
>,7,3'-tr ihydroxy-4'-methoxyflavone), was not 
.nistration to human volunteers.9 3 Hydrolys is of 
ed , and the e l im ina t ion of d iosmet in f rom plasma 
vv j m elimination of tritium was very slow after admini-
strât! ats.92 Absolute bioavailability of 5-methoxyflavone was 
led ,, and was high: 25% for rats, and 53% for dogs.94 
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Tissue distribution of flavonoids 
The extended elimination times observed for quercetin and diosmin in humans 
(Table 7) could point to temporary storage of flavonoids or their metabolites in 
tissues. Studies on tissue distribution were carried out with various labelled flavo-
noids. After oral administration of [3H]-diosmin to rats the highest concentration of 
3H was found in liver.92 However, 3H started to accumulate in tissue of veins and 
arteries after 4 hours and still was increasing at the last time (48 h) measured. It was 
suggested that a metabolite was accumulating in these tissues. The radioactivity 
associated with 3-[14C]methoxy-( + )-catechin was only recovered with the contents 
of the alimentary tract; this was caused by enterohepatic circulation of the major 
metabolite.57 The distribution of radioactivity in tissues of the rat after oral admini-
stration of [4-uC]quercetin28 showed no evidence for accumulation in any tissue. Six 
hours after administration the highest radioactivity (0.3% of the administered dose 
per gram wet organ) was found in the kidney, with liver and blood having some-
what lower concentrations. Because of the position of the label in the quercetin 
molecule, only quercetin and metabolites with an intact ring structure and phenyl-
propionic acids would have been detected. Recovery of radioactivity in organs of 
rats (liver, kidneys, spleen, stomach and gut) was 1.4% of the activity of orally 
administered [3-14C]hesperetin.31 
More than 98% of the quercetin in human plasma was bound to proteins.29 
Binding of quercetin to human albumin was 70% -80%.96 These observations were 
confirmed by ultrafiltration;97 after ultrafiltration to exclude proteins larger than 30 
kDa, quercetin was absent in the filtrate of plasma of rats fed quercetin and rutin. 
Binding of flavonoids to proteins is well-documented.98 Quercetin and rutin, but not 
( + )-catechin and 3-methoxy-( + )-catechin were selectively bound to platelets of 
rabbits in vitro." 
Thus, the limited data available do not point to storage of intact flavonoids 
in tissues. However, evidence for accumulation of metabolites was found for 
diosmin. 
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SUMMARY AND CONCLUSIONS 
Most studies on absorption and metabolism of flavonoids have focused on measur-
ing their urinary metabolites in rodents. Absorption was estimated by measuring 
urinary excretion using pure aglycones administered at unphysiologically high 
doses. Absorption as measured this way depended on the type of flavonoid and was 
between 4 and 58%. The extent of absorption from dietary sources is largely 
unknown; for instance, data on the catechins of tea, which is a major dietary source 
are virtually absent. In the diet, most flavonoids except catechins are present not as 
aglycones but as glycosides. It used to be thought that intact glycosides are not 
absorbed. However, recently it was found that quercetin glucoside was in fact ab-
sorbed much better than the aglycone; this topic thus needs rethinking. Proteins in 
the diet may theoretically affect flavonoid absorption because they bind polyphe-
nols.98 Circumstantial evidence for reduced absorption of tea polyphenols by 
complexation with milk proteins was found in humans;100 ingestion of tea caused 
a significant increase of the plasma antioxidant capacity, but not when tea was 
consumed with milk. However, these authors did not determine polyphenols in 
plasma. Research on this interaction needs to be done. 
The two major sites of flavonoid metabolism are the liver and the colonic 
flora. Only the liver has been investigated as a metabolic organ. Other tissues such 
as intestine wall and kidneys may play a role. Phase I biotransformation reactions 
of liver enzymes have been described only for synthetic flavonoids lacking hydroxyl 
groups, but evidence for phase II biotrans-formation is abundant. Absorbed 
flavonoids and their absorbed colonic metabolites are glucuronidated and sulfated 
by the liver in humans as well in rodents, but the types of glucuronides and the 
preference for sulfation may vary between species. O-methylation of catechol 
groups is found in humans and rodents. Unabsorbed flavonoids and flavonoid 
conjugates secreted with bile into the gut are degraded by bacteria in the colon. 
Hydrolysis of conjugates and glycosides, and ring fission of the aglycones to 
phenolic acids are the major bacterial reactions. In rats, the metabolites are then 
absorbed and excreted in urine. However, very few quantitative data on metabolism 
are available. In metabolism of ( + )-catechin ring fission is of minor importance in 
humans. With other flavonoids, the rather high excretion of C02 , about one third 
of the dose, points to notable ring fission in rats. 
In humans, conjugation and O-methylation of quercetin occurs only to a 
limited extent, whereas these reactions are of major importance for ( + )-catechin 
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metabolism. One would expect biliary secretion also to occur in man, as glucuro-
nides of flavonoids have molecular weights in excess of 500.39 However, the 
significance of biliary secretion and reabsorption in humans is unknown. 
Pharmacokinetic data on flavonoids are scarce, probably because selective 
and sensitive analytical methods to determine flavonoids and their metabolites in 
plasma, urine and tissues were lacking. Absolute bioavailability of flavonoids has 
not been determined, but it is becoming evident that relative bioavailability of 
flavonols differs markedly between foods. 
In order to evaluate the impact of dietary flavonoids on human health we 
need more information on how the nature of the glycoside moiety and of the food 
matrix affect absorption and metabolism. Such studies should be performed at the 
low levels of intake which occur naturally, as the high doses used in earlier studies 
may produce artefacts. Identification of metabolites in body fluids and tissues is also 
an important goal for further research. 
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Abstract 
Flavonols are dietary antioxidants which might prevent coronary heart disease. To 
be able to study absorption of flavonols in man, we developed a postcolumn 
derivatization with aluminum for HPLC with fluorescence detection. Variables 
governing postcolumn chelation, such as water content, buffer, and organic 
modifier of the eluent, concentration of Al3+ and presence of acetic acid in the 
postcolumn reagent, and temperature were studied and optimized. Of the 
flavonoids, only flavonols that contain a free 3-hydroxyl and 4-keto oxygen binding 
site form fluorescent complexes with Al3+. The method has a detection limit of 0.15 
ng/mL for quercetin, 0.05 ng/mL for kaempferol, 0.45 ng/mL for myricetin, and 0.05 
mg/mL for isorhamnetin, thus improving detectabiIity of quercetin 300 fold as 
compared to that possible with UV detection. The reproducibility relative standard 
deviation of the method is 1.4%. This extremely sensitive method enables, for the 
first time, determination of flavonols in body fluids after consumption of a normal 
diet. 
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INTRODUCTION 
Flavonoids are polyphenolic compounds that occur ubiquitously in foods of plant 
origin. Flavonoids are categorized into flavonols, flavones, catechins, flavanones, 
anthocyanidins, and isoflavonoids.1 Potent biological effects have been described 
in many in vivo and in vitro studies.2 These studies point to potentially beneficial 
health effects of dietary flavonoids.3 Recently, it was found that the intake of 
quercetin, the major representative of the flavonol subclass {Figure 7), was inversely 
associated with subsequent coronary heart disease in two prospective cohort 
studies,4,5 and a prospective cross-cultural study.6 The antioxidant properties of 
flavonoids7 offer a plausible explanation for the effect found.8,9 However, the extent 
of absorption of flavonoids is an important unsolved problem in judging their 
potential role in the prevention of coronary heart disease. 
For human absorption studies, we needed to determine flavonols in blood 
and urine. An HPLC method with UV detection previously developed10 did not 
meet the requirements of sensitivity and specificity in these biological fluids. Thus, 
extensive sample enrichment and cleanup procedures had to be considered. 
However, the enrichment attainable would most likely not be sufficient. 
Consequently, a very sensitive detection technique had to be explored. Fluorometry 
would be most suited to achieve the detection limit required. In addition, the 
potential gain in specificity over UV detection could simplify, or even make 
redundant, sample cleanup. 
Flavonols such as quercetin and morin can form fluorescent chelates with a 
variety of metal ions, and before the advent of atomic absorption spectroscopy at 
the end of the 1960s, morin was used to quantitate a variety of metal ions by 
fluorometry.11 Aluminum chloride as a complexing agent is used routinely in thin-
layer chromatography to aid identification of the flavonoid type.12 Nieder13 very 
briefly mentioned the use of aluminum chloride as a postcolumn reagent in HPLC 
with fluorescence detection to determine flavonols in plasma. However, no details 
about postcolumn reaction conditions were presented. 
The present study was designed to find optimum reaction conditions for 
postcolumn derivatization of quercetin with aluminum, as quercetin is the major 
dietary flavonol.4 In addition, we studied structural properties of flavonols that are 
required in order to form fluorescent chelates with aluminum. The HPLC conditions 
for separation of flavonoids previously optimized were used as a starting point. 
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OH 
Figure 1. Structures of flavonols, flavones and catechins. 
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EXPERIMENTAL SECTION 
Chemicals 
All chemicals were reagent grade or HPLC grade. 
Fluorescence spectrometer 
Fluorescence excitation and emission spectra were recorded with a Perkin Elmer LS 
50 B luminescence spectrometer equipped with Fluorescent Data Manager software 
(Perkin Elmer, Norwalk, CT). Wavelengths of excitation and emission maxima of 
each flavonoid were determined in 'Prescan mode', varying excitation wavelength 
from 200 to 450 nm and emission wavelength from 450 to 700 nm, with slits set at 
10.0 nm. The final spectra were recorded at 240 nm/min, with slits set at 5.0 nm. 
Spectra were processed with Slidewrite 6.0 (Advanced Graphics Software Inc., 
Sunnyvale, CA). Fluorescence spectra of flavonoid standards were recorded both in 
the eluent (acetonitrile/0.025 M phosphate buffer, pH 2.4, 31:69 v/v), and in the 
mixture of eluent and aluminum nitrate reagent (proportion, 1 : 0.4) present in the 
postcolumn reactor when using optimized HPLC conditions. The aluminum nitrate 
reagent consisted of 1.5 M AI(N03)3 in methanol containing 7.2% (v/v) acetic acid. 
Equimolar solutions (700 nM) of standards were tested in both conditions. 
Chromatography 
For HPLC analysis we injected 20 fjl of the sample onto an Inertsil ODS-2 column 
(4.6 mm x 150 mm, 5//m; GL Sciences Inc., Tokyo, Japan), protected by an MPLC 
Newguard RP-18 column (3.2 mm x 15 mm, 7/vm; Brownlee, Applied Biosystems 
Inc., Foster City, CA) using acetonitrile/0.025 M phosphate buffer pH 2.4 (31:69 v/v) 
as mobile phase, at a flow rate of 1 mL/min using a Merck Hitachi L-6200 A pump 
(Hitachi Ltd., Tokyo, Japan). The columns were placed in a column oven set at 30 
°C. The column effluent was mixed with 0.4 mL/min 1.5 M AI(N03)3 in methanol 
containing 7.2% (v/v) acetic acid in a postcolumn reactor placed in the column 
oven. The postcolumn reactor consisted of a 15 m (0.25 mm internal diameter) PTFE 
tubing (Upchurch Scientific Inc., Oak Harbor, WA) coiled to a diameter of 3 cm and 
connected to the HPLC column with a low-dead-volume tee (Upchurch Scientific 
Inc., Oak Harbor, WA). Column effluent and aluminum reagent entered the tee 
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countercurrently at an angle of 180°. A Merck Hitachi L-6000 A pump was used to 
generate the aluminum reagent. The fluorescence of the ensuing quercetin-metal 
complex was measured at 485 nm using a Jasco FP 920 Uasco Corporation, Tokyo, 
Japan) fluorescence detector with excitation wavelength set at 422 nm. The detector 
output was sampled using a Nelson (PE Nelson, Cupertino, CA) series 900 interface 
and Nelson integrator software (model 2600, rev. 5), and the peak area of the 
quercetin-metal complex was determined. 
RESULTS 
Fluorescence spectra 
None of the flavonols and flavones (Figure 1) showed native fluorescence in the 
eluent. However, fluorescence of certain flavonols dissolved in the mixture of 
eluent and aluminum reagent was high, indicating that aluminum had a profound 
effect {Figure 2). The fluorescence was stable within 10 s after mixing. The 
fluorescence intensities of the various AI3+-flavonol complexes varied considerably 
{Table 1). 
Postcolumn reaction conditions 
The residence time in the postcolumn reactor had to be at least 40 s to achieve a 
substantial enhancement of the detector response (Table 2). Increase of the length 
of the reactor coil beyond 20 m only had a marginal effect. Peak broadening caused 
by the increasing reactor volume was about 1 s (Table 2), which can be expected 
for tubular reactors.14 
Equimolar solutions of AI(N03)3 and AICI3 in methanol did not differ in 
detector response and band broadening. Other solvents such as ethanol, acetone 
and acetonitrile were not suitable, because the solubility of both salts in these 
solvents was limited. A solution of 0.8 M Al3+ could not be obtained. 
The detector response increased with the square root of the aluminum 
concentration (Figure 3). Although AI(N03)3 concentrations in excess of 1.5 M are 
expected to increase the detector response, the high viscosity of the reagent at 
1.5 M AI(N03)3 already required a very high pressure (5000 kPa) in order to reach 
a reagent flow of 0.4 mL/min. We observed that acetic acid added into the 
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Figure 2. Fluorescence excitation and emission spectra offlavonols after complex-
ation with aluminum. Flavonols were dissolved in the mixture of eluent and 
aluminum reagent present in the postcolumn reactor when using optimized 
conditions for quercetin. Fluorescence intensity is expressed in arbitrary units. 
Is, isorhamnetin; Ka, kaempferol; Mo, morin; My, myricetin; Qu, quercetin 
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aluminum reagent decreased the risk of clogging of the coil. As acetic acid also 
chelates with Al3 + , experiments were carried out with and without acetic acid. A 
fixed concentration of 7.2% (v/v) was used. No clear effect of acetic acid on the 
detector response was apparent (Figure 3). However, omission of acetic acid 
increased the frequency of clogging at high AI(N03)3 concentrations. 
Table 1. Wavelengths of excitation and emission maxima, and corresponding 
relative fluorescence intensities of various flavonoids dissolved in the mixture of 
eluent and aluminum reagent present in the postcolumn reactor when using 
optimized conditions for quercetin. 
Flavonoid 
Flavonols 
Morin 
Kaempferol 
Isorhamnetin 
Quercetin 
Myricetin 
Rutin 
Flavones 
Luteolin 
Apigenin 
Catechins 
( + )-catechin 
(-)-epicatechin 
Maxima 
^excitation 
(nm) 
418 
420 
430 
430 
428 
-
-
-
-
_ 
emission 
(nm) 
490 
470 
480 
480 
500 
-
. 
-
-
_ 
Relative 
fluorescence 
intensity 
(%) 
100 
56 
54 
21 
7 
0 
0 
0 
0 
0 
• no fluorescence could be observed 
The highest response was obtained at 34°C, although this maximum was 
rather broad (Figure 4). Thus, a rise in temperature from 24 to 34°C increased the 
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peak area by 30%. At temperatures higher than 30°C, the detector signal was less 
stable, as spikes were observed frequently. 
Methanol and acetonitrile are commonly used as organic modifiers in 
reversed-phase HPLC. Increasing water contents in the eluent caused a dramatic 
drop in detector response for both modifiers (Figure 5). Acetic acid added to the 
AI3(N03)3 reagent reduced this loss of response in the case of methanol. The 
detrimental effect of water in the acetonitrile-containing eluent was somewhat 
counteracted by acetic acid, but only at high water concentrations (>45%). To 
obtain an adequate separation on the reversed-phase column used, the water 
content of the eluent with acetonitrile has to be about 70%, thus reducing the 
detector response to only 20% of the maximum achievable value. The maximum 
detector response was similar for methanol and acetonitrile. The decrease in detec-
tor response at <10% water in acetonitrile probably is caused by the moderate 
solubility of AI(N03)3 in acetonitrile. 
Table 2. Length of reaction coil and HPLC detector response as a percentage of the 
maximum quercetin-Al-complex peak area. Postcolumn reagent: 0.8 M 
AI(N03 )3 ; internal diameter of coil in postcolumn reactor: 0.30 mm; temperature 
of column and postcolumn reactor: 22°C. 
Length coil 
(m) 
1.2' 
10 
20 
30 
Volume 
reactor 
w 
60 
710 
1415 
2120 
Detector 
response 
(%) 
19 
70 
89 
100 
Residence time* 
(sec) 
348 
389 
428 
471 
Peak variance 
(sec2) 
34 
39 
40 
43 
internal diameter coil postcolumn reactor - 0.25 mm 
total residence time in analytical column plus postcolumn reactor 
It was shown previously10 previously that a phosphate buffer (pH 2.4) 
improves the peak shape of flavonols in the reversed-phase chromatographic system 
used. This phosphate buffer enhanced the detector response (Figure 6). Highest 
response was obtained at buffer concentrations between 10 and 30 mM, which 
coincides with optimum chromatographic conditions for flavonols.10 Addition of 
phosphoric acid to the AI(N03)3 reagent decreased the detector response only when 
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when using the eiuent with phosphate buffer. 
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Figure 3. HPLC detector response to quercetin as a function of the AI(N03 )3 
concentration in the postcolumn reagent. Detector response is expressed as a 
percentage of the maximum quercetin-Al complex peak area. Each point represents 
the average detector response of two measurements. 
Eiuent: acetonitrile/25 mM phosphate buffer, pH 2.4 (31:69 v/v). Column and 
postcolumn reactor temperature: 30°C. 
; AI(N03 )3 with 7.2% acetic acid; o, Al(N03 )3 without acetic acid 
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Figure 4. HPLC detector response to quercetin as a function of the postcolumn 
temperature. Detector response is expressed as a percentage of the maximum 
quercetin-Al complex peak area. Each point represents the average detector 
response of two measurements. 
Eluent: acetonitrile/25 mM phosphate buffer, pH 2.4 (31:69 v/v). Postcolumn 
reagent: 1.5 M Al(N03 )3 with 7.2% acetic acid. 
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Figure 5. H PLC detector response to quercetin as a function of the water content 
in eluents. Detector response is expressed as a percentage of the maximum 
quercetin-Al complex peak are. Each point represents the average detector response 
of two measurements. 
Eluent: acetonitrile or methanol without phosphate buffer; postcolumn reagent: 1.5 
M Al(N03 )3 ; temperature of column and postcolumn reactor: 30°'C. 
•, acetonitrile, Al(N03 )3 with 7.2% acetic acid; o, acetonitrile, Al(N03 )3 without 
acetic acid; A, methanol, Al(N03 )3 with 7.2% acetic acid; A, methanol, Al(N03 )3 
without acetic acid. 
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Figure 6. H PLC detector response to quercetin as a function of the buffer concent-
ration (pH 2.4) in the eluent. Detector response is expressed as a percentage of the 
maximum quercetin-Al complex peak area. Each point represents the average 
detector response of two measurements. 
Eluent: acetonitrile/25 mM phosphate buffer, pH = 2.4 (31:69 v/v). Postcolumn 
reagent: 1.5 M AlfNO^j with 7.2% acetic acid. Temperature of column and 
postcolumn reactor: 30"C. 
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Linearity, precision, reproducibility and detection limit 
At optimized conditions (see Experimental section), the calibration graph was linear 
up to 5000 ng/mL, showing an extended dynamic range. The within-series relative 
standard deviation of the peak area of a 50 ng/mL standard quercetin was 1.2% (n 
= 12). Over a period of 1 month, the reproducibility relative standard deviation of 
the area of a 50 ng/mL standard quercetin was 3.2% (n = 12). Using a calibration 
graph for each series of analyses to convert this area into a concentration, as is done 
in quantitative analyses, improved the reproducibility of this 50 ng/mL standard 
quercetin to 1.4%. 
The limit of detection of standard solutions, i.e., the concentration of the 
flavonol resulting in a peak height of 3 times the standard deviation of the baseline 
noise, was 0.15 ng/mL for quercetin, 0.05 ng/mL for kaempferol, 0.45 ng/mL for 
myricetin, and 0.05 ng/mL for isorhamnetin. 
DISCUSSION 
We have found that flavonols can be determined by fluorescence detection with 
high sensitivity after chelation with Al3+ . We have set up a postcolumn HPLC 
system and optimized reaction conditions for chelation. A limit of detection of 0.15 
ng/mL can be achieved for quercetin without sample enrichment, thus improving 
detection considerably as compared to the detection limit of 50 ng/mL with 
ultraviolet detection.10 
Reaction conditions 
A high concentration of aluminum nitrate and an extended residence time in the 
postcolumn reactor were necessary to obtain sufficient fluorescence intensity. This 
indicates that the reaction conditions for formation of the complex are rather 
unfavourable. As a consequence, application in a postcolumn reactor needs careful 
optimization. The water content of the eluent required for adequate separation in 
reversed-phase chromatography had a disastrous effect on the detector response. 
Szabó and Beck15 found that the absorbance of Al-morin in ethanol decreased 
sharply with increasing water content of the reagent, and they speculated that the 
increasing dielectric constant enhanced dissociation of the Al-morin complex. 
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Alternatively, solvatation of Al3+ with water could lead to a less reactive compound 
compared to the aluminum ion complexes with methanol and acetonitrile. The 
beneficial effect of acetic acid could be explained on the basis of formation of a 
more reactive complex of Al3+ and acetic acid. The temperature of the postcolumn 
reactor was an important variable and showed an optimum, as also was observed 
by White and Lowe16 for the Al-morin complex. Addition of phosphate buffer to the 
eluent for improvement of the chromatographic process also enhanced the 
fluorescence response, possibly by decreasing the pH of the medium.17 Increasing 
amounts of phosphate buffer or phosphoric acid had only an inhibitory effect. 
Phosphates are known to remove metals from flavonols, and fluorometric methods 
for the determination of trace quantities of phosphates based on this principle have 
been described.1819 
Structural requirements for complexation 
Metal ions may bind to the 3-hydroxyl and 4-keto oxygen and to the 5-hydroxyl and 
4-keto oxygen (Figure 7).12,20 Two adjacent hydroxyls, such as the 3'- and 4'-
hydroxyls in quercetin, may also be involved in chelation, but in acid solution this 
complex is labile.12,20 Plant flavonols always contain both a 3- and a 5-hydroxyl 
group, but complexation occurs only at the 3-hydroxyl-4-keto-oxygen site.20 This 
study shows that the 3-hydroxyl-4-keto-oxygen site is essential for fluorescence. 
Flavonoids without a 3-hydroxyl group, viz., flavones and catechins, escape 
fluorescence detection. A free 3-hydroxyl group is essential, as rutin, containing a 
sugar bound to the 3-hydroxyl group, does not form a fluorescent chelate either. 
Morin, kaempferol and isorhamnetin show the highest fluorescence intensities 
{Figure 2, Table 1). Apparently, the adjacent hydroxyl groups at positions 3',4' or 
5' in quercetin and myricetin inhibit fluorescence. The tendency to form an 
additional Al3+ chelate involving these o-hydroxyl groups might inhibit its 
fluorescence. Thus, the increase in fluorescence caused by acetic acid and 
phosphate buffer could be explained by disrupture of the Al-quercetin chelate at 
position 3'-4' at low pH.1220 The high fluorescence of Al-morin may be caused by 
formation of an internal hydrogen bond between the 2'-OH and the heterocyclic 
oxygen at position 1. This confers molecular rigidity to the molecule, which 
increases fluorescence efficiency. 
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Application in sample analysis 
We have used this postcolumn HPLC system for the routine determination of 
quercetin in body fluids. Because of the high sensitivity and selectivity of this 
fluorescence detection technique, minimal sample preparation is required, and 40 
samples/day can be easily analyzed.2122 
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Abstract 
Quercetin is a dietary antioxidant that prevents oxidation of low density lipopro-
teins in vitro. Intake of quercetin was inversely associated with coronary heart 
disease mortality in elderly Dutch men. However, the extent of absorption of 
quercetin in humans is unclear. The aim of this study was to quantify absorption of 
various forms of quercetin. Nine healthy ileostomy subjects were studied, to avoid 
losses caused by colonic bacteria. They followed a quercetin-free diet for 12 days; 
on days 4, 8 and 12 they received a supplement of fried onions at breakfast (rich in 
quercetin glucosides) equivalent to 89 mg aglycone, pure quercetin rutinoside (the 
major quercetin compound in tea) equivalent to 100 mg aglycone, or 100 mg pure 
quercetin aglycone, in random order. Subsequently, participants collected ileostomy 
effluent and urine for 13 hours. In vitro incubations of quercetin or its glycosides 
with gastrointestinal fluids showed minimal degradation. Absorption of quercetin, 
defined as oral intake minus ileostomy excretion and corrected for 14% degradation 
within the ileostomy bag, was 52 ± 15% for quercetin glucosides from onions, 17 
± 15% for quercetin rutinoside, and 24 ± 9% for quercetin aglycone. Mean excre-
tion of quercetin or its conjugates in urine was 0.5% of the amount absorbed; quer-
cetin excretion in urine was negatively correlated with excretion in ileostomy 
effluent (r = -0.78, n = 27). We conclude that humans absorb appreciable amounts 
of quercetin and that absorption is enhanced by conjugation with glucose. 
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INTRODUCTION 
Flavonoids are polyphenols compounds that occur ubiquitously in foods of plant 
origin. Flavonoids are categorized into flavonols, flavones, catechins, flavanones 
and anthocyanidins.1 Quercetin (Figure I), the major representative of the flavonol 
subclass, is a strong antioxidant,2 and prevents oxidation of low-density lipoproteins 
in vitro.3 Oxidised low-density lipoproteins are atherogenic and are considered to 
be a crucial intermediate in the formation of atherosclerotic plaques.4 This agrees 
with our observation that the intake of flavonols and flavones was inversely 
associated with subsequent coronary heart disease in both the Zutphen Elderly 
Study,5 a prospective cohort study, and in the Seven Countries Study,6 a cross-
cultural study. 
Quercetin aglycone (I) 
Quercetin-3-O-ß-rutlnoside (IV) 
OH O 
HO OHT-OH 
Quercetln-4'-0-B-D-glucoslde (II) 
HO OHT-OH 
HO OÏr-OH 
Quercetln-3,4'-0-bis-ß-D-glucoside (III) 
Figure 1. Structure of quercetin aglycone (I) and quercetin glycosides; II and III are 
the major species in onions,'6'7 and IV is the major species in tea.13 
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The average dietary intake of quercetin in the Netherlands is 16 mg/day/ 
which is similar to that of vitamin E (7 -10 mg/day), ß-carotene (2 - 3 mg/day), and 
vitamin C (70 -100 mg/day).8 However, the extent of absorption of flavonoids is an 
important unsolved problem in judging their many alleged health effects.9 Indeed, 
it is often stated that flavonoids present in foods cannot be absorbed from the 
intestine because they are bound to sugars as glycosides.1 Only free flavonoids 
without a sugar molecule, the so-called aglycones, are considered to be able to pass 
through the gut wall, and no enzymes that can split these predominantly ß-
glycosidic bonds are secreted into the gut or present in the intestinal wall.110 
Hydrolysis only occurs in the colon by microorganisms, which at the same time 
degrade flavonoids.1 On the other hand, it was shown in one human study that the 
aglycone quercetin was not absorbed either.11 Nieder12 suggested that flavonol 
glycosides from Ginkgo biloba were absorbed in human subjects, but no inform-
ation on the extent of absorption was given. 
A major problem in studying the absorption of quercetin in humans is its 
degradation by microorganisms in the colon. For that reason measurement of faecal 
excretion in normal human subjects would lead to an overestimate of the amount 
absorbed. We therefore studied quercetin absorption in healthy ileostomy subjects 
with complete small intestines. Ileostomy subjects with minimal ileal resection were 
successfully employed previously to determine absorption of minerals and trace 
elements,13 dietary starch and nonstarch polysaccharides,14 and cholesterol.15 
The present study was designed to determine absorption of quercetin from 
onions and of a major glycoside from tea, because tea and onions are the main diet-
ary sources besides wine.7 Onions contain mainly quercetin glucosides, 16,17whereas 
quercetin rutinoside predominates in tea18 {Figure 1). Quercetin aglycone, i.e. free 
quercetin with no sugar attached, was included as a model compound. 
SUBJECTS AND METHODS 
Subjects 
Ileostomy subjects have had their large intestine completely removed and the 
terminal ileum brought out onto the anterior abdominal wall as a fistula. We 
recruited nine subjects (five females, four males), mean age 45 (range 22-62) years, 
mean body mass index 26 (range 21-33) kg/m2. All had had total colectomies for 
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ulcerative colitis or polyposis coli on average 13 (range 1 - 26) years ago. In the 
operation an average of 8 (range 0 - 40) cm of the terminal ileum had been 
removed. None of the subjects had evidence of Crohn's disease or malabsorption, 
and all had well-functioning ileostomies. Subjects were not hospitalized, and were 
leading normal active lives. One subject was a psychologist, one was a clerk, one 
was a fruit farmer, one was a cleaner, one was a student, one was a retired civil 
engineer, and the other three were housewives. They were all judged healthy by a 
gastroenterologist on the basis of a medical questionnaire and had no record of 
gastric surgery. All subjects were unmedicated. 
The protocol was approved by the Nijmegen University Hospital Ethical 
Committee and was fully explained to the participants, who gave their written 
informed consent. 
Study design, foods, and supplements 
Subjects followed a quercetin-free diet for 12 days. On days 4, 8, and 12 we fed 
them three different quercetin-containing supplements in random order, at breakfast 
at the Department between 7:45 and 9:30 am. After the quercetin-rich breakfast, 
participants collected ileostomy effluent and urine for 13 hours. Absorption was 
calculated as the difference between the amount of quercetin in the supplements 
and in the subsequent ileostomy effluent. 
To ensure a quercetin-free diet, participants were given a list of vegetables 
and fruits containing more than 15 mg quercetin/kg and of beverages with more 
than 4 mg quercetin/L,19,20 and were instructed not to consume any of them. 
Because proteins are known to bind polyphenols,21 the quercetin-supplemented 
breakfasts were low in protein; they consisted of protein-free bread, margarine, jams 
made from quercetin-free fruits and other sweets such as chocolate sprinkles, coffee 
without milk, quercetin-free soft drinks, and mineral water. We fried 333 g yellow 
onions with 20 g margarine, 15 g tomato ketchup and 1 g Italian herbs; 150 g of this 
dish, corresponding to 215 g raw yellow onions, constituted the onion supplement. 
It contained 89 ± 14 mg quercetin (n = 9) as determined by HPLC.22 For the two 
other breakfasts 220 mg quercetin-3-O-ß-rutinoside (Rutosidum DAB, #339994; 
OPG Farma, Utrecht, The Netherlands), equivalent to 100 mg aglycone, or 112 mg 
quercetin-dihydrate (#Q-0125; Sigma, St Louis), equivalent to 100 mg aglycone, 
were administered as capsules. The capsules also contained 80 mg para-
aminobenzoic acid (#361334; OPG Farma). Para-aminobenzoic acid is completely 
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absorbed and excreted with urine in humans.23 The onion breakfast was 
supplemented with a capsule containing 80 mg para-aminobenzoic acid. Subjects 
also ingested 25 radioopaque barium-salt-impregnated plastic ringlets (outer 
diameter 3 mm) as a recovery marker. Subjects were instructed not to eat anything 
and to drink only water or coffee without milk after the experimental breakfasts until 
lunch. 
Energy and nutrient intakes were calculated using the Dutch food compo-
sition table.24 The breakfasts provided 1.52 ± 0.61 MJ (362 ± 145 kcal), with 
protein accounting for 2.0 ± 1.6% of energy, fat for 41.2 + 12.6%, and carbo-
hydrates for 56.4 + 13.2%. The onion breakfast provided 3.8 ± 1.3% of energy 
from protein and the other breakfasts provided 1.0 + 0.5%; no differences were 
found for fat and carbohydrates between the three breakfasts supplied. Average 
energy intake on days 3, 7, and 11, according to 24-h dietary recalls, was 11.26 ± 
2.72 MJ, of which protein provided 14.6 + 3.7% of energy, fat 37.7 ± 5.9%, and 
carbohydrates 47.2 ± 5.3%, with no differences between breakfast periods. 
Collection of samples 
After the quercetin-rich breakfast, subjects returned home or went to work and 
collected urine and stoma effluent until they went to bed between 10:00 and 11:45 
pm. On average, effluent and urine were collected for 13.4 + 0.7 hours. Subjects 
changed the ileostomy bags every 2 to 5 hours (on average, 3.5 ± 1.5 hours) 
according to their normal routine and immediately stored the bags in a polystyrene 
box containing dry ice. They collected urine in plastic bottles containing 0.1 g 
thimerosal (#T-5125; Sigma) and stored each bottle in dry ice immediately after 
voiding. Three of the subjects (#1, #2, and #8) collected urine every two hours, 
which allowed us to study the rate of excretion of quercetin. 
Sample preparation 
The filled plastic ileostomy bags were kept frozen with liquid nitrogen, the bags 
were removed, and the frozen contents were freeze-dried, ground to pass through 
an 0.5 mm sieve, and stored at -20 °C until analyzed less than 21 weeks later. Urine 
samples were thawed in a water bath at 40 °C and mixed, and aliquots were taken 
within 30 min, frozen with liquid nitrogen, and stored at -40 °C until analyzed less 
than 7 weeks later. 
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Samples collected before breakfast (prebreakfast sample) and the final 
collection at the end of the day (final sample) were prepared separately, as were all 
samples from the three subjects who collected urine every two hours. The other 
samples were pooled by subject and treatment day and thoroughly homogenised. 
Incubation of quercetin supplements with gastrointestinal fluids in vitro 
Amounts of raw onions, quercetin-3-rutinoside, and quercetin corresponding to 3 
mg quercetin aglycone were incubated with 3 mL human gastric juice25 and 9 mL 
water at 37 °C for 0.5 and 2 hours. This mimicked stomach contents after the 
experimental breakfasts.26 
Similar amounts were also incubated with 1.5 mL human duodenal fluid27 
and 9 mL water at 37 °C for 1 and 4 hours, corresponding to the average and 
maximal transit time in the small intestine, respectively.28 
The stability of quercetin in ileostomy fluid was studied as follows. About 6 
months after the experiments, three of the volunteers followed a quercetin-free diet 
for two days. At noon of the second day, they applied an ileostomy bag containing 
either 30 mg quercetin aglycone emulsified with 6.7 g margarine or 50 g finely 
ground fried onions prepared as described. Subjects allowed ileostomy fluid to drain 
into the bag for 3 - 4 hours and kneaded the contents occasionally. The contents 
were then stored and studied as described above. 
Analytical methods 
Quercetin glycosides and glucuronides were simultaneously extracted and 
hydrolysed to the aglycone by using 2 M HCl in aqueous methanol. By varying acid 
concentration and the duration of extraction and hydrolysis the following procedure 
was found to be optimal for urine: 12.5 mL methanol containing 2 g tert-butyl 
hydroxyquinone/L and 5 mL 10 M HCl were added to 7.5 g urine followed by 
mixing, the extract was refluxed at 90 °C for two hours with regular swirling, 
allowed to cool and subsequently brought to 50 mL with methanol. For ileostomy 
effluent, 40 mL 62.5% (7V) aqueous methanol containing 2 g tert-butyl hydroxyquin-
one/L and 10 mL 10 M HCl were added to 0.500 g freeze-dried effluent and then 
mixed. The extract was refluxed at 90 °C for two hours with regular swirling, 
allowed to cool and subsequently brought to 100 mL with methanol. Urine and 
effluent extracts were sonicated for 5 min and filtered through a 0.45 jjm filter for 
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organic solvents (Acrodisc CR PTFE; Gelman Sciences, Ann Arbor, Ml) before HPLC 
analysis. We injected 10 JJL onto an Inertsil ODS-2 (GL Sciences Inc, Tokyo) 
column (4.6 x 150 mm, 5//m particle size) protected by an MPLC Newguard RP-18 
(Brownlee; Applied Biosystems Inc, San Jose, CA) column (3.2 x 15 mm, 7//m 
particle size) by using acetonitrile:0.025 M phosphate buffer pH 2.4 (31:69 (7V)) as 
the mobile phase, at a flow rate of 1 mL/min. The columns were placed in a column 
oven set at 30 °C. The eluent was mixed with 0.4 mL/min 1.5 M AI(N03)3 in 
methanol containing 7.5% (7V) acetic acid in a postcolumn stainless steel reaction 
coil (0.25 mm x 15 m) placed in the column oven. The fluorescence of the ensuing 
quercetin-metal complex was measured at 490 nm with a Merck Hitachi F-1000 
(Tokyo) fluorescence detector with the excitation wavelength set at 400 nm. Further 
details were described elsewhere.22 
The limit of detection, i.e. the concentration producing a peak height three 
times the standard deviation of the baseline noise, was 5 ng/g for urine and 2 /vg/g 
for ileostomy effluent. Recovery of quercetin in onion extract, of pure quercetin-3-
rutinoside, and of quercetin aglycone added at a quercetin concentration of 
800//g/gtofreeze-dried ileostomy effluent free of quercetin was 91.6 ± 3.0%, 91.6 
± 0.3%, and 90.0 ± 0.1% respectively (n = 2). Addition of 0.5 fjg quercetin 
aglycone per gram of urine yielded a recovery of 98.7 + 8% (n = 3). 
All determinations were carried out in duplicate. We included a control 
sample of freeze-dried effluent in each series of analyses; all values were within 868 
± 103 //g/g (mean ± 2 SD, n = 18). For urine analyses a urine sample of the 
previous series was always included. The between-series coefficient of variation was 
4% (n = 11). 
Quercetin absorption was calculated as the difference between the amount 
in the supplements and in the ileostomy effluent corrected for 9% analytical losses 
plus 5% degradation within the ileostomy bag (see Results). 
Para-aminobenzoic acid was determined photometrically by using 
fluorescamine (#F-9015; Sigma) after hydrolysis with 0.1 M HCl for 40 min in a 
boiling water bath.29 Addition of 0.15 mgpara-aminobenzoicacid per gram of urine 
yielded a recovery of 94.2 + 2% (n = 6). A urine control sample was included in 
each series of analysis; values were within 66.8 ± 3.1 mg(mean + 2 SD, n = 14). 
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Statistical analysis 
Because the amounts of quercetin excreted were expected to follow a log-normal 
distribution, values as proportions of intake were first converted to log10 values. The 
Shapiro-Wilk test for normality did not give evidence for nonnormality. Differences 
between treatments were tested by analysis of variance using the Statistical Package 
for Social Sciences, SPSS/PC + (SPSS Inc, Chicago) with subject, type of breakfast 
and previous type of breakfast as independent variables. The significance of 
differences was determined by paired t test. 
RESULTS 
Stability of quercetin and glycosides in gastrointestinal fluids 
Quercetin aglycone and glycosides were stable in vitro in gastric juice for at least 
2 hours and in duodenal fluid for at least 4 hours {Table 7). 
Incubation with ileostomy fluid for 3.25 hours yielded a recovery of 86% 
(Table 1). The analytical recovery of quercetin added to freeze-dried ileostomy fluid 
was 91 % (see Methods); therefore, the loss through degradation in an ileostomy bag 
carried on the body for 3.25 hours was about 5%. 
Compliance with the quercetin-free diet 
The average quercetin intake from regular foods on days 3, 7 and 11 according to 
24-h dietary recalls was 1.1 ± 1.4 mg. No difference in quercetin intake was 
observed between the three 4-day periods. Quercetin excretion in prebreakfast 
effluent samples was on average 3% of the total daily amount (Table 2) and on 
average 2% in prebreakfast urine (Table 3). 
Excretion of quercetin 
The total amount of quercetin excreted in ileostomy effluent (Figure 2) was highly 
dependent on the type of supplement (P < 0.01). After correction for 14% 
analytical losses plus degradation during time in the ileostomy bag, average 
absorption was 52% for quercetin from onions, 17% for quercetin-3-rutinoside, and 
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24% for the pure agiycone (Table 2). No significant relation with the subject or with 
the supplement given in the previous period was found. Excretion of quercetin in 
urine was also significantly higher for quercetin from onions than for the agiycone, 
which was again higher than that for the rutinoside (Table 3). Again, no statistically 
significant relation with the subject or the supplement of the previous period was 
found. Still, one subject, depicted by # in Figure 2, did excrete markedly less 
quercetin in ileostomy effluent after consumption of the quercetin-3-rutinoside and 
much more in urine than did the other subjects. 
Table 1. Stability of quercetin recovered from various sources during incubation 
with human gastric juice or duodenal fluid in vitro, or ileostomy effluent ex vivo. 
Source 
Onions 
Quercetin-3-
rutinoside 
Quercetin 
agiycone 
Gastric 
0.5 h 
(%) 
95.8 
91.9 
94.9 
juice1 
2 h 
(%) 
95.2 
92.7 
88.7 
Duodenal fluid1 
1 h 
(%) 
98.2 
95.7 
98.8 
4 h 
(%) 
97.4 
94.7 
108.4 
Ileostomy 
effluent5 
3.25 ± 0.6 h 
(%) 
86.8 ± 4.5 
-
85.9 ± 2.1 
" mean of duplicate determinations. 
§
 mean ± SD of incubations in ileostomy bags on the bodies of three volunteers. Analytical 
recovery after additions to freeze-dried effluent averaged 91.1 + 2.1% (n = 6). 
- not determined. 
Collection of effluent and urine 
Out of 25 radioopaque ringlets swallowed together with each supplement, on 
average 21 ± 8 were found after consumption of the onions, 17 ± 9 after the 
quercetin rutinoside, and 24 ± 2 after the quercetin agiycone supplements. On 7 
of 27 person-days fewer than 22 of the 25 radioopaque ringlets ingested were 
recovered in the effluent. In the effluent of one subject no ringlets were found at all 
after two of the breakfasts but quercetin excretion in this subject was similar to that 
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in the other subjects, indicating that all of the effluent was probably collected. A 
mechanical barrier in the connection between ileum and ileostomy bag may have 
caused the ringlets to be lost. 
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Figure 2. Total amount of quercetin (mg) excreted in daytime ileostomy effluent, 
and total amount of quercetin (fjg) excreted in daytime urine of nine subjects after 
consumption of various supplements. Each subject is depicted by a different 
symbol. Horizontal bars depict means. 
The final samples of effluent, collected just before bedtime, were analyzed 
separately. They contained on average 6% of the total amount of quercetin excreted 
after the onions and the aglycone breakfast and 15% after the quercetin-3-rutinoside 
breakfast (Table 2). This mean of 15% was caused by one subject, who excreted 
88% of the total amount in this final sample. His ringlet recovery was only 7 of 25, 
which also indicated a long transit time. Thus the total amount of quercetin excreted 
in effluent after rutinoside by this subject may have been even higher than the 86 
mg recovered in 13 hours, and absorption correspondingly lower. 
Urinary recovery of para-aminobenzoic acid was 85.5 ± 11.6%. Two 
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volunteers showed recoveries of para-aminobenzoic acid between 64% and 82% 
for all treatments, but their urinary quercetin output was above average, which 
speaks against lack of compliance in collecting urine. The final sample of urine, 
collected just before bedtime, contributed 3% on average to the total daily output 
of quercetin (Table 3), which indicated that the peak of urinary quercetin excretion 
lay well within the 13-hours period. 
Table 2. Intake of quercetin at breakfast and subsequent mean cumulative excretion 
in ileostomy effluent over 13 hours^ 
Supplement 
(to breakfast) 
Onions (n = 9) 
Quercetin-3-
rutinoside (n = 9) 
Quercetin 
aglycone (n = 9) 
Intake in 
terms of 
aglycone 
(mg) 
89 ± 14 
100 ± 5 
100 ± 5 
Excretior 
Pre-
breakfast 
sample 
(mg) 
1.8 ± 1.1 
1.3 + 0.9 
1.7 + 1.3 
in ileostomy effluent 
Total* 
(mg) 
37 + 11 
7 2 + 1 5 
66 + 9 
Final 
(prebedtime) 
sample 
(mg) 
2.9 + 3.3 
1 1 + 2 5 
3.4 + 5.5 
Absorption9 
(%) 
52 ± 15 
17 + 15 
24 + 9 
1
 Mean + SD. Total excretion as proportion of intake differed significantly (P < 0.02) among all 
three supplements after rejection of the outlying quercetin rutinoside results of subject #4 ( • 
in Figure 2). 
Includes the final but not the prebreakfast sample. 
s
 Corrected for 9% analytical loss plus 5% degradation within the ileostomy bag. 
Rate of urinary quercetin excretion 
The three subjects (#1, #2, and #8) who had collected urine every two hours 
(Figure 3) reached 90% of their cumulative excretion within 5.6 ± 0.3 hours after 
the onion supplement, and within 7.8 ± 1.3 hours after administration of quercetin 
aglycone. The rate of urinary quercetin excretion was significantly higher (P < 
0.05 ) after the onion supplement. Administration of quercetin-3-rutinoside did not 
yield measurable amounts of quercetin in urine in these three subjects. 
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Figure 3. Cumulative amount of quercetin (jjg) excreted in urine of subjects #1, #2, 
and #8 after consumption of onions and quercetin aglycone. Each subject is 
depicted by a different symbol. Time course of quercetin excretion after quercetin 
rutinoside is not shown because no measurable amounts were found. 
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Table 3. Intake of quercetin at breakfast and subsequent mean cumulative excretion 
of quercetin in urine over 13 hours*. 
Excretion in urine 
Supplement 
(to breakfast) 
Intake in Pre-
terms of breakfast 
aglycone sample 
Total* Final 
(pre-
bedtime) 
sample 
Total 
excretion as 
proportion of 
Intake 
(mg) (ßjg) (fjg) (vg) (%) 
8 9 + 1 4 1.2 ± 1.9 275 + 129 5.7 ± 3.5 0.31 ± 0.14 
100 + 5 3.6 + 5.1 73 + 190 1.7 ± 2 . 5 0.07 + 0.19 
Onions (n = 9) 
Quercetin-3-
rutinoside (n = 9) 
Quercetin 
aglycone (n = 9) 
100 + 5 1 .0+1.1 115 + 75 4.4 ± 6.0 0.12 + 0.08 
" Mean + SD. Total excretion as proportion of intake was significantly different for all three 
supplements (P < 0.02). 
Includes the final but not the prebreakfast sample. 
DISCUSSION 
We found that significant amounts of the quercetin glucosides present in onions 
and, to a lesser extent, of pure quercetin aglycone are absorbed by the human small 
intestine. This contradicts the widely held view that dietary flavonoids are poorly 
absorbed in humans and that the glycosides present in foods are especially poorly 
absorbed.110 Absorption amounted to 52% for onions, 17% for quercetin-3-rutino-
side, and 24% for quercetin aglycone. True absorption could be even higher if 
absorbed flavonoids are reexcreted with bile as was found in rats.10,30 However, no 
data on reexcretion of flavonoids in human studies are available. 
Validity of the ileostomy model 
We measured absorption as the difference between ingestion and excretion in 
healthy volunteers who lacked a colon. Jejunoileal absorption in such subjects is 
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probably equivalent to that in normal subjects with an intact colon, as indicated by 
their normal serum cholesterol concentrations'5 and absorption of para-amino-
benzoic acid. Excluding the data of two subjects in whom recovery of para-
aminobenzoic acid was low did not alter the results or conclusions. 
It is unlikely that any quercetin disappeared through degradation in the 
stomach or duodenum because in vitro incubations with gastric juice or duodenal 
fluid mimicking normal conditions showed no loss of quercetin. Incubation of 
onions and quercetin in ileostomy fluid for 3 h produced an apparent loss of 14%. 
Some 9% of this was in fact due to analytical losses as shown by the in vitro 
recovery experiments (Methods). Thus breakdown in the ileostomy effluent itself 
was only some 5%. Degradation of sterols by microorganisms in ileostomy fluid was 
previously also reported to be small.15 
Incomplete collection of ileostomy effluent by the volunteers is also unlikely 
in view of the high recoveries of the nonabsorbable marker and of the quercetin 
when fed as quercetin rutinoside. 
Quercetin excretion in urine was strongly and negatively correlated with 
excretion in ileostomy effluent (Figure 4). This again suggests that low output of 
quercetin in stoma effluent was truly due to high absorption. 
Comparison with previous studies 
Our results show that quercetin glucosides of onions are better absorbed than is the 
aglycone. Absorption of glycosides was also suggested by Nieder.12 However, no 
information about the nature of the glycosides was available. 
Cugleretal.11 found no quercetin in urine or plasma after oral administration 
of 4 g quercetin aglycone to humans and concluded that less than 1 % could have 
been absorbed. The high limit of detection and the high dose could account for the 
difference in absorption (1 % versus 24%) with the present study. Ueno et al.30 found 
that at least 20% of orally administered 14C labelled quercetin aglycone was 
absorbed in rats. The present study agrees with those results. 
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effluent in nine subjects who consumed three supplements in random order; 
r = -0.78, n = 27 
• , onions; A, quercetin-3-rutinoside; +, quercetin aglycone. 
Metabolism of quercetin 
Figure 3 suggests that the rate of urinary excretion of quercetin was higher for the 
glucoside from onions than for quercetin aglycone, because the time to reach 90% 
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of the cumulative excretion was about 2 hours shorter for the glucoside. This could 
be explained by more rapid absorption of the glucoside, assuming the rate of 
elimination of the glucoside and aglycone are the same. 
After the onion breakfast 41.1% was recovered in ileostomy fluid and 0.3% 
in urine. Thus, 58.6% went undetected, 2.5% of which may have been degraded 
in the ileostomy bag and another 3.3% was lost during sample preparation. Like 
many other compounds,31 absorbed quercetin is probably extensively modified 
before being excreted by the kidneys. Our assay would pick up quercetin 
glucuronides and similar conjugates, but O-methylated quercetin, a hepatic meta-
bolite in rats,10,30 would escape detection and so would metabolites in which the 
ring structure itself is altered. In addition to the formation of such undetectable 
metabolites an acute high dose such as was given here might also be partly stored 
and released slowly over subsequent days.32 
Mechanisms of absorption 
Quercetin glucosides from onions need to be liberated from the food matrix before 
being absorbed, whereas absorption of quercetin aglycone and quercetin rutinoside 
from the gut would probably be greater because these were administered as 
powders. Poor solubility of quercetin rutinoside does not seem to be a major factor 
because it was well absorbed in subject #4. Thus there is a predominant effect of 
the sugar moiety on the absorption of quercetin. We speculate that intestinal sugar 
carriers may play a role in flavonoid absorption. Model studies by Mizuma et al.33 
on the absorption of naphthol glycosides in everted small intestines of rats support 
such a mechanism. Absorption was higher for naphthol glucoside than for the 
galactoside, and higher for the ß-anomer than for the a-anomer; also the absorption 
of these glycosides was inhibited by the absence of Na+ which is needed for active 
NaVglucose cotransport, and by the inhibitor of glucose transport phloridzin. Such 
active transport of ß-glucosides of foreign compounds by the glucose transporter 
offers a possible explanation for the high absorption of quercetin from onions, in 
which it is present as ß-D-glucosides. The quercetin group might thus be drawn into 
the enterocyte by its glucose moiety, which is transported by the glucose carrier. 
The aglycone (i.e. free quercetin) would then fail to be absorbed because it lacks a 
sugar. However, experiments are needed to study the role of the active 
Na + /glucose cotransporter in the absorption of quercetin glucosides. The poor 
absorption of quercetin rutinoside is puzzling, especially in view of indications that 
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diosmin, the rutinoside of the flavone diosmetin, is absorbed in humans after oral 
administration.34 Studies of the absorption of rutinose itself and of various rutinos-
ides are required to solve this discrepancy. 
In contrast with the other eight subjects, subject #4 showed low ileostomy 
and high urinary excretion after consumption of the quercetin-3-rutinoside (Figure 
4). This may be due to a variant type of intestinal physiology; further studies of such 
subjects might yield clues to the mechanism of absorption of flavonoids. Rutinose 
is a disaccharide consisting of glucose and rhamnose (Figure 1). Possibly subject #4 
has a ß-glycosidase in the small intestine that splits off rhamnose and transforms the 
rutinoside into a well-absorbable glucoside. 
Thus quercetin glucoside as present in onions is absorbed efficiently in 
humans. If the glucose transporter is involved in this then quercetin will enter the 
blood stream as the glucoside; this might affect its distribution, metabolism and 
excretion. Quantitative data for separate quercetin glycosides in foods are needed 
for evaluation of the extent of absorption of quercetin from other foods such as tea. 
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Abstract 
Quercetin is a dietary antioxidant that prevents oxidation of low density lipoproteins 
in vitro by scavenging of free oxygen radicals. Its intake was inversely associated 
with coronary heart disease mortality in Dutch elderly men. However, data on 
absorption of quercetin in man are scarce and contradictory. We studied the time 
course of the plasma quercetin concentration in two subjects after ingestion of fried 
onions containing quercetin glucosides equivalent to 64 mg of quercetin aglycone. 
Peak plasma levels of 196 ng/ml were reached after 2.9 h, with a half-life of 
absorption of 0.87 h. The half-life of the distribution phase was 3.8 h, and of the 
subsequent elimination phase 16.8 h. After 48 h the plasma concentration was 
about 10 ng/ml. We conclude that quercetin glucosides from onions are absorbed 
and are eliminated slowly throughout the day. Thus, the dietary antioxidant 
quercetin could increase the antioxidant capacity of blood plasma. 
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INTRODUCTION 
Flavonoids {Figure 1) are polyphenolic compounds that occur ubiquitously in foods 
of plant origin. Flavonoids have a variety of biological effects in numerous mam-
malian cell systems, in vitro as well in v/'vo.1 Recently much attention has been paid 
to their antioxidant properties that affect oxygen free radicals and lipid peroxidation. 
Oxygen free radicals and lipid peroxidation might be involved in several patho-
logical conditions such as atherosclerosis, cancer, and chronic inflammation.2 The 
antioxidative and lipid peroxidation inhibiting potential of flavonoids predominantly 
resides in their radical-scavenging capacity.34 Most flavonoids are effective radical 
scavengers.5"7 
DH o 
Quercetln aglyeone (I) 
Quercetin-4'-O-B-D-gluco8id0 (II) 
OH 
HO OH^OH 
OH Vo-r< 
*<~> OhT^-OH HO 
Quercetin-3',4'-O-bis-0-D-glucoslde (III) 
Figure 1. Structure of quercetin aglyeone (I) and quercetin glucosides: II and III are 
the major species in onions'5'6 
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Quercetin, the major representative of the flavonol subclass of flavonoids, is 
a strong antioxidant.8 It prevents oxidation of low density lipoproteins in vitro,9 and 
may therefore contribute to the prevention of atherosclerosis.10 Indeed, we found 
that the intake of flavonols and flavones was inversely associated with subsequent 
coronary heart disease both in the Zutphen Elderly Study,11 a prospective cohort 
study, and in the Seven Countries Study,12 a cross-cultural study. The average 
dietary intake of quercetin in the Netherlands is 16 mg/day,13 mainly originating 
from tea, onions and apples. In US men,14 onions, together with tea, are the major 
sources. Onions contain mainly quercetin-4'-0-ß-D-glucoside and quercetin-3,4'-0-
bis-ß-D-glucoside15'16 {Figure 7). 
In judging a potential health effect of quercetin, its absorption is an important 
unsolved problem. Because flavonoids in foods are only present bound to sugars -
mainly as ß-glycosides - they are thought to be non-absorbable from the intestine.17 
In one human study quercetin without its sugar moiety (the aglycone) was not 
absorbed either.18 Nieder19 found that flavonol glycosides from Ginkgo biloba were 
absorbed in human subjects, but no information on the administered amount and 
type of glycosides was given. We now report results of a pilot study on the absorp-
tion of quercetin from onions in humans. 
MATERIALS AND METHODS 
Subjects 
We recruited two subjects (1 female, 1 male), ages 22 and 43 years, and Body Mass 
Index 20.9 and 23.7 kg/m2, respectively. They were both healthy based on a medi-
cal questionnaire. Their values for blood haematocrit and for leucocyte, platelet, 
and erythrocyte counts, mean erythrocyte cell volume, haemoglobin, and mean 
corpuscular haemoglobin concentration were normal. Subjects did not use any 
medication. The protocol was approved by the Wageningen University Ethical 
Committee, and was fully explained to the participants, who gave their written 
informed consent. 
Study design, foods, and supplements 
Subjects followed a quercetin-free diet for 5 days. They were given a list of those 
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vegetables and fruits that contain more than 15 mg/kg of quercetin and of beverages 
with more than 4 mg/l of quercetin,20,21 and were instructed not to consume any of 
these products. On day 4 at 8:00 am, a breakfast supplemented with freshly fried 
onions was served. As proteins are known to bind polyphenols,22 the breakfast was 
low in protein; we provided protein-free bread, margarine, jams made from quer-
cetin-free fruits, other sweets such as chocolate sprinkles, coffee without milk, 
quercetin-free soft drinks, and mineral water. We fried 333 g of yellow onions with 
20 g of margarine, 15 g of tomato ketchup, and 1 g of Italian herbs; 150 g of this 
dish, corresponding to 215 g of raw yellow onions, was added to the breakfast. 
Analysis of duplicate portions23 showed that the onions provided 64.2 mg of 
quercetin expressed as aglycone. Subjects were instructed not to eat anything and 
to drink only water or coffee without milk after the experimental breakfasts up until 
lunch. 
Collection of plasma samples 
Venous blood samples were taken into vacuum tubes containing EDTA before 
breakfast (0 h), and at the time intervals depicted in Figure 3; zero time was 10 min 
after the start of the breakfast. Plasma was prepared within 15 min by centrifugation 
at 20 °C for 10 minutes at 2000 g; it was stored at -80°C until analysis less than 5 
weeks later. 
Determination of quercetin in plasma 
Quercetin, quercetin glycosides, glucuronides, and sulfates were simultaneously 
extracted and hydrolysed to the aglycone using 2 M HCl in aqueous methanol.23 In 
a 4 ml vial (#WAT022468, Waters, Milford, MA, USA), 1000/vl of methanol contai-
ning 2 g/l tert-butyl hydroxyquinone (TBHQ) and 400 fj\ of 10 M HCl were added 
to 600 fj\ of plasma and mixed. The vial was sealed tightly with a cap (#72711, 
Waters, Milford, MA, USA) and septum (#73008, Waters, Milford, MA, USA), 
inserted into a preheated aluminum block (Reacti-Block C-1, Pierce Europe, Oud-
Beijerland, The Netherlands), heated in an oven at 90 °C for two hours, allowed to 
cool, and centrifuged at 1000 g for 15 min after addition of 2000//I of methanol 
containing 2 g/l TBHQ. For H PLC analysis we injected 20/vl of the upper layer onto 
an Inertsil ODS-2 column (4.6 x 150 mm, 5/vm; GL Sciences Inc., Tokyo, Japan) 
protected by an MPLC Newguard RP-18 column (3.2 x 15 mm, 7/vm; Brownlee, 
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Applied Biosystems Inc., Foster City, CA, USA) using acetonitrile/methanol/0.025 
M phosphate buffer pH 2.4, 10:38:52 (v/v/v) as mobile phase, at a flow rate of 1 
ml/min. The columns were placed in a column oven set at 30 °C. The column 
effluent was mixed with 0.4 ml/min 1.5 M AI(N03)3 in methanol containing 7.5% 
(v/v) acetic acid in a post-column stainless steel reaction coil (0.25 mm x 15 m) 
placed in the column oven. The fluorescence of the ensuing quercetin-metal 
complex was measured at 485 nm using a Jasco FP 920 Qasco Corporation, Japan) 
fluorescence detector with excitation wavelength set at 422 nm. 
Adequate resolution was achieved (Figure 2). Addition of 100 ng of 
quercetin aglycone per ml plasma yielded a recovery of 88 ± 11% (n = 5). All 
determinations were carried out in duplicate in one series of analyses. The 
standard deviation of duplicates was 12 ng/ml. The limit of detection, defined as 
0 2 4 6 10 12 14 16 
Time (min) 
Figure 2. Chromatogram of quercetin in plasma of subject 1, four hours after 
ingestion of the onion supplemented breakfast. 
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the concentration of quercetin in the sample resulting in a peak height of 3 x the SD 
of the baseline noise, was 5 ng/ml. 
Data analysis 
We used the two-compartment open model C(t) = - C e"kt + A e "at + B e ~ßt to 
describe the absorption and disposition of quercetin,24 and calculated the 
parameters of this model with nonlinear regression analysis using PCNONLIN 
version 4.0 (SCI Software, ClinTrials Inc., Lexington, KY, USA). 
RESULTS AND DISCUSSION 
The mean peak plasma level of quercetin was 196 ng/ml. Peak levels were reached 
2.9 h after ingestion of the onions (Figure 3), with an average half-life of absorption 
of 0.87 h (Table 7). Disposition of quercetin in plasma was biphasic. The half-life 
of the first phase, the distribution phase, was 3.8 h, and that of the subsequent 
elimination phase 16.8 h. We could still detect quercetin 48 h after ingestion of the 
onions; at that time the plasma concentration was about 10 ng/ml. 
Nieder19 found a similar absorption profile after administration of flavonol 
glycosides from Ginkgo biloba, but elimination was more rapid with a half-life of 
2 - 4 h. After oral administration of 4 g of quercetin aglycone, Gugler et al.18 could 
not detect any quercetin aglycone in plasma, using a limit of detection of 100 ng/ml. 
Neither quercetin aglycone nor quercetin conjugates were detectable in urine. After 
intravenous administration of 100 mg of quercetin aglycone Gugler et al.18 found 
an elimination half-life of 2.4 h. However, in both studies the plasma concentration 
was only measured regularly up until 9-12 hours after administration. Most likely, 
the distribution phase was erroneously identified as the elimination phase. After oral 
administration of diosmin, a glycoside of the flavone diosmetin,25 the elimination 
half-life of the aglycone diosmetin was between 26 to 43 hours in human subjects. 
It was suggested that this relatively slow elimination of diosmetin was caused by 
enterohepatic recirculation. Biliary excretion of quercetin has also been described 
in rats.26 However, no data are available on biliary excretion of quercetin glucu-
ronides in man and their potential subsequent reabsorption from the gut. 
The elimination half-life of 17 hours implies that repeated intake of quercetin 
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Figure 3. Quercetin concentration in plasma of two subjects after ingestion of 150 
g of fried onions containing quercetin glucosides equivalent to 64 mg of aglycone; 
o, subject 1; +, subject 2 
glucosides would lead to a buildup of the concentration in plasma. We have 
measured here a peak plasma concentration of 200 ng/ml or 0.6 /vM after admini-
stration of a single high dose of dietary quercetin, equivalent to four times the 
average Dutch daily intake.13 Concentrations of the dietary antioxidant ß-carotene 
in human plasma are similar to this value.27 Thus, plasma quercetin levels in 
subjects who regularly eat onions may approach those of ß-carotene. 
We have found that quercetin glucosides present in onions are absorbed 
moderately rapidly, and are eliminated slowly throughout the day. Possibly 
intestinal sugar carriers play a role.28 Quercetin could, thus, contribute significantly 
to the antioxidant defences present in blood plasma. The present data, together with 
our findings on quercetin excretion in ileostomy volunteers29 should put to rest any 
doubts as to whether the dietary antioxidant quercetin is absorbed in man. 
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Table 1. Kinetic parameters ofquercetin absorption and disposition in two subjects 
after ingestion of 150 g of fried onions containing quercetin glucosides equivalent 
to 64 mg of aglycone. C(t) = - C e " + A e' + B e' was used as a model, 
where t equals time and C(t) plasma quercetin concentration. 
Parameter 
Absorption 
absorption rate constant, k 
half-life, t,^(abs) 
peak level 
time to reach peak level 
Distribution 
slope, a 
half-life, t1/5(a) 
Elimination 
slope, ß 
half-life, t1/2(ß) 
(h"1) 
(h) 
(ng/ml) 
(h) 
(h"') 
(h) 
(h1) 
(h) 
Subject 1 
0.97 
0.71 
190 
2.7 
0.28 
2.5 
0.043 
16.3 
Subject 2 
0.68 
1.02 
204 
3.1 
0.14 
5.1 
0.040 
17.2 
Mean 
0.83 
0.87 
196 
2.9 
0.21 
3.8 
0.042 
16.8 
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Abstract 
The time course of the plasma quercetin concentration was studied in nine subjects 
after ingestion of major dietary sources, viz. fried onions containing 225 //mol 
glucose conjugates of quercetin, equivalent to 68 mg of quercetin aglycone, apples 
containing 325 //mol of both glucose- and non-glucose quercetin glycosides, and 
of 331 //mol quercetin-3-rutinoside. Peak plasma levels were 0.75 //mol/L (225 
ng/mL) less than 0.7 h after ingestion of the onions, 0.30//mol/L (90 ng/mL) 2.5 h 
after the apples, and 0.30//mol/L (90 ng/mL) 9 h after the rutinoside. Half-lives of 
elimination were 28 h for onions and 23 h for apples. Bioavailability of both querce-
tin from apples and of pure quercetin rutinoside was 30% relative to onions. We 
propose that the sugar moiety of the glycoside is an important determinant of 
absorption. Repeated consumption of quercetin-containing foods may lead to 
accumulation of quercetin in blood and increase the antioxidant capacity of blood 
plasma. 
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INTRODUCTION 
Flavonoids are polyphenols compounds that occur ubiquitously in foods of plant 
origin.1 Flavonoids can function as antioxidants because they scavenge radicals, 
inhibit lipid peroxidation, and chelate metals.2 Oxygen free radicals and lipid per-
oxidation are probably involved in the formation of atherosclerotic plaques, and 
have also been put forward as intermediates in cancer and chronic inflammation.3 
Quercetin, the major representative of the flavonoid subclass of flavonols, 
is a strong antioxidant4 and prevents oxidation of low density lipoproteins (LDL) in 
vitro.5Oxidised LDL has been found in atherosclerotic lesions of humans,6 
and increased plasma concentrations of autoantibodies against oxidized LDL occur 
in patients with atherosclerosis.7,8 Quercetin might therefore contribute to the 
prevention of atherosclerosis.9 Indeed, the intake of flavonols and flavones was 
inversely associated with subsequent coronary heart disease in several prospective 
studies,10'13 but not all studies.14'5 The average dietary intake of quercetin in the 
Netherlands is 16 mg/day (53 /vmol/day),16 mainly originating from tea, onions and 
apples. 
In order to act as an antioxidant, quercetin first has to be absorbed from the 
diet, and subsequently reach plasma and tissue levels that can contribute to the 
antioxidant defenses of the human body. Formerly, flavonols were thought to be 
poorly absorbed from the intestine' because in foods they are present bound to 
sugars, mainly as ß-glycosides which cannot be hydrolysed by pancreatic enzymes. 
However, we found that human absorption of quercetin-ß- glucosides from onions 
was 52%, whereas absorption of quercetin without its sugar moiety, the so-called 
aglycone, was 24%, and of quercetin-ß-rutinoside, also called rutin, was only 
17%.17 In a subsequent pilot study we showed that when subjects consumed fried 
onions, their peak plasma quercetin concentration was reached within 3 h and then 
decreased slowly throughout the day.18 These data suggest that the sugar moiety of 
quercetin glycosides is an important determinant of their absorption. Onions 
contain mainly glucose glycosides of quercetin, i.e. glucosides,19,20 apples a variety 
of quercetin glycosides, e.g. galactosides, arabinosides, rhamnosides, xylosides, and 
glucosides,21"23 and quercetin rutinoside is a major glycoside in tea 24(Figure I). The 
present study was designed to determine the pharmacokinetics of these various 
quercetin glycosides from important dietary sources of quercetin. 
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Figure 1. Structure of quercetin aglycone (I), quercetin glucoside (II) of onions, 
quercetin galactoside (III) of apples and quercetin rutinoside (IV). 
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MATERIALS AND METHODS 
Subjects 
We recruited 9 subjects (5 females, 4 males), mean age 24.8 (range 20 - 47) years, 
with a mean Body Mass Index of 23.2 (range 19.3 - 30.9) kg/m2. They had no record 
of gastric or intestinal surgery and were all healthy based on a medical question-
naire, and the absence of glucose or protein in urine. Their values for blood 
haematocrit, for leucocyte and platelet counts, for haemoglobin concentration, 
alanine amino transferase, aspartate amino transferase, alkaline phosphatase, and 
y-glutamyl transferase were normal. Subjects did not use any medication. The 
protocol was approved by the Wageningen University Ethical Committee, and was 
fully explained to the participants, who gave their written informed consent. 
Study design, foods, and supplements 
Subjects followed a quercetin-free diet during three experimental periods each of 
5 days. They were given a list of those vegetables and fruits that contain more than 
15 mg/kg (50 /ymol/kg) of quercetin and of beverages with more than 4 mg/L (13 
ji/mol/kg) of quercetin;25,26 they were instructed not to consume any of these 
products during each of the three 5-day periods. These periods were separated by 
9 days without treatment and without a prescribed diet. On day 4 of each experi-
mental period we provided one out of three different quercetin-containing 
supplements in random order. Supplements were given at breakfast at the 
Department between 7:40 and 8:20 am. After the quercetin-rich breakfast blood 
samples were collected periodically over the next 36 hours and urine continuously 
for 24 hours. 
Because proteins are known to bind polyphenols,27 the quercetin-
supplemented breakfasts were low in protein; they consisted of protein-free bread, 
margarine, jams made from quercetin-free fruits and other sweets such as chocolate 
sprinkles, coffee without milk, quercetin-free soft drinks, and mineral water. We 
fried 330 g yellow onions with 20 g margarine, 15 g tomato ketchup and 1 g Italian 
herbs; 150 g of this dish constituted the onion supplement. We freeze-dried apple 
peels, variety Jonagold, ground them, and mixed 41.24 g of the powder with 400 
g of apple sauce; 434 g of this mixture was supplemented to each subject. Analysis 
of duplicate portions28 showed that the onions provided 225 ± 43 /ymol (68 ± 13 
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mg quercetin equivalents) and apples 325 ± 7 jjmo\ (98 + 2 mg quercetin 
equivalents) of quercetin. For the third experimental breakfast 220 mg quercetin-3-
O-ß-rutinoside (Rutosidum DAB, #339994; OPG Farma, Utrecht, The Netherlands), 
331 /vmol equivalent to 100 mg aglycone was administered in a capsule. The 
breakfasts were also supplemented with a capsule containing 80 mg para-
aminobenzoic acid (#361334; OPG Farma) as a recovery marker. Para-
aminobenzoic acid is completely absorbed and is excreted with urine.29 Subjects 
were instructed not to eat anything and to drink only water or coffee without milk 
from after the experimental breakfasts until lunch. At lunch at the Department, 
subjects swallowed another capsule with para-aminobenzoic acid, and they were 
instructed to swallow a third capsule with 80 mg para-aminobenzoic acid at dinner 
at home. 
Energy and nutrient intakes were calculated using the Dutch food 
composition table.30 Average energy intake on day 3 of each period according to 
24-h dietary recalls, was 10.4 ±1 .5 MJ, of which protein provided 13.2 ± 1.8% 
of energy, fat 33.9 ± 5.4%, and carbohydrates 52.5 ± 5.7%, with no differences 
between treatment periods. 
Collection of samples 
Venous blood samples were taken into vacuum tubes containing EDTA before 
breakfast, and at the time intervals depicted in Figure 2; zero time was 10 min after 
the start of the breakfast. Platelet-rich plasma was prepared within 15 min by 
centrifugation at 20 °C for 10 minutes at 200 g; it was stored at -80°C until analysis. 
Subjects collected urine in plastic bottles containing 0.13 g thymol (# 8167; 
Merck) for 24 hours after each supplemented breakfast. They stored each bottle in 
dry ice immediately after voiding. Three of the subjects, #1, #2, and #4, collected 
their 24-h urines in 9 to 10 separate portions, which allowed us to study their rates 
of excretion of quercetin. Upon arrival at the laboratory, urine samples were thawed 
in a water bath at 40 °C and mixed, and aliquots were taken within 30 min, frozen 
with liquid nitrogen, and stored at -40 °C until analyzed. Samples from the three 
subjects who had collected urine every few hours were homogenised per subject 
per period. The other samples were pooled per subject and per treatment day and 
thoroughly homogenised. 
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Analytical methods 
Quercetin, quercetin glycosides, glucuronides, and sulfates were extracted from 
plasma or urine and simultaneously hydrolysed to the aglycone form using 2 M HCl 
in aqueous methanol.28 For plasma 1.00 mL of methanol containing 2 g/L tert-butyl 
hydroxyquinone (TBHQ) and 0.40 mL of 10 M HCl were added to 0.60 mL of 
plasma in a 4 mL vial (#WAT022468, Waters, Milford, MA, USA) and mixed. The 
vial was sealed tightly with a cap (#72711, Waters, Milford, MA, USA) and septum 
(#73008, Waters, Milford, MA, USA), inserted into a preheated aluminum block 
(Reacti-Block C-1, Pierce Europe, Oud-Beijerland, The Netherlands), heated in an 
oven at 90 °C for 5 hours, allowed to cool, and centrifuged at 1000 g for 15 min 
after addition of 2.00 mL of methanol containing 2 g/L tert-butyl hydroxyquinone 
(TBHQ). We transferred 1.5 mL of the upper phase into an HPLC vial and added 15 
/vL 100 g/L ascorbic acid. For urine 15.0 mL methanol containing 2 g tert-butyl 
hydroxyquinone/L and 5 mL 10 M HCl were added to 5 g urine followed by mixing, 
the extract was refluxed at 90 °C for 8 hours with regular swirling, allowed to cool 
and subsequently brought to a final volume of 50 mL with methanol containing 2 
g/L ascorbic acid. Urine extracts were sonicated for 5 min and filtered through a 
0.45//m filter for organic solvents (Acrodisc CR PTFE; Celman Sciences, Ann Arbor, 
Ml) before HPLC analysis. 
For HPLC analysis we injected 20 //L onto a reversed-phase C18 column 
connected to a postcolumn reaction coil, where quercetin was transformed into a 
quercetin-aluminum complex. The fluorescence of the quercetin-metal complex was 
measured.31 
The limit of detection, i.e. the concentration producing a peak height three 
times the standard deviation of the baseline noise, was 0.007 /vM (2 ng/mL) for 
plasma and 0.01 /vM (3 ng/mL) for urine. Recovery of 0.33 nmol (100 ng) quercetin 
aglycone added to 1 mL plasma was 88 ± 3% (n = 6). Addition of 0.83 nmol (250 
ng) quercetin aglycone per gram of urine yielded a recovery of 99 + 7% (n = 3). 
Determinations in urine were carried out in duplicate. The relative standard 
deviation of duplicates was 4 % for plasma and 6 % for urine. We included a 
control sample of plasma and urine in each series of analyses; all values were within 
0.23 ± 0.046 //M (mean ± 2 SD, n = 15) for plasma and within 3.02 ± 0.55 //M 
(mean + 2 SD, n = 15) for urine. 
Para-aminobenzoic acid in urine was hydrolysed with 0.1 M HCl for 40 min 
in a boiling water bath and determined photometrically by using fluorescamine 
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(#F-9015; Sigma).32 A urine control sample was included in each series of analysis; 
values were within 66.7 ± 6.1 mg (mean ± 2 SD, n = 7). 
Data analysis 
We used the two-compartment open model C(t) = - C e "kt + A e ~at + B e * 
to describe the absorption and disposition, i.e. distribution, metabolism and 
elimination, of quercetin.33 We calculated the parameters of this model with 
nonlinear regression analysis using PCNONLIN version 4.0 (SCI Software, ClinTrials 
Inc., Lexington, KY, USA). 
Quercetin excreted in urine, the area under the plasma concentration - time 
curves (AUC), quercetin peak plasma levels as proportion of intake, and times to 
reach quercetin peak plasma levels were converted to log10 values for statistical 
testing. Differences between treatments were tested by analysis of variance using the 
Statistical Package for Social Sciences, SPSS/PC+ (SPSS Inc, Chicago) with subject, 
type of quercetin source, and type of quercetin source in preceding period as 
independent variables. The significance of differences was determined by paired t 
test. 
RESULTS 
Compliance with the quercetin-free diet 
The average quercetin intake from regular foods according to 24-h dietary recalls 
on the third day of the three diet periods was 1.5 ± 0.9 mg (5 ± 3 //mol). No 
difference in quercetin intake was observed between the three diet periods. Plasma 
quercetin concentration in the pre-breakfast plasma samples was on average 0.017 
± 0.013 / /M, whereas in the plasma samples 36 h after the supplements it was still 
0.040 ± 0.027 JJM. Thus, compliance with the quercetin-free diet was excellent. 
Plasma concentration of quercetin. 
Intake of onions and apples led to a rapid rise, and of the rutinoside (rutin) to a very 
slow rise of quercetin levels in plasma. The area under the plasma concentration -
time curve (AUC), the quercetin peak plasma level, and the time to reach the peak 
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Figure 2. Total quercetin concentration (mean ± SE) in plasma of nine subjects after 
ingestion of fried onions conatining 225 /jmol quercetin glycosides, apples 
containing 324 fjmol quercetin glycosides and 331 /jmol rutin. Each subject 
received each supplement in random order. 
• , onions; o, apples; k, rutinoside 
plasma level were all significantly (P <0.001) dependent on the type of supplement 
(Table 1). No significant relation with individual subject or with supplement given 
in the preceding period was found. 
The mean peak plasma level of quercetin was 0.74 //M (224 ng/mL) after 
onions, 0.30//M (92 ng/mL) after apples, and 0.30//M (90 ng/mL) after quercetin-3-
rutinoside. Peak levels were reached 0.7 h after ingestion of the onions, 2.5 h after 
the apples, and 9 h after the quercetin-3-rutinoside (figure 2, Table 1). In 4 out of 
9 subjects the quercetin concentration had reached its maximum observed 
concentration already at 0.5 h after the onions supplement, the first data point after 
consumption of the supplement. Therefore, the time needed to reach the peak level 
may have been overestimated, and the height of the peak underestimated. 
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To our knowledge no data are available on the tissue distribution of quercetin 
in man or animals, after absorption. In such a case, compartmental models are 
useful to describe the time course of the plasma quercetin concentration. A 
compartment should be interpreted as a collection of tissues that have similar blood 
flow and quercetin affinity. The change in quercetin concentration in each 
compartment is described by first-order kinetics.33 Disposition, i.e. distribution, 
metabolism and elimination, of quercetin in plasma after the onions and apples 
supplements was best described by a two-compartment model (Figure 2). 
Regression analysis was only possible for onions and apples; rutin (quercetin-3-
rutinoside) escaped the model because the delayed absorption resulted in too few 
data points to perform a proper regression analysis. The average half-lives of the 
absorption phase, the distribution phase, and the subsequent elimination phase 
were not statistically different between onions and apples (Table 1). We could still 
detect quercetin 36 h after ingestion of the supplements; at that time the mean 
plasma concentration was 0.060 ± 0.027/vM after onions, 0.030 ± 0.030//M after 
apples, and 0.027 ± 0.023 //M for quercetin-3-rutinoside (Figure 2). 
We calculated the relative bioavailability by comparing the areas under the 
plasma concentration - time curve (AUC) and found that the bioavailabilty of 
quercetin from both apples and the rutinoside was 30% of that of quercetin from 
onions (Table 1). 
Completeness of collection of urine 
Urinary recovery of para-aminobenzoic acid was 87.3 ± 10.0%, indicating 
acceptable compliance in collecting urine.29 On 6 out of 27 person-days subjects 
reported not to have swallowed the para-aminobenzoic acid capsule at dinner, so 
compliance of these subjects at evening could not be checked. As quercetin was 
almost completely excreted in urine within the first 10 h after the supplemented 
breakfasts (Figure 4), this uncertainty is of minor importance. 
Urinary excretion of quercetin 
The total amount of quercetin excreted in urine depended on the type of 
supplement (Table 2). No relation .with subject ór with supplement given in the 
previous period was found. Excretion of quercetin and its conjugates in urine was 
higher for quercetin from onions with 1.39% of the administered dose, than for 
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Kinetic parameters of quercetin absorption and disposition^ in nine subjects after 
one-time ingestion of fried onions containing 225 fjmol quercetin glycosides, apples 
containing 325 fjmol quercetin glycosides and 331 fjmol rutin. Each subject 
received each supplement in random order. Data for onions and apples were fitted 
to a model C(t) = - C e'kt + A é°" + B e~fo, where t equals time and C(t) plasma 
quercetin concentration. The correlation coefficient r was 0.99 for onions and 0.98 
for apples. 
Parameter 
Absorption 
half-life 
peak level 
time to reach peak 
level 
Distribution 
half-life 
Elimination 
half-life 
A U C o , . 
AUC0_36h 
(h) 
(fjM) 
(ng/ml) 
(h) 
(h) 
(h) 
(h.ng/mL) 
(h.ng/mL) 
Onions 
0.13 ± 0.09 
0.74 ± 0.05a 
224 ± 15a 
0.70 ± 0.36a 
4.4 + 1.4 
27.8 ± 30.5 
2974 ± 772 
2330 ± 283a 
Supplement 
Apples 
1.10 + 0.51 
0.30 ± 0.02b 
92 ± 6b 
2.51 ± 0.24b 
2.4 + 1.2 
22.6 + 10.6 
1334 ± 155 
1061 ± 125b 
Rutinoside 
-
0.30 ± 0.10b 
90 ± 31b 
9.3 ± 0.6C 
-
-
-
983 ± 326b 
1
 mean ± SE 
a,b,c
 results with a different superscript letter differ significantly (P < 0.001) 
not calculated; regression failed because of too few data points 
quercetin from apples with 0.44%, and for the rutinoside with 0.35% {Table 2). One 
subject (#3) excreted much more quercetin in urine after consumption of the 
quercetin-3-rutinoside than did the other subjects (Figure 3). Quercetin excretion of 
this subject after the rutinoside was only 30% less than that after the onions, 
whereas all the other subjects excreted at least 80% less after the rutinoside than 
after the onions. 
Subjects #1, #2, and #4, who had collected urine every few hours (Figure 4), 
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reached 90% of their cumulative excretion within 7.9 ± 0.8 hours after 
administration of the onions supplement, within 8.5 ±1 .1 hours after the apples, 
and within 12.9 h ± 7.0 hours after the rutinoside. 
The area under the plasma concentration - time curve (AUC0,36h) correlated 
highly with 24-h urinary excretion of total quercetin per subject (Figure 3) in these 
three supplements. 
Table 2. Intake of quercetin at breakfast and subsequent mean cumulative excretion 
of total quercetin in urine over 24 hours^. Each subject received each supplement 
in random order. 
Supplement 
(to breakfast) 
Onions (n = 9) 
Apples (n = 9) 
Rutin (n = 9) 
Intake 
(fjmol) 
225 ± 43 
325 ± 7 
331 + 7 
Excretion 
Total 
(jjmol) 
3.22 + 1.60 
1.45 + 0.71 
1.17+1.34 
in urine 
Total excretion as 
proportion of 
intake 
(%) 
1.39 + 0.49a 
0.44 ± 0.22b 
0.35 + 0.41b 
1 
a,b 
Mean + SD. 
'' Results with a different superscript letter differ significantly (P < 0.001). 
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Figure 3. Correlation between plasma total quercetin AUC0^36lv standardized at a 
dose of 7 00 mg quercetin equivalents, and urinary excretion as a percentage of the 
ingested dose in nine subjects who consumed three supplements in random order; 
r = 0.93, n = 27. 
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Figure 4. Cumulative amount of total quercetin (fjmol) excreted in urine of subjects 
#1, #2, and #4 after consumption of onions, apples and rutin (quercetin rutinoside). 
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DISCUSSION 
We found that the dietary antioxidant quercetin can readily enters the circulation 
after consumption of major dietary sources of quercetin. Absorption kinetics were 
highly dependent on the type of supplement. A major difference between these 
supplements is the type of glycoside. Quercetin from onions, which contain only 
glucosides, was rapidly absorbed, whereas pure quercetin-3-rutinoside, a major 
species in tea, showed a markedly delayed absorption. The absorption rate from 
apples, which contain a variety of glycosides, was intermediate. The bioavailabilty 
of quercetin from apples and of the rutinoside was only one third of that from 
onions. Thus, these results point to a predominant role of the sugar moiety in the 
absorption of dietary quercetin in the human body. However, it cannot be ruled out 
that differences between apples and onions in cell wall structures, location of 
glycosides in cells or their binding to cell constituents, also affect the liberation of 
quercetin from these foods in the gastrointestinal tract. 
Pharmacokinetics 
The biphasic concentration profile in the elimination of quercetin from plasma 
(Figure 2) could point to access of quercetin to poorly perfused tissues, where it may 
be transiently stored, or tissue binding. However, various conjugates formed upon 
or after absorption also may cause such a profile. 
After consumption of a single portion of onions and apples, a considerable 
fraction of the absorbed quercetin was present in plasma throughout the day as is 
indicated by the elimination half-lives of about 24 h. The time course of the plasma 
quercetin concentration after the rutinoside indicates a similar slow elimination. 
However, to get a more accurate estimation of these half-lives, the plasma samples 
should have been taken up to 3 days. The long half-lives implicate that repeated 
intake of onions, apples, and possibly tea would lead to a build-up of quercetin in 
plasma. The different rates of absorption of quercetin measured after ingestion of the 
various supplements will cause quercetin to enter the plasma continuously for a few 
hours following a mixed meal containing a variety of quercetin sources. We found 
a peak plasma concentration of 0.75 /vM or 225 ng/mL after administration of a 
single high dose of dietary quercetin equivalent to 4 times the average Dutch daily 
intake.16 Concentrations of the dietary antioxidant ß-carotene in human plasma are 
similar to this value.34 Thus plasma quercetin levels in subjects who regularly eat 
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onions may approach those of ß-carotene. 
Although urine was only collected for 24 hours, 24-h urinary excretion of 
quercetin predicted the area under the plasma concentration - time curve 
(AUC0,36h) excellently in these supplements (Figure 3). Thus, the relative bioavaila-
bility of quercetin from foods possibly can be predicted by measuring the 24-h 
quercetin excretion in urine. 
Our assay measures total quercetin after hydrolysis of native glycosides and 
of any glucuronides and sulfates formed by conjugation in the liver or the small 
intestine.28 Methylated quercetin formed in the liver35 is not included, because it is 
not hydrolysed in our assay. Thus, the concentrations in plasma reflect these 
conjugates only. It is possible that glucuronides, sulfates and glycosides, if present 
in plasma, each show a somewhat different distribution and elimination. In addition, 
for apples each separate glycoside probably is absorbed at its own rate. Thus, the 
pharmacokinetic parameters calculated reflect the overall absorption and disposition 
of various conjugates. However, at present no methods are available for the specific 
determination of these conjugates in plasma. 
Comparison with previous studies 
Apart from the faster absorption our results for onions are in agreement with those 
of a pilot study.18 We also previously showed that quercetin glycosides from onions 
and quercetin aglycone were absorbed in healthy ileostomy subjects.17 Absorption 
profiles of flavonols were determined in human studies by Nieder36 after adminis-
tration of flavonol glycosides from Ginkgo biloba. However, Nieder36 only studied 
2 subjects, and did not specify the types nor the amounts of flavonol glycosides 
administered with the extract, whereas urinary excretion was not studied. Gugler 
et al.37 could not detect any quercetin aglycone in plasma of human subjects after 
oral administration of even 4 g of quercetin aglycone, using a limit of detection of 
0.33 ji/M (100 ng/mL). However, their assay did not include quercetin conjugates. 
The elimination half-lives of 2 - 4 hours measured by Nieder36 after oral, and 
Gugler et al.37 after intravenous administration were much shorter than those 
reported here, possibly because in both studies the plasma concentration was only 
measured regularly up until 9 - 1 2 hours after administration. Most likely, these 
authors erroneously identified the distribution phase as the elimination phase. Cova 
et al.38 measured a slow elimination with a half-life of 32 hours in human subjects 
after oral administration of diosmin, a glycoside of the flavone diosmetin. 
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Disposition of diosmetin also was biphasic, which agrees with our data. 
Binding to plasma and urine constituents 
We needed a hydrolysis period of 5 to 8 hours to completely liberate quercetin from 
plasma and urine. This long period came as a surprise. It is to be expected that 
quercetin in plasma and urine is present either as glucuronide or sulfate.35 Sulfates 
are easily hydrolysed,39 whereas we previously have shown that glucuronides of 
quercetin are completely hydrolysed within 2 hours.28 Possibly, other types of 
conjugates, e.g. glycine conjugates33 are formed. No data are available on hydrolysis 
conditions required for these conjugates. In addition, quercetin aglycone added to 
plasma18 and urine17 was completely recovered within two hours of hydrolysis. The 
extended hydrolysis period suggests that binding of conjugates to plasma and urine 
constituents differs from that of the aglycone. Alternatively, the active process of 
absorption as opposed to the in vitro addition of the aglycone could lead to a 
different type of binding. Binding of polyphenols to protein in plasma is to be 
expected. Manach et al.40 reported binding to plasma albumin of circulating 
quercetin and of added aglycone. The nature of the urinary binding constituents or 
conjugates remains to be solved. 
Quercetin concentrations did not differ between platelet-rich and platelet-
poor plasma (results not shown). Thus, we could not confirm that quercetin is 
selectively bound to platelets after absorption from foods as was found by 
Gryglewski et al.41 with rabbit platelets in vitro. 
Metabolism 
Only 0.4 - 1.4% of the administered quercetin was recovered in urine. We have 
shown previously that human absorption of quercetin glucosides from onions 
amounted to 52%, whereas absorption of the pure aglycone was 24%, and of rutin 
17%.17 Thus, like many other compounds,42 absorbed quercetin is probably exten-
sively modified before being excreted by the kidneys. Our assay would pick up 
quercetin glucuronides and sulfates, but O-methylated quercetin, a hepatic 
metabolite in rats,35-43 would escape detection and so would metabolites which 
cannot be converted back into the aglycone by the hydrolysis procedure. Biliary 
secretion of quercetin glucuronides and sulfates has been described in rats.35,43 Only 
a part of these secreted quercetin conjugates will be reabsorbed and detected in 
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urine. However, no data are available on biliary secretion and reabsorption of 
quercetin in man. Thus, conjugates of quercetin formed by phase II liver metabolic 
reactions,33 except possibly O-methylated quercetin, only make up a small fraction 
of the metabolites formed. Hitherto, metabolites of quercetin caused by phase I 
metabolism have not been described.44 Bacteria of the colon constitute a second 
metabolic compartment, and transform quercetin into phenolic acids, which can be 
found in urine.45,46 Depending on their hydroxylation pattern, these are antioxidants 
themselves.47 In addition to the formation of such undetectable metabolites 
quercetin might also be partly stored and released slowly over subsequent days.48 
Mechanisms of absorption 
The short time to reach peak levels after onion glucosides points to absorption in 
the stomach or small intestine, whereas the prolonged time needed for the 
rutinoside to reach its peak, suggests that it transits the small intestine and is 
absorbed in the colon. We previously showed that intact glucosides are absorbed 
well.17 Hydrolysis of the rutinoside may be necessary before absorption can occur, 
which is in accordance with conventional thinking on flavonoid absorption.1 
Because the rutinoside is a ß-glycoside, only microorganisms in the colon can 
mediate hydrolysis, but at the same time they also degrade the liberated aglycone.1 
In contrast with the present study, we indeed found practically no urinary excretion 
of quercetin or its conjugates after administration of the rutinoside to ileostomy 
subjects who lack a colon.17 Again this provides evidence for a role of the colon in 
the absorption of quercetin rutinoside a major species in tea and in the diet of 
populations where tea is a common beverage. The area under the plasma quercetin 
concentration - time curve and the urinary quercetin excretion of subject #3 after 
rutin were both considerably higher than those of the other subjects (Figure 3). 
However, the time to reach a peak level of quercetin in plasma did not differ. 
Possibly this subject's absorption of rutin in the colon is more efficient. We 
previously reported another subject with an enhanced absorption of rutin.17 The 
reasons for these pronounced interindividual differences deserve further study. 
These mechanisms explain the limited bioavailability of the rutinoside in 
comparison with the glucoside. This study suggests that the sugar moiety has a 
predominant effect on the absorption and plasma levels of quercetin.17 
We found that quercetin glycosides present in major food sources of flavonols 
are absorbed, and are eliminated slowly throughout the day. Quercetin could thus 
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contribute significantly to the antioxidant defences present in blood plasma. Data 
for separate quercetin conjugates in foods and plasma are needed to fully evaluate 
the role of the dietary antioxidant quercetin in human health. 
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Abstract 
The role of the sugar moiety in the absorption of quercetin glycosides was studied. 
Nine fasting subjects ingested pure solutions of quercetin-4'- glucoside (311 /vmol) 
and quercetin-3-rutinoside (311 /ymol).Intake of quercetin glucoside led to a much 
more rapid and larger rise of quercetin levels in plasma than intake of the 
rutinoside. The mean peak plasma level of quercetin was 3.20 /vM after the 4'-
glucoside and only 0.23 JJM after quercetin-3-rutinoside. Peak levels were reached 
<0.6 h after ingestion of the 4'-glucoside, and 5.6 h after the 3-rutinoside. 
Elimination of quercetin from plasma was similar for the two sources with half-lives 
of about 24 h. We conclude that the 4'-glucoside was rapidly absorbed from the 
small intestine, whereas the 3-rutinoside was only absorbed from the colon. We 
propose that the sodium-glucose cotransporter in the brush border membranes of 
the small intestine plays a role in the absorption of the 4'-glucoside. 
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INTRODUCTION 
Flavonoids are polyphenols compounds from plants. Human diets provide several 
hundred milligrams per day from vegetables, fruits, tea and wine. Flavonoids are 
antioxidants; they scavenge radicals and inhibit lipid peroxidation.1 Lipid peroxida-
tion is probably involved in the formation of atherosclerotic plaques.2 Indeed, the 
intake of one class of flavonoids, the flavonols, was inversely associated with 
cardiovascular disease in several3"6 though not all78 studies in man. However, ab-
sorption of flavonoids is thought to be marginal, because most flavonoids are 
present in foods as ß-glycosides non-hydrolysable by pancreatic enzymes.9 These 
are thought to be non-absorbable, but in fact our earlier studies10 (Chapter 6) with 
foods suggested that the sugar moiety plays an important role in their absorption. 
We now studied the absorption in man of two pure quercetin glycosides: quercetin-
4'-0-ß-D-glucoside, a major flavonol in onions,11 and quercetin-3-O-ß-rutinoside 
(Figure 1) occurring in tea, apples and wine,1213 the major dietary sources of querce-
tin.6 
OH 
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Figure 1. Structure of the quercetin glycosides used. 
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METHODS 
The study was approved by the Nijmegen University Hospital Ethical Committee, 
and was fully explained to the participants, who gave their written informed 
consent. Nine healthy volunteers followed a quercetin-free diet 10 during two 
periods of 5 days. On the morning of day 3 we fed 311 //mol of quercetin-4'-0-ß-D-
glucoside (Spiraeosid 4564, Brunschwig Chemie B.V.) or 311 /vmol quercetin-3-O-ß-
rutinoside (Rutosidum DAB, OPC Farma) in 10 ml ethanol plus 200 ml water 
containing 2 g NaCI in random order to fasting subjects. Venous blood samples 
were taken at the times depicted in Figure 2. Quercetin and quercetin conjugates 
were extracted from plasma and hydrolysed to the aglycone free form using HCl/ 
methanol (Chapter 6) and analysed as described.22 
RESULTS AND DISCUSSION 
The absorption kinetics of quercetin-4'-glucoside and quercetin-3-rutinoside differed 
substantially (Figure 2). Intake of the glucoside led to a much more rapid and larger 
rise of quercetin levels in plasma than intake of the rutinoside. The mean peak 
plasma level of quercetin was 3.20 ± 0.40 //M (mean + SE) after the glucoside and 
only 0.23 + 0.05//M after the rutinoside. Peak levels were reached 0.61 ± 0.07 h 
after ingestion of the glucoside, and 5.6 ± 1.0 h after the rutinoside (Figure 2). In 
7 out of 9 subjects the quercetin concentration had reached its maximum already 
at the first time point, 0.5 h after ingestion of the supplement; therefore the actual 
maximum may have been even higher and reached earlier than suggested by Figure 
2. Elimination of quercetin from plasma was similar for the two sources with half-
lives of 33.7 ± 4.0 h after the 4'-glucoside and 23.3 + 5.7 h after the rutinoside 
(Figure 2). The bioavailability of the rutinoside, as judged by the area under the 
plasma concentration - time curve was only 18% of that of the glucoside. 
The short time to reach peak levels after the glucoside points to absorption 
from the small intestine, whereas the rutinoside apparently transits the small 
intestine without absorption and is only absorbed from the colon. Evidently the 
sugar moiety has a predominant effect on the absorption of quercetin glycosides. 
Enzymatic hydrolysis of ß-glycosides in the stomach or small intestine,9 or 
hydrolysis by HCl14 in the stomach is highly improbable. Similar to sugars, diffusion 
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Figure 2. Total quercetin concentration (mean ± SD) in plasma of nine subjects 
after ingestion of quercetin-4'-0-ß-D-glucoside (•) and quercetin-3-O-ß-rutinoside 
(O). Each subject received each supplement in random order. 
of hydrophilic polar glycosides across endothelial membranes is unlikely, thus 
absorption of the glucoside from the stomach can be excluded. We propose that the 
intestinal Na+-glucose cotransporter carries flavonoid glucosides into the enterocyte. 
The short time to reach peak levels of quercetin is similar to that for D-glucose.15 
Naphthol glycosides were transported across the intestinal wall of rats by the Na+-
glucose cotransporter.16 Absorption was better for the naphthol glucoside than for 
the galactoside, and the ß-anomer was absorbed better than the ct-anomer,16 in 
agreement with the known affinities of the sugar transporter.17 Studies on the 
structural requirements of phenyl glucosides for binding to this carrier concluded 
that transportable ß-D-glucosides have similar three-dimensional structures.18 
Phenyl-a-D-glucosides did not interact with the sugar carrier. Transport by the 
glucose cotransporter of methylazoxymethanol-ß-D-glucoside19 and sulphametha-
zine-D-glucoside was reported.20 This active transport of ß-D-glucosides offers an 
explanation for the extensive absorption of quercetin from onions10 (Chapter 6) in 
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which it is present as a ß-D-glucoside. The intermediate rate of absorption of 
quercetin from apples (Chapter 6) also fits in, because the major glycosides of 
apples are ß-D-galactosides and ß-D-xylosides.12 D-xylose and D-galactose are 
transported by the sugar cotransporter, but xylose less efficiently than glucose and 
galactose.17,21 The slow absorption of quercetin-3-rutinoside can be explained 
because rutinose cannot be transported by Na+-glucose cotransporter, hence it can 
only be absorbed after hydrolysis in the colon. 
Our data implicate that the glucose carrier in man will efficiently absorb 
glucose even when attached to a bulky molecule such as quercetin. Absorption of 
both food components and drugs might therefore be enhanced by attachment of a 
glucose molecule. 
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GENERAL DISCUSSION 
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The research described in this thesis focused on the following questions: 
- To what extent is dietary quercetin absorbed in humans? 
- Which factors affect its absorption from foods? 
- How does the concentration of quercetin in plasma change with time after 
ingestion of various quercetin-rich products? 
- What is the bioavailability of quercetin from major dietary sources? 
To answer these questions, we performed studies with quercetin-rich supplements 
or pure quercetin glycosides in healthy ileostomy subjects who lack a colon 
(Chapter 4) or in normal healthy volunteers (Chapters 5,6,7). We developed a 
sensitive analytical method (Chapter 3) to be able to measure quercetin in plasma 
and urine. 
We have found that absorption of quercetin glycosides from the diet can be 
appreciable: up to 52%. The sugar moiety of the glycoside was a major determinant 
of absorption. The concentration of quercetin in plasma increased quickly after 
consumption of quercetin-4'-glucoside, and only slowly after the quercetin-3-
rutinoside. We propose that the sodium-glucose cotransporter is involved in the 
absorption of quercetin-4'-glucoside. The elimination half-life of about 24 hours was 
independent of the type of glycoside. Accumulation of quercetin in plasma will 
occur because of this long half-life; steady-state levels of 0.2 JJM are attainable. The 
bioavailability of quercetin of apples and of the rutinoside was 30% relative to 
onions. 
Absorption of glycosides versus aglycones 
Quercetin glucosides contained in onions were well absorbed, whereas the free 
aglycone and the rutinoside were less well absorbed (Chapter 4). Except for the 
rutinoside, these results contradict conventional thinking on absorption of ß-glyco-
sides (Chapter 2). This traditional way of thinking assumed that ß-glycosides are 
non-absorbable from the intestine, because they are too hydrophilic for diffusion 
across intestinal membranes. Following this explanation, the aglycone is expected 
to have more favourable properties for diffusion. However, model studies on 
absorption of flavonoid aglycones and glycosides across intestinal membranes to 
substantiate this aglycone hypothesis are lacking. 
As ß-glycosides are only hydrolysable by bacteria in the colon,1 absorption 
in ileostomy volunteers would be negligible, because bacteria are practically absent 
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in these subjects. This provides a way for experimental testing. We indeed found 
that only a little amount of quercetin was excreted in urine after ingestion of the 
rutinoside, except in one subject. Absorption of the agiycone was somewhat higher 
than that of the rutinoside, but the conventional agiycone hypothesis would not 
predict the high absorption of the glycosides of onions as compared to the agiycone 
(Chapter 4). 
However, non-enzymatic hydrolysis of glycosides by HCl in the stomach 
would be conceivable. Differences in hydrolysis rates of various glycosides and in 
situ liberation of the agiycone could then possibly favour absorption of the 4'-
glucoside.To test this, we mimicked gastric conditions in an in vitro incubation 
experiment with quercetin-4'-glucoside present in onions, and quercetin-3-rutino-
side and showed that hydrolysis was completely absent (Table 1). This fits with our 
experience in vitro that hydrolysis of glycosides is only complete after boiling with 
hydrochloric acid at 90°C for at least 2 h.2 
Thus, these results contradict that ß-glycosides are only absorbable via the 
agiycone after hydrolysis. Although we only indirectly measured absorption in the 
study with ileostomy volunteers, plasma quercetin values in normal volunteers 
(Chapters 6 and 7) confirmed that the quercetin glucoside of onions was absorbed 
far better than the rutinose glycoside. 
Table 1. Resistance of quercetin ß-glycosides against hydrolysis by hydrochloric 
acid. Quercetin agiycone and glycosides, 100 ng/ml each, were incubated in 0.1 
M HCl at 37 "C. The concentration of free quercetin agiycone in the acid solutions 
was measured after the periods indicated. 
Incubation per 
(min) 
5 
10 
20 
od 
Free quercetin agiycone 
Quercetin 
agiycone 
112 
91 
101 
Quercetin-4' 
glucoside 
< 2 ' 
<2 
<2 
(ng/ml) 
Quercetin-3-
rutinoside 
<2 
< 2 
< 2 
limit of detection 
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Mechanisms of absorption 
Small intestine 
All three studies (Chapters 4,6,7) showed that absorption of quercetin contained in 
onions was markedly more efficient and substantially faster than that of the 
rutinoside. This suggests different mechanisms of absorption. The time to reach peak 
levels of quercetin in plasma after consuming onions was less than 0.7 h (Chapter 
6), and suggests absorption from the stomach or small intestine.3 A major glycoside 
of onions is quercetin-4'-glucoside, and the study with a pure solution of this 
glucoside gave very similar results (Chapter 7) to the study with onions (Chapter 6). 
Thus, the matrix of onions did not affect the time to reach peak levels in plasma.On 
the other hand, absorption of a pure solution of quercetin-4'-glucoside was 
substantially higher and faster than that of a pure solution of quercetin-3-rutinoside. 
Consequently, the sugar moiety of the glycoside probably is an important 
determinant for its absorption. As was shown above, hydrolysis of glycosides in the 
stomach is highly improbable. Analogous to sugars, diffusion of the hydrophilic 
polar glycosides across endothelial membranes is unlikely, thus absorption of the 
glucoside from the stomach can be excluded. We hypothesize that the active 
sodium-glucose cotransporter, a transport protein complex resident in the brush 
border membrane of the small intestine, is involved in the absorption of quercetin-
4'-glucoside. However, the involvement of this active transporter has to be confir-
med in a model system. Brush border membrane vesicles of rabbits or rats would 
constitute a suitable in vitro system4,5 to do this. 
If the sodium-glucose cotransporter is involved in the active absorption of 
quercetin-4'-glucoside, it can be predicted that other quercetin glycosides also have 
an efficient absorption. Apart from glucose, galactose has a high affinity for this 
carrier, whereas xylose also will bind, though with a lower affinity.4,6,7 In addition, 
quercetin galactosides and xylosides present in foods also have the favourable ß-
anomeric configuration for transport.8 Results for apples, rich in these glycosides, 
but also containing substantial amounts of the rutinoside,9 were consistent with the 
proposed absorption mechanisms. We observed a broad peak in the plasma querce-
tin concentration versus time curve, indicating that the various glycosides were 
absorbed at different rates (Chapter 6). 
Results of the pilot study with onions (Chapter 5) were not entirely consistent 
with the other onion study (Chapter 6). In the pilot study, the rate of absorption was 
smaller. However, peak levels and elimination half-lives were similar. These studies 
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used different batches of onions. Onions also contain quercetin-3,4'-diglucoside in 
addition to the 4'-glucoside.10 No information on the individual glucosides was 
available as only total quercetin glycosides were determined. We speculate that the 
proportion of these two glucosides differed between these studies. This would 
imply that the 3,4'-diglucoside and the 4'-glucoside were absorbed at different rates. 
In addition, between-persons variation in absorption also could be an explanation. 
We found that one of the subjects of the pilot study had a similar slower absorption 
of the pure 4'-glucoside solution (results not shown). 
Colon 
The relatively long time needed to reach peak concentrations of quercetin in plasma 
after ingestion of the 3-rutinoside indicates that the rutinoside was predominantly 
absorbed from the colon (Chapter 7). This time to reach peak levels was at least 9 
times longer than that after the 4'-glucoside. We obtained a similar ratio when com-
paring onions and the rutinoside (Chapter 6). The indispensable role of the 
microflora in the absorption of the rutinoside was apparent by comparing ileo-
stomists (Chapter 4) with normal volunteers (Chapters 6). When we excluded the 
high absorber of rutinoside in each study (see next paragraph), the average urinary 
excretion as a percentage of rutinoside intake in the ileostomy study was only 
0.010% (95% Confidence lnterval:0.002% - 0.018%) as opposed to 0.22% (0.13% -
0.31%) in normal volunteers. 
In each study we found a subject with an enhanced absorption of the 
rutinoside (Chapters 4,6,7). As the times to reach peak values were not different 
from the other subjects, it can be hypothesised that they also absorb the rutinoside 
from the colon, but more efficiently. This could point to inter-individual variations 
in gastro-intestinal microflora or an aberrant type of colonic absorption. 
Implications for enhancement of absorption of beneficial components 
The potential involvement of the sodium-glucose carrier in the absorption of 
quercetin-4'-glucoside suggests that it has a certain degree of tolerance for 
substituents in the glucose molecule. Apparently a large substituent at carbon atom 
C1 of the glucose moiety is possible in the ß-configuration. Previous studies found 
that smaller substituents, viz. various ß-phenylglucosides, were transported by the 
sodium-glucose cotransporter.811 It was also found that larger substituents are 
possible in the ß-configuration at C1 than for the a-configuration.4,8. Knowledge on 
requirements of glycoside structures for transport by the sugar-carrier may be used 
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to design sugar-conjugated components with improved absorption. Thus, not only 
the absorption efficiency of a beneficial component might be improved, but also its 
site of absorption might be chosen. 
Bioavailability 
We performed single dose studies with onions and apples to compare the 
bioavailability of quercetin in these foods (Chapter 6). Bioavailability of both the 
quercetin form contained in apples and of pure quercetin rutinoside, was one third 
relative to onions. However, black tea is the major dietary source of quercetin in the 
Netherlands.12 A single dose study with tea was not feasible because of the low 
quercetin concentration of tea infusion. The major glycosides of quercetin in black 
tea are quercetin-3-rutinoside, quercetin-3-glucoside and quercetin-3-galactoside.13 
At a rough estimate, the rutinoside accounts for about 50%, the glucoside for 30% 
and the galactoside for 20% of the quercetin glycosides present in tea leaves. The 
limited data available indicate that these proportions may vary depending on the 
origin of the tea.13 Thus, our choice for the rutinoside to represent tea in these 
studies was fair. Assuming that both the 3-glucoside and the 3-galactoside are as 
well absorbed as the 4'-glucoside, which is probably too optimistic, we estimate 
that the bioavailability of quercetin glycosides of tea is less than two thirds of that 
of onions. 
This estimation of the bioavailability of quercetin contained in tea indicates 
that the exposure of quercetin from tea was overestimated relative to that of onions 
in the epidemiological studies (Chapter 7). This may be relevant in the Dutch cohort 
studies, especially when large differences between individuals in tea intake existed. 
In that case, misclassification of individuals in groups of real quercetin exposure 
may have occurred. 
These differences in bioavailability may also have affected the cross-cultural 
study, where large differences in dietary quercetin sources between the countries 
were observed.14 However, bioavailability from wine, an important dietary source 
in some of the countries, has not been determined. 
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Prospects for bioavailability research 
We have shown that the type of glycoside is a major determinant of the bioavaila-
bility of quercetin in foods. Hence, the amounts and types of quercetin glycosides 
of a particular food will predict the bioavailability of the quercetin present. To do 
so, the bioavailability of individual pure quercetin glycosides will have to be 
determined. Relevant quercetin glycosides have to be chosen, and it can be 
predicted that less than 10 different types of glycosides will significantly contribute 
in major dietary sources of quercetin. After determination of the contents and types 
of glycosides in a particular food, its bioavailability of quercetin can then be 
calculated using these data on bioavailability of individual glycosides. This 
'molecular approach' will make dietary trials with human volunteers superfluous. 
Without this knowledge, dietary trials with each type of food would be necessary, 
and these would have little or no predictive value for other foods. In addition, it 
would be difficult to control all variables in a dietary trial, which would lead to 
imprecise outcomes. 
Accumulation of quercetin in plasma 
We measured elimination half-lives for quercetin of about 24 h (Chapters 5,6,7). 
Elimination half-life values for the glucoside and rutinoside of quercetin, as well as 
those obtained after ingestion of onions and apples were similar. This indicates that, 
independent of the source, absorbed quercetin is cleared from the body by the same 
route of elimination. The elimination half-life (24 h) is at least equal, but probably 
larger than the average consumption interval (3-24h) for quercetin-containing foods. 
As a consequence, daily habitual consumption of quercetin-rich foods will lead to 
accumulation of quercetin in plasma, causing a steady-state level in blood. Habitual 
consumption once a day of quercetin-rich products with an elimination half-life of 
24 h, will accumulate the amount of quercetin in the body as compared to the daily 
dose by a factor 1.4.15 Assuming a linear dose-response relation, an average steady-
state level in plasma of 0.18 JJM (55 ng/ml) quercetin can be predicted through 
habitual consumption once a day of 100/vmol (30 mg) quercetin in the form found 
in onions. This amount of quercetin is equivalent to 100 g of onions. The minimum 
plasma concentrations will then be about 0.13 /vM (40 ng/ml) and the maximum 
concentration 0.25 /vM (75 ng/ml).15 However, other quercetin-containing foods, 
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e.g. tea, will normally be consumed several times during the day, which will 
decrease the variation in plasma quercetin concentrations. 
Analytical aspects 
Postcolumn chelation of quercetin enhanced fluorescence intensity considerably 
(Chapter 3) and allowed us to detect quercetin in plasma at levels as low as 7 nM 
(2 ng/ml). This limit of detection was sufficiently low to adequately monitor the 
elimination of quercetin from plasma. A drawback of this derivatization procedure 
is the requirement of a free hydroxyl group in the 3-position of the quercetin 
molecule. Conjugation at this position blocked chelation and subsequent detection. 
Therefore, hydrolysis of plasma samples prior to analysis was imperative. 
Quercetin proved to be tightly bound to plasma and possibly also to urine 
constituents. A relatively long hydrolysis period was required (Chapter 6). Our 
attempts to measure quercetin in whole blood were unsuccessful. In vitro recovery 
experiments with quercetin aglycone revealed a high quercetin binding capacity of 
erythrocytes in our extraction medium. Even prolonged hydrolysis periods were not 
sufficient to remove quercetin bound to erythrocytes. We could not find any querce-
tin in whole blood of subjects, whereas we did find normal values in the plasma 
prepared from these blood samples. 
Metabolism 
Only a small fraction of the ingested dose of quercetin, 1.4% or less, was excreted 
in urine, whereas absorption of quercetin of onions was 52% (Chapters 4 and 6). 
These data suggest extensive metabolism of quercetin. Our plasma and urine values 
included quercetin aglycone and its conjugates that are hydrolysable with hydro-
chloric acid. In addition to quercetin conjugates we found 3'-methoxyquercetin 
conjugates in plasma and urine, but not 4'-methoxyquercetin, a metabolite 
described in rats.16 However, the concentration of this metabolite also was small. 
Biliary excretion of absorbed quercetin could be a significant route of excretion 
(Chapter 2). This would expose quercetin conjugates to microbiological degrada-
tion. Bacteria can split the heterocyclic oxygen-containing ring of quercetin giving 
rise to various hydroxyphenolic acids (see Chapter 2, page 41). These metabolites 
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can evidently be absorbed because many researchers have reported their presence 
in urine (Chapter 2). 
Thus, we only could detect a small fraction of the orally administered 
quercetin. Unlike the situation with rodents, the metabolism of quercetin by 
humans has not been extensively studied. Quantitative data on metabolism of quer-
cetin in rodents are limited but it does point to extensive metabolism {Chapter 2). 
Plasma concentration and antioxidant activity 
A question to be answered by these studies was whether the plasma quercetin 
concentration after habitual consumption of quercetin-containing foods, may have 
a potential protective antioxidant effect. As calculated above, average steady-state 
levels of 0.2 yuM quercetin with modest fluctuations throughout the day are 
attainable. This concentration will be reached after consumption of onions 
containing 30 mg of quercetin, corresponding to the intake in the highest tertile of 
the Zutphen Study showing reduction of risk.17 Average plasma concentrations of 
antioxidant nutrients are 0.3 - 0.6//M for ß-carotene, 15 - 40//M for a-tocopherol, 
and 3 0 - 1 5 0 //M for ascorbic acid.18 The antioxidant activity of an individual 
component has to be taken into account to be able to compare its contribution to 
the total antioxidant potential of plasma. The Trolox equivalent antioxidant activity 
(TEAC) of quercetin is 4 fold higher than that of the antioxidant (pro)vitamins.19 
However, quercetin metabolism introduces groups bound to the phenolic hydroxyls 
(Chapter 2). These modifications will decrease the antioxidant activity, because 
quercetin is a hydrogen-donating antioxidant.20,21 Quercetin was able to inhibit low 
density lipoprotein (LDL) oxidation in vitro, with IC50 values of 2 - 20 JJM.2223 These 
data suggest that physiological quercetin concentrations are possibly too low to 
affect LDL oxidation in plasma. Oxidation of LDL occurs primarily in the arterial 
wall (intima), into which LDL particles can penetrate.24,25 It is not known whether 
quercetin can reach this site of oxidation. Thus, it is not clear whether dietary 
quercetin can play a role in the protection of LDL particles. However, quercetin 
protected cells in vitro against the cytotoxic effect of previously oxidized LDL with 
an IC50 value of only 0.1 //M.23 
As was discussed above, bacterial metabolism can cleave the quercetin 
molecule generating absorbable hydroxyphenolic acids. These molecules also have 
phenolic hydroxyl groups and show antioxidant activity. Trolox equivalent antioxi-
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dant activity (TEAC) values of hydroxyphenolic acids, e.g. hydroxycinnamic acids, 
are equal or higher than TEACs of antioxidant vitamins.19,20 Thus, in addition to the 
parent quercetin molecule, its metabolites may contribute to the antioxidant effect 
of dietary quercetin in the body. 
Apart from its concentration and antioxidant activity, the relative importance 
of an individual antioxidant in plasma depends on the nature of the oxidant, the 
type of target molecules to be protected, and its ability to reach the target molecules 
or cellular and subcellular membranes.18,26 In vitro systems to measure the 
antioxidant activity should therefore be adapted to its putative biological action.20 
Ultimately, only studies that measure in vivo antioxidant effects of a given molecule 
can be decisive for its potential protective properties. 
Do dietary polyphenols contribute to the antioxidant defences of the body? 
There are many clinical conditions in which oxygen free radicals are thought to be 
involved.27 Consequently, antioxidants in the diet which complement the actions 
of the antioxidant enzymes could play an important role in the prevention of 
oxidative damage by these radicals. Much of the research has been focused on 
coronary heart disease. The role of oxidised LDL proposed in the pathogenesis of 
atherosclerosis has generated much research. In the laboratory, a whole range of 
antioxidants has been shown to be able to prevent LDL-oxidation when added to 
isolated LDL. Not surprisingly, polyphenols20,22,23'28,29 which by their chemical 
nature are antioxidants, or food extracts rich in polyphenols such as wine,30"34 also 
show this protective action towards in vitro LDL-oxidation. However, the clinical 
relevance of these laboratory findings is still obscure. 
Oxygen free radicals can cause structural damage to DNA, activate signal 
transduction pathways that are related to growth, differentiation, and cell death. 
They also can modulate the activity of stress proteins and stress genes.35 Because of 
these properties oxygen free radicals are carcinogens,35 which implies that anti-
oxidants might protect against cancer. Indeed, anticarcinogenic properties of tea 
polyphenols and tea extracts have been demonstrated in many animal models.36 In 
contrast to these experimental studies, epidemiological studies on tea consumption 
are inconclusive.37,38 No protective effects on stomach or lung cancer were record-
ed.37 A protective effect of green tea in colon cancer was suggested.37 Possibly, be-
neficial effects from tea are confined to high intakes in high-risk populations.37 
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The family of polyphenols occurring in plant foods is vast, and comprises of 
galloyl and hexahydrodiphenoyl esters and their derivatives, condensed proantho-
cyanidins, flavonoids, and hydroxybenzoic and hydroxycinnamic acids.39 An 
estimation of the total polyphenol intake is difficult, because only very limited data 
on food contents of these various polyphenols are available. The often quoted 
intake of all flavonoids of 1 g/day in the U.S.A.,40 or 650 mg/day expressed as 
aglycones, is most certainly too high. We estimate the daily intake of all flavonoids 
to be a few hundreds of milligram per day expressed as the aglycones (Chapter 2, 
page 24). The flavonol/flavone subgroups accounted for 23 mg/day in the 
Netherlands.41 The intake of antioxidant (pro)vitamins is much lower than that of 
polyphenols. It was recently estimated in the Second Dutch National Food Con-
sumption Survey of 1992, a representative sample of households composed of 6200 
Dutch persons aged 1 - 92 years.42 The average intake of vitamin C was 73 mg/day, 
of vitamin E 13.7 mg/day and of ß-carotene 1.2 mg/day. 
In vitro data on the antioxidant activity of polyphenols show that they are 
better antioxidants than the classic antioxidant vitamins.19,20 Thus, if the antioxidant 
activity is an important biological property, the potential role of dietary polyphenols 
in disease prevention is very promising. However, different from the antioxidant 
vitamins, only little is known on the human physiology of polyphenols. This thesis 
shows that absorption of quercetin can be appreciable, and that plasma concen-
trations are comparable to ß-carotene. But nothing whatsoever is known about 
tissue distribution and target tissues for quercetin. Data on absorption of other 
polyphenols in humans are not known, except for catechins. However, the data 
available show that absorption is more than marginal, thus exposure of body tissues 
to dietary flavonoids seems feasible at least. 
To be able to evaluate the role of dietary antioxidants in disease prevention, 
there is a need to develop assays for assessing in vivo free radical damage and pro-
tection against it. Isoprostanes as markers for lipid peroxidation in vivo look 
favourable.43 Autoantibodies against oxidised LDL44 seem a more promising tool 
than the old Esterbauer test.45 Important questions to be addressed are: what bio-
molecule is the dietary antioxidant supposed to protect, and will the compound be 
present in vivo at or near the biomolecule in sufficient concentration? Research on 
these questions has only very recently been started. Ultimately a benefit to cardio-
vascular disease or cancer has to be proved in randomised clinical trials. Even the 
supposed benefits of the antioxidant vitamins to cardiovascular disease remain to 
be demonstrated in clinical trials.46 
764 CHAPTER 8 
CONCLUSIONS 
Absorption 
• Absorption of quercetin glycosides can be appreciable: at least 50%. 
• The sugar moiety of quercetin glycosides is a major determinant of absorption: 
conjugation with glucose enhances absorption. 
• Quercetin-4'-glucoside is absorbed from the small intestine; the active sodium-
glucose cotransporter is probably involved. 
• Quercetin-3-galactoside and quercetin-3-xyloside may also be transported by 
the sodium-glucose carrier. 
• Glucosylation of a beneficial compound potentially offers opportunities for 
enhancement of its absorption. 
• Quercetin-3-rutinoside is absorbed from the colon: hydrolysis of the sugar 
moiety by bacteria is required. 
Metabolism 
• Quercetin is extensively metabolised: less than 1.5% of the ingested quercetin 
excreted in urine had an intact flavonoid structure. 
Bioavailability 
• Bioavailability of both the quercetin form found in apples and of pure 
quercetin rutinoside was 30% relative to onions. 
• Bioavailability of the quercetin form found in tea is estimated at less than 66% 
relative to onions based on the composition of quercetin glycosides of tea. 
• Quantitative data for separate glycosides of a food can predict the bioavail-
ability of quercetin contained in it. 
Plasma concentration 
• Steady-state levels of quercetin of about 0.2 //M are attainable, due to 
accumulation. 
• Plasma concentration is comparable to ß-carotene, but smaller than that of 
antioxidant vitamins. 
• The concentration of quercetin in plasma is probably too low to prevent LDL-
oxidation. 
• Metabolites of quercetin potentially may play an antioxidant role. 
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Summary 
Flavonoids are secondary plant metabolites belonging to the large and diverse group 
of polyphenols. The ubiquitous occurrence of flavonoids in plant foods is of interest 
because it may help to explain the inverse association between consumption of 
vegetables and fruits and risk of chronic diseases. Flavonoids are antioxidants, 
because of their phenolic hydroxyl groups. Oxidative damage to tissues is 
hypothesised to play an important role in cancer and cardiovascular disease. 
Quercetin, a flavonoid occurring in tea, onions, apples and red wine, is a strong 
antioxidant and prevents oxidation of low density lipoproteins (LDL) in vitro. Oxidi-
sed LDL has been found in atherosclerotic lesions of humans, and increased plasma 
concentrations of autoantibodies against oxidized LDL occur in patients with 
atherosclerosis. Indeed, the intake of quercetin was inversely associated with 
subsequent cardiovascular disease in some but not all studies (Chapter 1). Sufficient 
absorption from the diet is a prerequisite for its potentially protective role in 
cardiovascular disease. This thesis describes studies on the human absorption and 
elimination kinetics of dietary quercetin glycosides, the predominant form in foods. 
In Chapter 2 we reviewed results of studies on the absorption, metabolism 
and pharmacokinetics of flavonoids reported in the literature. Most studies have 
been carried out with free flavonoid aglycones in rodents using unphysioiogically 
high doses. Absorption depended on the type of flavonoid and was between 4 and 
58%. The absorption from dietary sources, containing flavonoid glycosides, is 
largely unknown. In the metabolism of flavonoids the liver and the colon are 
important. Evidence for phase II biotransformation reactions in the liver is abundant. 
Colonic bacteria are involved in hydrolysis of glycosides and conjugates and in ring 
fission producing phenolic acids which are absorbed. Three types of ring fission 
depending on the structure of the flavonoid C-ring have been described. The 
susceptibility to ring cleavage is determined by the pattern of free hydroxyl groups 
in the flavonoid molecule. Very few quantitative data on metabolism are available. 
Pharmacokinetic data on flavonoids are scarce and absolute bioavailability of 
dietary flavonoids has not been determined. 
To be able to study the absorption of flavonols in man, we developed a 
postcolumn derivatization technique for flavonols in HPLC with fluorescence 
detection using aluminum (Chapter 3). Variables governing postcolumn chelation 
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of quercetin, such as water content, buffer and organic modifier of the eluent, 
concentration of Al3+ and presence of acetic acid in the postcolumn reagent, and 
temperature were studied and optimized. Of the flavonoids, only flavonols that 
contain a free 3-hydroxyl and 4-keto oxygen binding site form fluorescent 
complexes with Al3+. The method has a detection limit of 0.50 nM (0.15 ng/mL) for 
quercetin, 0.17 nM (0.05 ng/mL) for kaempferol, 1.5 nM (0.45 ng/mL) for myricetin, 
and 0.17 nM (0.05 mg/mL) for isorhamnetin, thus improving detectability of quer-
cetin 300 fold as compared to that possible with UV detection. The reproducibility 
relative standard deviation of the method was 1.4%. 
In Chapter 4, we studied the absorption of various forms of quercetin. Nine 
healthy ileostomy subjects were studied, to avoid losses of quercetin caused by 
colonic bacteria. They followed a quercetin-free diet for 12 days; on days 4, 8 and 
12 they received a supplement of fried onions, rich in quercetin glucosides (295 
/ymol), at breakfast, pure quercetin rutinoside (331 /ymol), a major quercetin 
compound in tea or 331 //mol (100 mg) pure quercetin aglycone, in random order. 
Subsequently, participants collected ileostomy effluent and urine for 13 hours. In 
vitro incubations of quercetin or its glycosides with gastrointestinal fluids showed 
minimal degradation. Absorption of quercetin, defined as oral intake minus 
ileostomy excretion and corrected for 14% degradation within the ileostomy bag, 
was 52 + 15% for quercetin glucosides from onions, 17 ± 15% for quercetin 
rutinoside, and 24 + 9% for quercetin aglycone. Mean excretion of quercetin or its 
conjugates in urine was 0.5% of the amount absorbed; quercetin excretion in urine 
was negatively correlated with excretion in ileostomy effluent (r —0.78, n = 27). 
Thus, humans absorb appreciable amounts of quercetin and absorption is enhanced 
by conjugation of quercetin with glucose. 
We studied the time course of the plasma quercetin concentration in two 
subjects after ingestion of fried onions containing 212 /ymol quercetin glucosides 
(Chapter 5). Peak plasma levels of 0.65 /vM (196 ng/ml) were reached after 2.9 h, 
with a half-life of absorption of 0.87 h. The half-life of the distribution phase was 3.8 
h, and of the subsequent elimination phase 16.8 h. After 48 h the plasma concen-
tration was about 0.033 /vM (10 ng/ml). These data showed that quercetin 
glucosides contained in onions are absorbed and are eliminated slowly throughout 
the day. Thus, the dietary antioxidant quercetine could increase the antioxidant 
capacity of blood plasma. 
In Chapter 6 we studied the absorption and elimination kinetics of quercetin 
contained in major dietary sources, viz. fried onions containing 225 /ymol glucose 
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compounds of quercetin, apples containing 325 /vmol of both glucose- and non-
glucose quercetin glycosides, and of 330/ymol quercetin-3-rutinoside. Peak plasma 
levels were 0.75 //M (225 ng/ml) 0.7 h after ingestion of the onions, 0.30 //M (90 
ng/ml) 2.5 h after the apples, and 0.30 //M (90 ng/ml) 9 h after the rutinoside. Half-
lives of elimination were 28 h for onions and 23 h for apples. Bioavailability of both 
quercetin from apples and of pure quercetin rutinoside was 30% relative to onions. 
Urinary excretion of quercetin was 1.39% of the ingested dose for onions, 0.44% 
for apples, and 0.35% for quercetin-3-rutinoside. We concluded that quercetin 
glucosides contained in onions are absorbed rapidly, that the rutinoside is absorbed 
slowly, and that the overall absorption rate of quercetin glycosides contained in 
apples is intermediate. We propose that the sugar moiety of the glycoside is an 
important determinant of absorption. Absorbed quercetin was eliminated only 
slowly from the blood. Repeated consumption of quercetin-containing foods may 
therefore lead to accumulation of quercetin in blood and increase the antioxidant 
capacity of blood plasma. 
The role of the sugar moiety in the absorption of quercetin glycosides was 
studied in Chapter 7. Nine fasting subjects ingested pure solutions of quercetin-4'-
glucoside (311 /ymol) and quercetin-3-rutinoside (311 //mol). Intake of quercetin 
glucoside led to a much more rapid and larger rise of quercetin levels in plasma 
than intake of the rutinoside. The mean peak plasma level of quercetin was 3.20//M 
after the glucoside and only 0.23 //M after the rutinoside. Peak levels were reached 
<0.6 h after ingestion of the glucoside, and 5.6 h after the rutinoside. Elimination 
of quercetin from plasma was similar for the two sources with half-lives of about 24 
h. We concluded that the glucoside is rapidly absorbed from the small intestine, 
whereas the rutinoside is only absorbed from the colon. We propose that the 
sodium-glucose cotransporter in the brush border membranes of the small intestine 
plays a role in the absorption of the glucoside. 
In conclusion (Chapter 8), absorption of quercetin glycosides present in foods 
can be appreciable. The sugar moiety of the glycoside is an important determinant 
of its absorption, and absorption of glycosides is possible without prior hydrolysis 
of the sugar bond. We propose that quercetin-4'-glucoside is drawn into the 
enterocyte by its glucose moiety, which is carried by the sodium-glucose 
cotransporter. The composition of a food in terms of quercetin glycosides will 
predict the bioavailability of the quercetin contained in it. After absorption, 
quercetin is only slowly eliminated from plasma. This will lead to accumulation of 
quercetin in plasma after regular consumption of quercetin-containing foods.The 
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plasma concentration of quercetin can be comparable to ß-carotene, but is smaller 
than that of the antioxidant vitamins. Antioxidant metabolites of quercetin formed 
after ingestion may contribute to the potential antioxidant protection by dietary 
quercetin. 
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Samenvatting 
Flavonoiden zijn secundaire plantenmetabolieten die tot de grote en diverse groep 
van polyfenolen behoren. Het wijdverspreid voorkomen van flavonoïden in 
plantaardige voedingsmiddelen is interessant omdat dit mogelijk een verklaring 
biedt voor het inverse verband tussen groente- en fruitconsumptie en het risico voor 
chronische ziekten. Flavonoïden zijn antioxidanten doordat ze fenolische 
hydroxylgroepen bevatten. Er wordt verondersteld dat oxidatieve schade aan 
weefsels een belangrijke rol speelt in hart- en vaatziekten en kanker. Quercetine, 
een flavonoïd dat voorkomt in thee, uien, appels en rode wijn, is een krachtige 
antioxidant en voorkomt oxidatie van lage dichtheids lipoproteïnen (LDL) in het 
laboratorium {in vitro). In een aantal, maar niet alle, epidemiologische studies werd 
dan ook een invers verband gevonden tussen de inneming van quercetine en hart-
en vaatziekten (Hoofdstuk 1). Een voorwaarde voor deze mogelijk beschermende 
rol in hart- en vaatziekten is dat quercetine voldoende geabsorbeerd wordt uit 
voedingsmiddelen. Dit proefschrift beschrijft onderzoek naar de kinetiek van 
absorptie en eliminatie bij de mens van quercetine glycosiden, de voornaamste 
vorm in levensmiddelen. 
In Hoofdstuk 2 gaven we een overzicht van studies over absorptie, 
metabolisme en farmacokinetiek gerapporteerd in de literatuur. De meeste van deze 
studies werden uitgevoerd met vrije flavonoïd aglyconen in knaagdieren, waarbij 
niet-fysiologische hoge doses werden gebruikt. De absorptie hing af van het type 
flavonoïd en bleek tussen 4 en 58% te liggen. De absorptie uit de voeding, waarin 
glycosiden van flavonoïden voorkomen, is grotendeels onbekend. De lever en het 
colon zijn belangrijk voor het metabolisme van flavonoïden. Er is overvloedig 
bewijs voor phase II biotransformatie reacties in de lever. Bacteria in het colon zijn 
betrokken bij de hydrolyse van glycosiden en conjugaten en bij ringsplitsing, 
waarbij fenolische zuren ontstaan die geabsorbeerd kunnen worden. Er zijn drie 
soorten ringsplitsing beschreven, die afhankelijk zijn van de structuur van de C-ring 
van het flavonoïd. De gevoeligheid voor ringsplitsing wordt bepaald door het 
patroon van vrije hydroxylgroepen in het flavonoïdmolecuul. Er zijn slechts weinig 
kwantitatieve gegevens over metabolisme beschikbaar. Farmacokinetische gegevens 
zijn er nauwelijks, en de absolute biobeschikbaarheid van flavonoïden die 
aanwezig zijn in voedingsmiddelen is niet bepaald. 
Om de absorptie van flavonolen bij de mens te kunnen bepalen, ontwikkel-
den we voorflavonolen een postcolumn derivatiseringstechniek met aluminium, toe 
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te passen in H PLC met fluorescentiedetectie (Hoofdstuk 3). Variabelen die de 
postcolumn complexering van quercetine beïnvloeden, ni. het watergehalte, de 
buffer en de organische modifier van het eluens, de concentratie van Al3+ en de 
aanwezigheid van azijnzuur in het reagens voor de postcolumnreactie, en de 
temperatuur werden bekeken en geoptimaliseerd. Alleen flavonolen die als bind-
ingsplaatsen een vrije 3-hydroxyl en een 4-keto zuurstof hebben, konden fluores-
cerende complexen met Al3+ vormen. De methode had een detectiegrens van 0.50 
nM (0.15 ng/ml) voor quercetine, 0.17 nM (0.05 ng/ml) voor kaempferol, 1.5 nM 
(0.45 ng/ml) voor myricetine en 0.17 nM (0.05 ng/ml) voor isorhamnetine. Dit 
betekent dat de detecteerbaarheid van quercetine met een factor 300 vergroot wordt 
in vergelijking to UV-detectie. De reproduceerbaarheids relatieve standaard-
afwijking van de methode was 1.4%. 
In Hoofdstuk 4 bestudeerden we de absorptie van verschillende vormen van 
quercetine. Negen gezonde proefpersonen met een ileostoma namen deel. Deze 
proefpersonen werden gekozen om verliezen van quercetine door bacteriële 
afbraak in het colon te voorkomen. Ze volgden een quercetinevrij dieet gedurende 
12 dagen; op de dagen 4, 8 en 12 kregen ze bij het ontbijt in willekeurige volgorde 
een supplement van gebakken uien, die quercetine glucosiden (295 //mol) bevat-
ten, of zuiver quercetine rutinoside (331 //mol), een belangrijk glycoside in thee, of 
331 //mol (100 mg) zuiver aglycon. Vervolgens verzamelden de proefpersonen hun 
ileostoma vloeistof en urine gedurende 13 uur. In vitro incubatie van quercetine en 
quercetine glycosiden met gastro-intestinale vloeistoffen liet slechts minimale 
afbraak zien. De absorptie van quercetine, gedefinieerd als orale inneming minus 
uitscheiding met ileostoma vloeistof en gecorrigeerd voor 14% afbraak in de 
ileostoma zak, was 52 ± 15% voor de quercetin glucosiden uit uien, 17 ± 15% 
voor het quercetine rutinoside, en 24 + 9% voor het quercetine aglycon. De 
gemiddelde uitscheiding van quercetine of quercetine conjugaten met de urine was 
slechts 0.5% van de geabsorbeerde hoeveelheid; de uitscheiding van quercetine in 
de urine was negatief gecorreleerd met de uitscheiding in ileostoma effluent (r = 
-0.78, n = 27). Absorptie van quercetine bij de mens is dus aanzienlijk en wordt 
versterkt door conjugatie van quercetine met glucose. 
We bepaalden het tijdsverloop van de concentratie van quercetine in plasma 
bij twee proefpersonen na inneming van gebakken uien die 212 //mol quercetine 
glucosiden bevatten {Hoofdstuk 5). Piek plasmawaarden van 0.65 //M (196 ng/ml) 
werden bereikt na 2.9 uur; de halfwaardetijd voor de absorptie was 0.87 uur. De 
halfwaardetijd voor de distributiefase was 3.8 uur, en die voor de eliminatiefase 
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16.8 uur. Na 48 uur was de concentratie in plasma ongeveer 33 nM (10 ng/ml). Uit 
deze gegevens volgt dat quercetine glucosiden uit uien geabsorbeerd worden en 
slechts langzaam gedurende de dag worden geëlimineerd. De antioxidant 
quercetine aanwezig in de voeding zou dus de antioxidantcapaciteit van bloed 
plasma kunnen vergroten. 
In Hoofdstuk 6 werd de kinetiek van absorptie en eliminatie van quercetine 
uit belangrijke bronnen in de voeding bepaald, nl. uit gebakken uien die 225/vmol 
glucoseverbindingen van quercetine bevatten, uit appels die zowel glucose als niet-
glucoseglycosiden van quercetine bevatten (325/vmol), en van 330/ymol querce-
tine-3-rutinoside. Piek plasmawaarden waren 0.75 JJM (225 ng/ml) 0.7 uur na 
consumptie van de uien , 0.30/YM (90 ng/ml) 2.5 uur na de appels, en 0.30//M (90 
ng/ml) 9 uur na het rutinoside. De eliminatie halfwaardetijd was 28 uur voor uien 
en 23 uur voor appels. De biobeschikbaarheid van zowel quercetine uit appels als 
van het quercetine rutinoside was 30% vergeleken met uien. De uitscheiding van 
quercetine in urine was 1.39% van de geconsumeerde hoeveelheid met de uien. 
Dit was 0.44% voor de appels en 0.35% voor het quercetine-3-rutinoside. We 
concludeerden dat de quercetine glucosiden uit uien snel worden geabsorbeerd, dat 
het rutinoside langzaam wordt geabsorbeerd, en dat de overall absorptiesnelheid 
van quercetine glycosiden uit appels er tussenin ligt. Volgens ons is de suikergroep 
van het glycoside een belangrijke bepalende factor voor absorptie. Het geabsorbeer-
de quercetine werd slechts langzaam uit het bloed verwijderd. Herhaalde 
consumptie van quercetine bevattende voedingsmiddelen zal daarom leiden tot 
accumulatie van quercetine in het bloed en derhalve de antioxidant capaciteit van 
het bloed verhogen. 
De rol van de suikergroep bij de absorptie van quercetine glycosiden werd 
bekeken in Hoofdstuk 7. Negen nuchtere proefpersonen kregen oplossingen van 
quercetine-4'-glucoside (311 /ymol) en quercetine-3-rutinoside (311 yumol) te 
drinken. Inneming van het quercetine glucoside leidde tot een veel snellere en 
grotere stijging in quercetine spiegels in plasma dan inneming van het rutinoside. 
De gemiddelde piekwaarde van quercetine in plasma was 3.20 /vM na het glucoside 
en slechts 0.23 /vM na het rutinoside. De piekwaarden werden < 0.6 uur na de 
inneming van het 4'-glucoside bereikt en 5.6 uur na het rutinoside. De eliminatie 
van quercetine uit plasma was vergelijkbaar voor beide bronnen: de halwaardetij-
den waren ongeveer 24 uur. We conludeerden dat het glucoside snel wordt 
geabsorbeerd in de dunne darm, terwijl het rutinoside slechts langzaam in het colon 
wordt geabsorbeerd. We veronderstellen dat de natrium-glucose cotransporter in 
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de 'brush border' membranen van de dunne darm een rol speelt bij de absorptie 
van het glucoside. 
Geconcludeerd wordt (Hoofdstuk 8) dat de absorptie van quercetine 
glycosiden aanwezig in voedingsmiddelen aanzienlijk kan zijn. De suikergroep van 
het glycoside is een belangrijke bepalende factor voor absorptie, en absorptie van 
glycosiden is mogelijk zonder voorafgaande hydrolyse van de suikerbinding. We 
veronderstellen dat quercetine-4'-glucoside de enterocyt ingetrokken wordt via de 
suikergroep, die vervoerd wordt door de natrium-glucose cotransporter. Kennis van 
de samenstelling van een voedingsmiddel voor wat betreft de quercetine glycosiden 
maakt het mogelijk de biobeschikbaarheid van quercetine te voorspellen. Na ab-
sorptie wordt quercetine slechts langzaam verwijderd uit het plasma. Dit veroor-
zaakt accumulatie van quercetine in plasma bij geregelde consumptie van 
quercetine bevattende voedingsmiddelen. De concentratie van quercetine in plasma 
kan vergelijkbaar zijn met die van ß-caroteen, maar is kleiner dan die van de 
antioxidantvitamines. Metabolieten met antioxidantwerking gevormd na consump-
tie dragen mogelijk bij aan de potentiële antioxidantbescherming door quercetine 
bevattende produkten. 
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Dankwoord 
Blijkbaar is na mijn afstuderen, nu al weer heel wat jaren geleden, het onderzoeks-
vuurtje altijd blijven smeulen. Martijn, jij hebt in de afgelopen jaren dit vuurtje 
vakkundig opgestookt door voor de benodigde brandstof en zuurstof ('de brain-
storms', discussies, ideeën, opmerkingen, kritische vragen, kontakten, E-mailtjes) te 
zorgen. Jouw aanstekelijke enthousiasme om uit te zoeken hoe iets nu precies in 
elkaar steekt ("...maar worden die stoffen ook geabsorbeerd?"...) maakte mij duide-
lijk dat onderzoek heel spannend kan zijn. En dat was dit onderzoek zeker! En als 
ons onderzoek dan opgeschreven moest worden, dan was er altijd dat onverbid-
delijke potlood. Het potlood dat geen wollig taalgebruik duldt, duidelijke grafieken 
(groter!) vraagt, vage beweringen schrapt, en heldere conclusies eist. 
Als ik me goed herinner begonnen mijn eerste kontakten met de Vakgroep 
Humane Voeding zo rond 1984. Twijfels waren er toen over de vergelijkbaarheid 
van de doodgewone analyses voor eiwit, koolhydraten, vet enz. in voedingsmid-
delen. Dat moest maar eens 'geringtest' worden in internationaal verband. Toevallig 
hadden wij daar bij het RIKILT enige ervaring mee, en het samenwerkingsverband 
was gauw gelegd. Dit project liep blijkbaar tot beider tevredenheid, want in de loop 
der jaren nam het aantal projecten waarin we samenwerkten gestaag toe. Een inten-
sivering van de samenwerking ontstond toen het RIKILT besloot zich sterker te 
profileren als onderzoeksinstituut, en daar de consequentie uit trok dat er AIO-
projekten moesten komen. Professor Hautvast, voor u was het een vanzelfsprekende 
zaak dat er een Voedings-AIO zou moeten komen; en uiteraard kwam hij er ook: 
Michael Hertog. Uw inspanningen om het voedingsonderzoek binnen de land-
bouwkundige onderzoeksinstituten de plaats te geven die het toekomt, werden 
hiermee beloond. Ik heb altijd met erg veel plezier op uw vakgroep rondgelopen 
en heb hier veel inspirerende kontakten kunnen leggen. Hierdoor is in de loop der 
jaren bij mij het 'thuisgevoel' gestadig gegroeid. 
Het leek zo simpel Jeanne. We geven een aantal proefpersonen flink wat uien 
en appels te eten en kijken dan wat we in het bloed zien verschijnen. Van jou heb 
ik geleerd dat een gecontroleerde voedingsproef heel wat meer inhoudt. Door jouw 
efficiënte manier van werken liepen de proeven met vrijwilligers steeds op rolletjes. 
Zonder mijn achterland, de analytische chemie, zo ruim vertegenwoordigd 
op het RIKILT-DLO, was dit proefschrift nooit tot stand gekomen. Wim de Wit, j i j 
gaf me de mogelijkheid dit promotie-onderzoek te starten. Bert-Jan, je had er 
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gelukkig begrip voor dat een promovendus niet al te veel andere dingen aan zijn 
hoofd wil hebben: je hebt me efficiënt afgeschermd van een aantal taken. 
De vele uren die ik vooral in het begin van dit onderzoek in het laboratorium 
heb doorgebracht hebben mij er opnieuw van overtuigd dat analytische chemie een 
ontzettend leuk vak is. John, Dini, Michel en Betty, ik heb jullie analytische 
vakkennis altijd hard nodig gehad. John, jouw aandacht en interesse voor automati-
sering en GLP (je labjournaals zijn wat mij betreft de 'gouden' standaard) zijn 
onmisbaar geweest voor het succesvol lopen van de toch wel heel precaire 
postcolumn-methode. Dini, ofschoon je slechts voor een beperkt deel van je tijd 
aan dit project deelnam, leverde jouw rijke ervaring met flavonoïdenonderzoek 
goede ideeën op. Bovendien kon ik met een gerust hart andere zaken aan jou 
overlaten. Michel, je kwam er pas later bij toen we dreigden te verdrinken in grote 
aantallen monsters. Die monster-stromen verdwenen als sneeuw voor de zon omdat 
jij je handen stevig liet wapperen en er geen been in zag weken achter elkaar tot na 
zevenen 's avonds door te werken. Daarnaast wist je te zorgen voor een prima 
werksfeer. Betty, jouw interesse in en betrokkenheid bij ons flavonoïdenonderzoek 
heb ik steeds erg weten te waarderen. 
Jan en Matti, jullie degelijk maalwerk stond aan de basis van veel van onze 
analyses. Marcel, jij verhoogde mijn absorptiesnelheid van de farmacokinetiek 
aanzienlijk, waardoor je o.a. voorkwam dat ik met een verkeerd beeld over 
bioavailability opgezadeld werd. Jacques, met plezier denk ik terug aan onze 
gesprekken, aan de koffietafel of op ons zonovergoten terras, die over meer dan 
alleen plasmawaarden of renale klaring gingen. En dan was er natuurlijk Jacob, die 
altijd wel in was voor een goed gesprek dat meestal al vlot vooral niet over het 
onderzoek ging. Tini, jouw belangstelling en enthousiasme voor 'het onderzoek' 
was verfrissend en zeer stimulerend. 
Onno Korver, Lilian en Karin, jullie bijstand in woord maar vooral ook in 
daad was onmisbaar voor het onderzoek. Ik heb het steeds erg plezierig gevonden 
met jullie ideeën uit te wisselen; dat moesten we maar lang instandhouden. 
Zonder proefpersonen geen voedings- of supplementenproef, en daarom 
vanaf deze plaats bedankt voor jullie bereidwilligheid, uithoudingsvermogen, 
trouw, humor, gezelligheid En dan waren er gelukkig ook studenten die hun 
afstudeeropdracht Voeding op het RIKILT wilden uitvoeren. Jullie leverden kleur-
rijke, originele, en altijd enthousiaste bijdragen, en zorgden daarbij voor heel wat 
afwisseling op het lab: Henriette (pionier), Coby en Lotje (kruidig), Sonja (Murphy 
kreeg jou niet klein) en Saskia (groente- en fruitkoningin), Martijn (talloze 
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prikmomenten en pompoensoep), Else en Yvonne (day and night shifts), Hanneke 
(chips,.... kilo's uien), Thomas (...van krantenjongen tot..). 
Onze proefpersonen lieten zich steeds zeer gewillig bloed afnemen, en dat 
kwam zeker niet op de laatse plaats door de vakkundige prikkers Joke, Jan, Robert, 
en Marga. Monique, je hebt door je prikwerk een essentiële proef mogelijk 
gemaakt: geen moeite was je teveel zodat alles gladjes verliep. Het was daarnaast 
ook heel gezellig daar in dat verre vroege Nijmegen. 
Onderzoek doen is leuk, maar het wordt dubbel zo leuk als je er ook nog 
over kunt praten met promovendi-lotgenoten. Rob, Martine, Karin, Annet, Saskia, 
Marjolein, Ingeborg, Peter, Kees, Nynke, Gerda, Marijke, en Reggy, onze PhD-tour 
in de V.S. staat in mijn geheugen gegrift. Behalve wetenschappelijk interessant, was 
het voor mij onvergetelijk in Atlanta samen te genieten van 'Grease', dé film uit 
jullie jeugd. Overigens was daar ook de niet te versmaden 'Beach Club'. 
Shelagh and Mike, thank you very much for polishing my English. And Mike, 
I hope we will continue to meet anywhere in Europe. 
Pa, ik ben natuurlijk apetrots op de prachtige pastel die mijn boekje opsiert. 
Dat flavonoïden kleur geven aan de wereld om ons heen weet jij natuurlijk al lang 
gezien de prachtige impressies van de natuur die je in de loop der jaren op papier 
en linnen hebt gemaakt. Ik vind het erg leuk dat 'mijn' uien je geïnsprireerd hebben 
tot een prachtige serie pastels en aquarellen. 
Onderzoek houdt zich niet aan de kantoortijden en vreet daarnaast veel vrije 
tijd. Paula, Pascal en Danielle, dat tijd een schaars artikel is hebben jullie aan den 
lijve moeten ondervinden. Jullie waren de allerbeste supporters die ik me wensen 
kon. Zonder jullie was dit proefschrift misschien wel nooit geschreven, en vooral, 
er zou helemaal niks aan geweest zijn! 
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